citalopram profile

Citalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It was first synthesized in the 1980s and was approved for medical use in 1989. Citalopram works by increasing the levels of serotonin in the brain. Serotonin is a neurotransmitter that plays a role in regulating mood, sleep, appetite, and other functions. By increasing serotonin levels, citalopram helps to alleviate symptoms of depression, anxiety, and other mental health conditions. Citalopram is generally well-tolerated, but it can cause side effects such as nausea, headache, and sexual dysfunction. It is important to note that citalopram should not be taken by pregnant women or breastfeeding mothers. Citalopram is an important medication for the treatment of depression and other mental health conditions. It is widely prescribed and has been shown to be effective in reducing symptoms and improving quality of life. Research on citalopram continues to focus on understanding its mechanisms of action, identifying new therapeutic applications, and optimizing its use in clinical practice.'

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	2771
CHEMBL ID	549
CHEBI ID	77397
CHEBI ID	3723
SCHEMBL ID	946
MeSH ID	M0023529

Synonym
AB00513896-11
BRD-A47598013-004-02-0
MLS000028578
nitalapram
cipram
lu-10-171
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1,3-dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
lu 10-171
5-isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-
citalopramum [inn-latin]
einecs 261-891-1
cytalopram
1-(3-(dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
5-isobenzofurancarbonitrile, 1,3-dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-isobenzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro[3,4]benzofuran-5-carbonitrile
hsdb 7042
celexa
BPBIO1_000929
LOPAC0_000258
citadur (tn)
citalopram (usp/inn)
D07704
BSPBIO_000843
[3h]cytalopram
bdbm25870
chembl549 ,
[3h]lexapro
[3h]escitalopram
[3h]citalopram
AB00513896
citalopram
C07572
59729-33-8
DB00215
smr000465669
PRESTWICK3_000692
NCGC00025160-02
HMS2090O09
HMS2093A14
inchi=1/c20h21fn2o/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12h,3,10-11,14h2,1-2h3
wseqxvzvjxjvfp-uhfffaoysa-
NCGC00015267-07
L001223
chebi:77397 ,
citadur
STL058639
FT-0657967
FT-0660873
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile
A832440
1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile ,
[3h]-citalopram
HMS3259B10
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carb onitrile
CCG-204353
AKOS005711003
NCGC00015267-04
NCGC00015267-05
0dhu5b8d6v ,
citalopramum
perrigo citalopram
citalopram [usp:inn:ban]
unii-0dhu5b8d6v
NCGC00015267-09
gtpl4621
citalopram [vandf]
citalopram [mart.]
citalopram [usp impurity]
citalopram [inn]
citalopram [who-dd]
citalopram [mi]
gtpl7547
lu-10171b
AB00513896-09
NC00711
BBL029066
SCHEMBL946
bonitrile
5-isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-
1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
5-isobenzofurancarbonitrile,1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-
1-(3-dimethylamino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5-carbonitrile
5-cyano-1-(4-fluorophenyl)-1-(3-dimethylaminopropyl)-1,3-dihydro-isobenzofuran
1-(3'-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
1-[3-(dimethylamino) propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
1-(3-(dimethylamino)propyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
MLS006011858
AB00513896_12
AB00513896_13
DTXSID8022826 ,
AC-8894
SR-01000003129-8
SBI-0050246.P002
MRF-0000302
NCGC00015267-12
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo[b]furancarbonitrile
Q409672
C3149
1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile
BRD-A47598013-004-06-1
SDCCGSBI-0050246.P003
NCGC00015267-20
NCGC00015267-11
AS-76503
HY-121203
CS-0081223
EN300-304884
ps18 - citalopram/norcitalopram
citalopramum (latin)
n06ab04
citalopram (usp impurity)
citalopramum (inn-latin)
dtxcid802826
chebi:3723
citalopram (mart.)
citalopram (usp:inn:ban)
rac-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile

Excerpt	Reference	Relevance
"Citalopram (CIT) is a highly selective serotonin reuptake inhibitor (SSRI) frequently used in the treatment of major depressive disorders. "	( Analytical methodologies for the enantiodetermination of citalopram and its metabolites. Budău, M; Hancu, G; Muntean, DL; Rusu, A, 2020)	2.25
"Citalopram is a selective serotonin reuptake inhibitor, and although widely used as an antidepressant, this drug has also demonstrated interesting repairing properties leading to motor recovery and pathology amelioration in animal models of stroke and degeneration. "	( Citalopram Administration Does Not Promote Function or Histological Recovery after Spinal Cord Injury. Assunção-Silva, R; Gomes, ED; Lima, R; Monteiro, S; Morais, M; Salgado, AJ; Silva, NA; Vasconcelos, NL, 2020)	3.44
"Escitalopram is a selective serotonin reuptake inhibitor (SSRIs) antidepressant, drug that is currently used as first-line agents for the treatment of depression and it is also used in the treatment of other psychiatric disorders. "	( Sustained escitalopram administration affects glucose metabolism in the rat brain. Berrocoso, E; Desco, M; Mico, JA; Perez-Caballero, L; Soto-Montenegro, ML, 2021)	1.72
"Citalopram is a safe and tolerable medication in patients with acute IS, which could improve the outcome in these patients."	( Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. Abbaszade, Z; Ghazanfari Amlashi, S; Golzari, SEJ; Hashemilar, M; Nikanfar, M; Rikhtegar, R; Sadeghi Bazargani, H; Sadeghihokmabadi, E; Savadi Oskouie, D; Sharifipour, E, 2017)	2.28
"Citalopram is a selective serotonin reuptake inhibitor used for treatment of depression. "	( Citalopram overdose and severe serotonin syndrome in an intermediate metabolizing patient. Morris, AJ; Picard, L; Schult, RF; Wiegand, TJ, 2019)	3.4
"Citalopram (CIT) is an antidepressant drug from the group of selective serotonin reuptake inhibitors in which it is the most potent selective inhibitor of serotonin uptake currently available. "	( How to combine non-compartmental analysis with the population pharmacokinetics? A study of tobacco smoke's influence on the bioavailability of racemic citalopram in rats. Florek, E; Jawień, W; Kulza, M; Majcherczyk, J; Piekoszewski, W, 2013)	2.03
"Citalopram is an antidepressant drug often prescribed to pregnant women."	( Histological changes in the liver of fetuses of pregnant rats following citalopram administration. Azarnia, M; Mirabolghasemi, G; Mohammadi, Z; Shiravi, A, )	1.09
"Escitalopram appears to be a superior antidepressant to racemic citalopram. "	( The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse. Cajina, M; Caron, MG; Dalvi, P; Du, Y; Jacobsen, JP; Khoo, KS; Morillo, CS; O'Neill, SP; Pehrson, AL; Plenge, P; Roberts, W; Robinson, TJ; Rudder, ML; Sachs, BD; Zhang, X, 2014)	1.44
"Citalopram is a selective serotonin reuptake inhibitor (SSRI) with cardiac and neurologic toxicities as well as the potential for serotonin syndrome. "	( Citalopram Overdose: a Fatal Case. Kraai, EP; Seifert, SA, 2015)	3.3
"Escitalopram is a commonly prescribed antidepressant of the selective serotonin reuptake inhibitor class. "	( In vivo investigation of escitalopram's allosteric site on the serotonin transporter. Murray, KE; Owens, MJ; Ressler, KJ, 2016)	1.45
"Citalopram is an antidepressant drug, which acts by inhibiting the re-uptake of serotonin from the synaptic cleft into the pre-synaptic nerve ending. "	( Waterborne citalopram has anxiolytic effects and increases locomotor activity in the three-spine stickleback (Gasterosteus aculeatus). Hallgren, S; Hansen, SH; Kellner, M; Olsén, KH; Porsch-Hällström, I; Porseryd, T, 2016)	2.27
"Citalopram (CTR) is a worldwide highly consumed antidepressant which has demonstrated incomplete removal by conventional wastewater treatment. "	( Identification of biotransformation products of citalopram formed in activated sludge. Aalizadeh, R; Beretsou, VG; Fenner, K; Gago-Ferrero, P; Psoma, AK; Thomaidis, NS, 2016)	2.13
"Citalopram is a clinically applied selective serotonin re-uptake inhibitor for antidepressant pharmacotherapy. "	( The allosteric citalopram binding site differentially interferes with neuronal firing rate and SERT trafficking in serotonergic neurons. Bahri, S; Haddjeri, N; Lau, T; Martí, Y; Matthäus, F; Rovera, R; Sánchez, C; Schloss, P, 2016)	2.23
"S-citalopram is a drug used to treat depression and anxiety by binding to the serotonin transporter with high-affinity, blocking serotonin reuptake."	( Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram. Coleman, JA; Gouaux, E; Green, EM, 2016)	1.2
"Citalopram is a substrate for 2C19 and inhibition of its metabolism may result in serotonin toxicity."	( Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion. Cortes-Ladino, A; Levin, TT; Palomba, ML; Weiss, M, )	1.11
"Escitalopram (ESC) is a novel selective serotonin reuptake inhibitor that seems to have a favorable side effect profile."	( The safety of the electroconvulsive therapy-escitalopram combination. Florakis, A; Markatou, M; Masdrakis, VG; Oulis, P; Papadimitriou, GN; Valamoutopoulos, T, 2008)	1.16
"Citalopram (Séropram) is an antidepressant of the selective serotonin (5-HT) reuptake inhibitor (SSRI) class, composed of equal amounts of S-enantiomer, escitalopram, and R-enantiomer, R-citalopram. "	( [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter]. El Mansari, M; Haddjeri, N; Mnie-Filali, O; Sánchez, C; Scarna, H; Zimmer, L, 2007)	2.4
"Escitalopram is a good therapeutic option for the long-term treatment of MDD, particularly in severely depressed patients."	( Superiority of escitalopram to paroxetine in the treatment of depression. Baldwin, DS; Boulenger, JP; Kasper, S; Larsson Lönn, S, 2009)	1.25
"Escitalopram (ES-CIT) is a widely used, highly specific antidepressant. "	( Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. Abumaria, N; Danker-Hopfe, H; Fuchs, E; Hellweg, R; Hiemke, C; Schulte-Herbrüggen, O; Ziegler, A, 2009)	1.44
"Citalopram is a racemic mixture of equal proportions of the S(+) and R(-) enantiomers."	( Specific effects of escitalopram on neuroendocrine response. Delva, NJ; Hawken, ER; Hudson, RW; Owen, JA, 2009)	1.39
"Escitalopram is a stronger and safer SSRI with an earlier onset of action."	( [Mechanism of action of new generation antidepressants under development in Japan: focusing on dopamine neurotransmission]. Nakayama, K, 2009)	0.91
"Escitalopram is a selective serotonin reuptake inhibitor (SSRI), and is the second antidepressant to be approved for use in treating major depressive disorder (MDD) in adolescent patients (aged 12-17 years) in the US. "	( Escitalopram: in the treatment of major depressive disorder in adolescent patients. Scott, LJ; Yang, LP, 2010)	1.8
"Citalopram is an effective, well-tolerated agent in managing hot flashes. "	( Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. Atherton, PJ; Barton, DL; Diekmann, B; Dyar, M; Flynn, KA; Johnson, DB; LaVasseur, BI; Loprinzi, CL; Sloan, JA; Stawis, AN, 2010)	2.05
"Escitalopram is a serotonin reuptake inhibitor used in the treatment of depression and anxiety disorders. "	( Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test. Engel, D; Gabilan, NH; Rodrigues, AL; Zomkowski, AD, 2010)	1.28
"Escitalopram is a widely used antidepressant for the treatment of patients with major depression. "	( Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Haddjeri, N; Sánchez, C; Zhong, H, 2012)	1.82
"Citalopram (CIT) is a widely used antidepressant which acts by a selective serotonin reuptake inhibition. "	( Correlation of QTc interval prolongation and serum level of citalopram after intoxication--a case report. Deckert, J; Pfuhlmann, B; Unterecker, S; Warrings, B, 2012)	2.06
"Escitalopram is a serotonin reuptake inhibitor prescribed for depression and anxiety. "	( Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study. Einarson, A; Einarson, T; Klieger-Grossmann, C; Koren, G; Panchaud, A; Pistelli, A; Weitzner, B, 2012)	1.37
"Citalopram is a selective serotonin reuptake inhibitor with a favorable cardiac-safety profile. "	( Prolonged QTc interval and torsades de pointes induced by citalopram. Abuissa, H; Airey, K; Alla, V; Deshmukh, A; Ulveling, K, 2012)	2.07
"Citalopram is a selective serotonin reuptake inhibitor (SSRI), widely used in the treatment of depressive disorders. "	( 5-HT(3) receptor mediates the dose-dependent effects of citalopram on pentylenetetrazole-induced clonic seizure in mice: involvement of nitric oxide. Amouzegar, A; Bahremand, A; Dehpour, AR; Payandemehr, B; Rahimian, R; Sharifzadeh, M; Ziai, P, 2012)	2.07
"Escitalopram is an antidepressant drug shown to reverse the depressive-like features caused by this stress model."	( Escitalopram improves memory deficits induced by maternal separation in the rat. Batalha, VL; Couto, FS; Data-Franca, J; Lopes, LV; Ribeiro, JA; Valadas, JS, 2012)	1.66
"Citalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is widely used in clinical practice. "	( Citalopram and cardiac toxicity. Cooke, MJ; Waring, WS, 2013)	3.28
"Citalopram is a selective serotonin reuptake inhibitor (SSRI) mainly prescribed to treat major depression."	( Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. Chen, B; Chen, C; Chen, H; Jiang, T; Li, H; Lu, Y; Rong, Z; Shen, Y; Sun, J; Xie, Y; Xu, Y, 2013)	2.07
"Citalopram appears to be a safe and effective treatment for compulsive shopping. "	( Citalopram treatment of compulsive shopping: an open-label study. Bullock, KD; D'Andrea, V; Elliott, MA; Hartston, HJ; Koran, LM, 2002)	3.2
"Escitalopram is a new antidepressant drug, available for clinical use in many countries. "	( Escitalopram: efficacy and tolerability in the treatment of depression. Baldwin, DS, 2002)	1.76
"Citalopram alone is an efficacious treatment for perimenopausal and postmenopausal women with depression. "	( Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. Alexander, AB; Cohen, LS; Poitras, JR; Prouty, J; Shifren, JL; Soares, CN, 2003)	2.14
"Escitalopram is a very selective 5-HT reuptake inhibitor. "	( Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Bergqvist, PB; Brennum, LT; Gupta, S; Hogg, S; Larsen, A; Sánchez, C; Wiborg, O, 2003)	1.76
"Citalopram is a selective serotonin reuptake inhibitor antidepressant that has not yet been fully evaluated with respect to its potential for cytochrome P450 3A4-mediated drug interactions in vivo."	( Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. Hall, J; Herrmann, N; Naranjo, CA; Sproule, BA, 2003)	1.27
"Citalopram appears to be a safe and effective treatment for compulsive shopping disorder. "	( Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. Bullock, KD; Chuong, HW; Koran, LM; Smith, SC, 2003)	3.2
"Citalopram is a highly selective serotonin reuptake inhibitor antidepressant."	( Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. Hudson, JI; Keck, PE; Malhotra, S; McElroy, SL; Nelson, EB; Welge, JA, 2003)	2.48
"Citalopram is a highly selective serotonin reuptake inhibitor (SSRI) that has been prescribed to >30 million patients in >70 countries. "	( Overview of the safety of citalopram. Nemeroff, CB, 2003)	2.06
"Citalopram is a racemic mixture of two stereoisomers, (R)- and (S)-citalopram. "	( Regional pattern of binding and c-Fos induction by (R)- and (S)-citalopram in rat brain. Helboe, L; Thomsen, C, 2003)	2
"Citalopram is a racemic drug with 50:50 of the S- and R- enantiomers."	( Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19. Ahlner, J; Carlsson, B; Dahl, ML; Druid, H; Holmgren, P; Lindblom, B; Scordo, MG; Zackrisson, AL, 2004)	1.34
"Escitalopram is a highly selective serotonin reuptake inhibitor (SSRI). "	( [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder]. Azorin, JM; Despiegel, N; Llorca, PM; Verpillat, P, )	1.47
"Citalopram is a racemate consisting of a 1:1 mixture of the R(-)- and S(+)-enantiomers. "	( Escitalopram versus citalopram: the surprising role of the R-enantiomer. Braestrup, C; Bøgesø, KP; Ebert, B; Reines, EH; Sánchez, C, 2004)	2.49
"Escitalopram is a cost-effective alternative compared to (generic) citalopram in the first-line treatment of MDD in Austria."	( Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Einarson, TR; Hemels, ME; Kasper, S; Walter, E, 2004)	1.33
"Citalopram is a promising treatment for functional pediatric recurrent abdominal pain and deserves additional study with a randomized, placebo-controlled clinical trial."	( Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study. Axelson, D; Birmaher, B; Brent, DA; Bridge, J; Campo, JV; Di Lorenzo, C; Ehmann, M; Kalas, C; Lucas, A; Monk, K; Perel, J; Ryan, N, 2004)	3.21
"Escitalopram is an effective, well-tolerated treatment for major depressive disorder in both primary and specialist settings. "	( Efficacy of escitalopram in patients with severe depression: a pooled analysis. Azorin, JM; Despiegel, N; Llorca, PM; Verpillat, P, 2005)	1.41
"Citalopram is a selective serotonin reuptake inhibitor used in the treatment of depression. "	( Activity of citalopram on adenosine and serotonin circulating levels in depressed patients. Auteri, A; Blardi, P; Bossini, L; Castrogiovanni, P; de Lalla, A; Dell'Erba, A; Urso, R, 2005)	2.15
"Escitalopram 10 mg/day is an effective and well-tolerated antidepressant. "	( Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. Bose, A; Goodman, WK; Wang, Q, 2005)	1.3
"Citalopram is an antidepressant drug within the group of the selective serotonin reuptake inhibitors (SSRI). "	( Case report of a fatal intoxication by citalopram. Centini, F; Luchini, D; Morabito, G, 2005)	2.04
"Citalopram is a selective serotonin reuptake inhibitor indicated for depression. "	( Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Einarson, A; Koren, G; Sarkissian, L; Shuhaiber, S; Sivojelezova, A, 2005)	3.21
"Escitalopram is a selective serotonin reuptake inhibitor (SSRI); it is the therapeutically active S-enantiomer of the racemic mixture, citalopram. "	( [Escitalopram for treatment of major depressive disorder in adults]. Brousse, G; Llorca, PM; Schwan, R, )	1.47
"Escitalopram (ESC) is a new selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression. "	( Outcomes after supratherapeutic escitalopram ingestions. Knight, J; LoVecchio, F; McDowell, T; Watts, D; Winchell, J, 2006)	1.33
"Escitalopram is a selective serotonin reuptake inhibitor antidepressant indicated for use in adults. "	( A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. Findling, RL; Jonas, J; Saikali, K; Ventura, D; Wagner, KD, 2006)	1.3
"Escitalopram, which is a recently marketed selective serotonin reuptake inhibitors (SSRI), has no such reputation."	( Sertraline, escitalopram and tianeptine related abnormal movements but not with bupropion: a case report. Akarsu, ES; Ayhan, IH; Cankurtaran, ES; Cekic, T; Ozalp, E; Palaoglu, O; Soygur, H; Turhan, L, 2006)	1.25
"Citalopram is a racemate, consisting of a 1:1 mixture of the S- and R-enantiomers."	( [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study]. Arbus, C; Schmitt, L; Tonnoir, B, )	1.14
"Escitalopram is a dual serotonin reuptake inhibitor (SSRI) approved for the treatment of depression and anxiety disorders. "	( In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Asenbaum, S; Attarbaschi, T; Dudczak, R; Geiss-Granadia, T; Holik, A; Kasper, S; Klein, N; Lanzenberger, R; Mossaheb, N; Pötzi, C; Sacher, J; Spindelegger, C; Tauscher, J, 2006)	1.26
"Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that has shown efficacy in both acute and continuation treatment of major depressive disorder."	( Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. Bose, A; Gandhi, C; Kornstein, SG; Li, D; Saikali, KG, 2006)	1.61
"Citalopram is an effective alternative treatment option for patients who do not want to take HT for the alleviation of climacteric symptoms. "	( Efficacy of citalopram on climacteric symptoms. Demir, B; Haberal, A; Kalay, AE; Kalay, M; Kandemir, O, )	1.95
"As escitalopram is a highly specific SSRI, the results suggest that an increased serotonergic activity disrupts habituation, but not PPI in healthy volunteers."	( The effects of increased central serotonergic activity on prepulse inhibition and habituation of the human startle response. Glenthøj, BY; Jensen, KS; Oranje, B; Wienberg, M, 2007)	0.79
"Escitalopram is a highly selective inhibitor of serotonin re-uptake that is used to treat anxiety disorders. "	( Anxiolytic and panicolytic effects of escitalopram in the elevated T-maze. Del-Ben, CM; Graeff, FG; Pinheiro, SN; Zangrossi, H, 2008)	1.33
"Citalopram is a very potent and highly selective inhibitor of neuronal serotonin (5-hydroxytryptamine, or 5-HT). "	( First time, low dose citalopram use-related serotonin syndrome. Eraydin, I; Gunduz, A; Hos, U; Kalkan, A; Turedi, S, 2007)	2.1
"Escitalopram (eCIT) is a highly selective serotonin reuptake inhibitor (SSRI) that can be an effective treatment for a number of neuropsychiatric disorders including major depression. "	( Escitalopram regulates expression of TRH and TRH-like peptides in rat brain and peripheral tissues. Blood, J; Pekary, AE; Sattin, A, 2008)	1.79
"Escitalopram is an effective first-line option in the management of patients with major depression, including severe forms, and various anxiety disorders."	( Escitalopram for the treatment of major depression and anxiety disorders. Höschl, C; Svestka, J, 2008)	1.63
"Citalopram is a new, highly selective inhibitor of 5HT re-uptake."	( Treatment of severe obesity with a highly selective serotonin re-uptake inhibitor as a supplement to a low calorie diet. Elsborg, L; Szkudlarek, J, 1993)	1.01
"Citalopram is an SSRI drug with an attractive pharmacokinetic profile, i.e."	( Scandinavian experience with citalopram in the elderly. Gottfries, CG, 1996)	1.31
"Citalopram is a selective serotonin reuptake inhibitor widely used in the treatment of depression (20-40 mg/day)."	( Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Bergman, J; Eronen, E; Hietala, J; Kuoppamäki, M; Någren, K; Syvälahti, E; Tiihonen, J, 1996)	1.02
"Citalopram is a serotonin reuptake inhibitor which has been demonstrated to be highly selective and with a superior tolerability profile to the classical tricyclic antidepressants. "	( The effect of citalopram in panic disorder. Koponen, HJ; Lepola, U; Pedersen, T; Pedersen, V; Wade, AG, 1997)	2.1
"Citalopram, is an extremely potent inhibitor of neuronal serotonin reuptake. "	( Citalopram enhances the activity of chloroquine in resistant plasmodium in vitro and in vivo. Berk, M; Butkow, N; Evans, SG; Havlik, I; Kirchmann, N; Stilwell, C, 1998)	3.19
"Citalopram (CIT) is an antidepressive drug of the group of selective serotonin reuptake inhibitors (SSRIs). "	( Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Baumann, P; Boss, G; Gillet, M; Kosel, M; Rochat, B; Testa, B, 1998)	1.97
"Citalopram is an antidepressant belonging to the class of selective serotonin-reuptake inhibitors (SSRIs) available for the treatment of depression. "	( Citalopram in the treatment of depression. Brown, CS; Parker, NG, 2000)	3.19
"Citalopram is an SSRI antidepressant with a more specific and selective pharmacological profile than other antidepressants of its class. "	( Citalopram--a review of pharmacological and clinical effects. Aleksic, I; Bezchlibnyk-Butler, K; Kennedy, SH, 2000)	3.19
"Citalopram is a selective serotonin re-uptake inhibitor that has demonstrated antidepressant efficacy in numerous controlled clinical trials. "	( Citalopram: a comprehensive review. Pollock, BG, 2001)	3.2
"Citalopram is a member of the selective serotonin reuptake inhibitor class of antidepressants. "	( QTc interval prolongation associated with citalopram overdose: a case report and literature review. Catalano, G; Catalano, MC; Epstein, MA; Tsambiras, PE, )	1.84
"Citalopram is a selective serotonin reuptake inhibitor that is N-demethylated to N-desmethylcitalopram partially by CYP2C19 and partially by CYP3A4 and N-desmethylcitalopram is further N-demethylated by CYP2D6 to the likewise inactive metabolite di-desmethylcitalopram. "	( Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Brøsen, K; Naranjo, CA, 2001)	1.99
"Citalopram appears to be an effective treatment for pathological gambling, and this benefit was independent of its antidepressant properties. "	( An open-label study of citalopram in the treatment of pathological gambling. Breen, RB; Posternak, MA; Zimmerman, M, 2002)	2.07
"Citalopram is a relatively new selective serotonin reuptake inhibitor (SSRI) that is becoming widely administered for the treatment of depression. "	( Citalopram-induced priapism. Brown, WC; Dent, LA; Murney, JD, 2002)	3.2
"Citalopram is a chiral antidepressant drug. "	( Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Baumann, P; Brawand-Amey, M; Eap, CB; Steinacher, L; Vandel, P; Zullino, DF, 2002)	1.99
"Citalopram is a bicyclic phthalate compound approved in 1998 by the U.S. "	( Disposition of citalopram in biological specimens from postmortem cases. Gubanich, K; Jenkins, AJ, 2002)	2.11
"Citalopram is an antidepressant belonging to a new class of drugs which enhance serotoninergic neurotransmission through potent and selective inhibition of serotonin reuptake. "	( Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Goa, KL; Milne, RJ, 1991)	3.17
"Citalopram (CIT), is a selective serotonin (5-HT) reuptake blocker and a clinically effective antidepressant. "	( Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Blier, P; Chaput, Y; de Montigny, C, 1986)	1.97
"Citalopram is a potent and selective inhibitor of neuronal serotonin uptake. "	( Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. D'Amato, RJ; Largent, BL; Snowman, AM; Snyder, SH, 1987)	1.95
"Citalopram is a bicyclic phtalane derivative. "	( Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor--a dose-response study in depressed patients. Bjerkenstedt, L; Edman, G; Flyckt, L; Hagenfeldt, L; Sedvall, G; Wiesel, FA, 1985)	1.99

Excerpt	Reference	Relevance
"Escitalopram has a predictable tolerability profile with generally mild to moderate and transient adverse events, and a low propensity for drug interactions."	( Escitalopram: a review of its use in the management of major depressive disorder in adults. Garnock-Jones, KP; McCormack, PL, 2010)	1.64
"Citalopram has an anti-apoptotic effect on PC12 cells. "	( Effects of citalopram on serum deprivation induced PC12 cell apoptosis and BDNF expression. Cai, W; Duan, J; Li, Y; Tan, Y, 2010)	2.19
"Escitalopram has a small effect on the QTc interval."	( A question about the potential cardiac toxicity of escitalopram. Howland, RH, 2012)	1.19
"Escitalopram has a straightforward pharmacokinetic profile, little effect on hepatic metabolism, and is relatively safe in overdose."	( Managing depressive and anxiety disorders with escitalopram. Thase, ME, 2006)	1.15
"Citalopram has a favorable adverse effect profile, and thus may be useful in treating depressed patients who cannot tolerate anticholinergic or cardiovascular adverse effects associated with TCAs."	( Citalopram in the treatment of depression. Brown, CS; Parker, NG, 2000)	2.47
"Escitalopram has some unique features among selective serotonin reuptake inhibitors. "	( Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial. Dastgheib, SA; Modarresi, F; Mowla, A, 2018)	1.2
"Escitalopram has been shown to have better efficacy and safety profile than other selective serotonin reuptake inhibitor and serotonin norepinephrine reuptake inhibitor drugs, including racemic citalopram."	( Clinical pharmacology review of escitalopram for the treatment of depression. Gobburu, J; Pastoor, D, 2014)	1.24
"Escitalopram has widely been recognized as one of the most frequently used antidepressants, with superior tolerability and great efficacy in preventing major depressive disorder (MDD) relapse and recurrence. "	( Anhedonia among patients with Major Depressive Disorder: A comparison between patients on escitalopram and healthy controls. Loh, HS; Ng, CG; Wong, SK; Yee, A, )	1.07
"But citalopram has fewer side effects especially in the first week."	( Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis. Ding, L; Hong, H; Huang, X; Tan, S, 2015)	1.21
"Citalopram has been shown to improve agitation in patients with Alzheimer's disease. "	( Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. Devanand, DP; Drye, LT; Frangakis, C; Leonpacher, AK; Lyketsos, CG; Makino, KM; Mintzer, JE; Munro, CA; Newell, JA; Peters, ME; Pollock, BG; Porsteinsson, AP; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016)	2.27
"Escitalopram has shown some different pharmacologic properties compared to its racemic molecule, citalopram. "	( [Escitalopram versus serotonin reuptake inhibitors]. Millet, B, 2008)	1.69
"Escitalopram has proven efficacy in the short-term treatment of SAD and prevention of relapse."	( Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. Aballéa, S; Auquier, P; Despiegel, N; François, C; Montgomery, SA; Roïz, J, 2008)	1.12
"Citalopram has been regarded as the most toxic of the selective serotonin reuptake inhibitors in overdose; however, hypoglycaemia is not one of the documented features of overdose."	( Severe hypoglycaemia in citalopram overdose. Armstrong, PA; Duncan, RA; Paterson, B, 2008)	1.37
"Escitalopram has at least comparable efficacy to available serotonin-norepinephrine reuptake inhibitors, venlafaxine XR and duloxetine, and may offer some tolerability advantages over these agents."	( Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression. Leonard, B; Taylor, D, 2010)	1.64
"Escitalopram has never been demonstrated to be useful in the treatment of chronic low back pain (CLBP), while duloxetine has demonstrated analgesic effect in chronic pain states. "	( Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. Mazza, M; Mazza, O; Mazza, S; Padua, L; Pazzaglia, C, 2010)	1.8
"Escitalopram has a predictable tolerability profile with generally mild to moderate and transient adverse events, and a low propensity for drug interactions."	( Escitalopram: a review of its use in the management of major depressive disorder in adults. Garnock-Jones, KP; McCormack, PL, 2010)	1.64
"Citalopram has an anti-apoptotic effect on PC12 cells. "	( Effects of citalopram on serum deprivation induced PC12 cell apoptosis and BDNF expression. Cai, W; Duan, J; Li, Y; Tan, Y, 2010)	2.19
"Escitalopram has shown efficacy and tolerability in the prevention of relapse in elderly patients with major depressive disorder (MDD). "	( Are old-old patients with major depression more likely to relapse than young-old patients during continuation treatment with escitalopram? Gorwood, P; Katona, C; Lyketsos, CG; Weiller, E, 2011)	1.3
"Escitalopram has a small effect on the QTc interval."	( A question about the potential cardiac toxicity of escitalopram. Howland, RH, 2012)	1.19
"Escitalopram has linear pharmacokinetics, so that plasma levels increase proportionately and predictably with increased doses and its half-life of 27 - 32 h is consistent with once-daily dosing."	( Escitalopram. Burke, WJ, 2002)	1.59
"Citalopram has been associated with seizures, ECG abnormalities, rhabdomyolysis and coma after overdose."	( Adult respiratory distress syndrome and renal failure associated with citalopram overdose. Bateman, DN; Flanagan, RJ; Kelly, CA; Spencer, EP; Upex, A, 2003)	1.27
"R-citalopram has been shown to counteract the 5-HT enhancing properties of escitalopram in acute studies in animals."	( R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Gruca, P; Papp, M; Sánchez, C, 2003)	1.6
"Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder. "	( Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Bose, A; Davidson, JR; Korotzer, A; Zheng, H, 2004)	1.77
"Escitalopram has demonstrated efficacy for the acute treatment of social anxiety disorder (SAD) in two placebo-controlled trials and for long-term treatment in a relapse-prevention study. "	( Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. Andersen, EW; Kasper, S; Lader, M; Nil, R; Stein, DJ, 2004)	1.77
"Escitalopram has proven efficacy in the short-term treatment of generalized social anxiety disorder (SAD). "	( A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. Boulenger, JP; Dürr-Pal, N; Loft, H; Montgomery, SA; Nil, R, 2005)	1.29
"Escitalopram has demonstrated a robust and dose-dependent efficacy in the treatment of generalized anxiety disorder (GAD) for up to 3 months. "	( Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Allgulander, C; Florea, I; Huusom, AK, 2006)	1.3
"Escitalopram has previously been shown to be effective and well tolerated in the acute treatment of GAD."	( Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. Bose, A; Davidson, JR; Wang, Q, 2005)	1.19
"Escitalopram has a straightforward pharmacokinetic profile, little effect on hepatic metabolism, and is relatively safe in overdose."	( Managing depressive and anxiety disorders with escitalopram. Thase, ME, 2006)	1.15
"Escitalopram has been proven safe and efficacious in the treatment of major depressive disorder (MDD) in short-term studies. "	( Escitalopram in the long-term treatment of major depressive disorder. Despiegel, N; Heldbo Reines, E; Wade, A, )	1.57
"Oral citalopram has also been used, but unsatisfactory results were obtained with a dose of 20 mg."	( Usefulness of serotoninergic challenge with oral citalopram. Franco, VA; Gonçalves, JC; Mattos, P; Noel, F; Segenreich, D, 2006)	1.04
"Escitalopram has low protein binding (56%) and is not likely to cause interactions with highly protein-bound drugs."	( The clinical pharmacokinetics of escitalopram. Rao, N, 2007)	1.17
"Escitalopram has favourable pharmacokinetics: it is rapidly absorbed, has a bioavailability of 80% and is not affected by food intake."	( The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Altamura, AC; Bareggi, SR; Dell'Osso, B; Mundo, E, 2007)	1.27
"2. Citalopram has no antagonistic activity towards DA, NA, 5-HT, histamine, gamma aminobutyric acid (GABA), acetylcholine, and morphine receptors."	( Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Hyttel, J, 1982)	2.22
"Citalopram has been well tolerated in both short- and long-term use, and the profile seen in trials has been confirmed in the clinic."	( The safety and tolerability of citalopram. Muldoon, C, 1996)	1.3
"Citalopram has a favorable adverse effect profile, and thus may be useful in treating depressed patients who cannot tolerate anticholinergic or cardiovascular adverse effects associated with TCAs."	( Citalopram in the treatment of depression. Brown, CS; Parker, NG, 2000)	2.47

Excerpt	Reference	Relevance
"Citalopram showed lower concentration changes and faster reuptake profiles compared with escitalopram, so the racemic mixture of citalopram does not change reuptake as much as the S-isomer."	( SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila. Dunham, KE; Venton, BJ, 2022)	1.44
"Escitalopram could increase GDNF and BDNF levels and 5-HT content in serum and brain tissue in obsessive-compulsive disorder rats, which contributes to a function on the treatment of obsessive-compulsive disorder."	( Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive-Compulsive Disorder Rats. Guo, HR; Huang, BL; Lv, PP; Ma, QG; Ren, YM; Wang, YL; Zhang, YY, 2020)	1.5
"Escitalopram may cause rare cases of AUR and may often times be overlooked possibly because of the paucity of reporting."	( Escitalopram-associated acute urinary retention. Garrett, K; Harrison, M; Trombetta, D, 2013)	1.67
"Escitalopram did not enhance the efficacy of modafinil to reduce any measure."	( Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: a randomized, double blind, placebo-controlled human laboratory study. De La Garza, R; Haile, CN; Mahoney, JJ; Newton, TF; Thompson-Lake, DG; Verrico, CD, 2014)	1.25
"Escitalopram showed lower fasting and post-lunch blood sugar values on follow up, which was clinically and statistically significant."	( Depression and diabetes: impact of antidepressant medications on glycaemic control. Agari, AD; Dhavale, HS; Ghulghule, M; Jadhav, BS; Panikkar, V, 2013)	0.95
"Citalopram overdose may produce bradycardia, QT prolongation, and torsades de pointes (TdP). "	( Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. Hoffman, RS; Nelson, L; Tarabar, AF, 2008)	3.23
"Citalopram overdose can produce life-threatening cardiac toxicity with a clinical onset that may be delayed beyond a routine observation period of 6 hours. "	( Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. Hoffman, RS; Nelson, L; Tarabar, AF, 2008)	3.23
"Escitalopram did not produce greater changes than placebo in panic responses or in ventilatory abnormalities seen during CO2 exposure. "	( Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study. Coryell, W; Rickels, H, 2009)	1.44
"Citalopram patients had lower mean pharmacy charges than did sertraline patients (US dollars 255 vs Us dollars 267; 0.036)."	( A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges. Eaddy, MT; Grudzinski, AN; McLaughlin, TP, 2004)	1.34
"Citalopram-induced increase in serotonin levels was strongly enhanced by adjunctive methylphenidate in the hippocampus, but attenuated in the cortex."	( Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain. Kehr, J; Weikop, P; Yoshitake, T, 2007)	1.31
"Citalopram prevented the increase in sucrose consumption in the PCA+CVS rats, and in 5-HT-depleted animals blocked the increase in struggling and reduced the number of defecations in the forced swim test."	( Rat behavior after chronic variable stress and partial lesioning of 5-HT-ergic neurotransmission: effects of citalopram. Eller, M; Häidkind, R; Harro, J; Kõiv, K; Mällo, T; Tõnissaar, M, 2008)	1.28
"Citalopram promotes proliferation and differentiation of NPCs from embryonic rat hippocampus."	( [The effects of citalopram on proliferation and differentiation of neural precursor cells from embryonic rat hippocampus]. Chen, BA; Guo, YJ; Teng, GJ; Wang, SH; Zhang, ZJ, 2007)	2.13
"Citalopram does not cause anticholinergic or cardiovascular adverse effects associated with the TCAs."	( Citalopram in the treatment of depression. Brown, CS; Parker, NG, 2000)	2.47

Excerpt	Reference	Relevance
"Escitalopram pretreatment had no relevant effect on positive mood effects of psilocybin but significantly reduced bad drug effects, anxiety, adverse cardiovascular effects, and other adverse effects of psilocybin compared with placebo pretreatment."	( Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Becker, AM; Duthaler, U; Eckert, A; Grandinetti, T; Grünblatt, E; Holze, F; Klaiber, A; Kolaczynska, KE; Liechti, ME; Toedtli, VE; Varghese, N, 2022)	1.55
"Citalopram-treated animals (n = 13) showed a significant increase in impaired forepaw use in the staircase task compared with saline-treated animals (n = 12) 2, 3 and 7 weeks post stroke but no difference in neurological score at any time point examined."	( Delayed citalopram administration reduces brain inflammation and enhances skilled motor function after ischaemic stroke in 'MacGreen' mice. Bennet, L; Chen, S; McGregor, AL, 2022)	1.88
"Citalopram treatment reduced the Aβ1-42:40 ratio in control but not in fAD PSEN1 cells."	( The effect of citalopram treatment on amyloid-β precursor protein processing and oxidative stress in human hNSC-derived neurons. Aldred, S; Crowe, JA; Dunleavy, C; Elsworthy, RJ; Fisher, E; Hill, EJ; King, MC; Ludlam, A; Parri, HR, 2022)	1.8
"Citalopram treatment did not seem to modify this association."	( Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark. Andersen, G; Blauenfeldt, RA; Damsbo, AG; Johnsen, SP; Mortensen, JK; Vestergaard, SB, 2023)	1.9
"Escitalopram treatment can significantly reverse NAc miRNA abnormality induced by chronic stress. "	( Expression alteration of microRNAs in Nucleus Accumbens is associated with chronic stress and antidepressant treatment in rats. Li, H; Li, X; Lin, GN; Ning, A; Peng, S; Shen, Y; Song, W; Yu, S; Zhang, R; Zhang, Y, 2019)	1.24
"Escitalopram treatment was associated with changes in the symptom networks in IBS patients with panic disorder. "	( Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo. Drukker, M; Kreiter, D; Kruimel, JW; Leue, C; Masclee, AAM; Mujagic, Z; Rutten, BPF; van Os, J; Vork, L, 2021)	1.54
"Citalopram-treated APP mice relative to citalopram-untreated APP mice exhibited improved cognitive behavior."	( Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease. Bunquin, LE; Kshirsagar, S; Morton, H; Reddy, AP; Reddy, PH; Sawant, N; Yin, X, 2021)	1.61
"Citalopram treatment (30±5.8 mg/d) resulted in similar 6-month efficacy compared to both quetiapine (94.0±40.4 mg/d) and olanzapine (5.2±1.6 mg/d), lower occurrence of falls than olanzapine [odds ratio (OR) = 0.81, 95% confidence interval (CI) = 0.68-0.97, P = .012], lower incidence of orthostatic hypotension than both quetiapine (OR = 0.80, 95% CI = 0.66-0.95, P = .032) and olanzapine (OR = 0.75, 95% CI = 0.69-0.91, P = .02), and less all-cause hospitalizations than both quetiapine (OR = 0.92, 95% CI = 0.88-0.95, P = .016) and olanzapine (OR = 0.78, 95% CI = 0.64-0.92, P = .004), after multiple adjustment for potentially confounding variables. "	( Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia. Chiriac, IM; Ettorre, E; Viscogliosi, G, 2017)	2.21
"Escitalopram-treated MDD patients with higher social desirability achieved more rapid decrease in symptom severity. "	( Personality traits and escitalopram treatment outcome in major depression. Aluoja, A; Eller, T; Maron, E; Raag, M; Tõru, I; Võhma, Ü, 2018)	1.51
"Citalopram treatment altered levels of select components of the cellular protein homeostatic machinery that may be expected to enhance the capacity to refold and/or degrade mutant ATXN3."	( Citalopram Reduces Aggregation of ATXN3 in a YAC Transgenic Mouse Model of Machado-Joseph Disease. Ashraf, NS; Costa, MDC; Duarte-Silva, S; Maciel, P; Paulson, HL; Shaw, ED; Teixeira-Castro, A, 2019)	2.68
"Escitalopram treatment (10 mg/d) was administered for 8 consecutive weeks."	( Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder. He, Q; Liu, Y; Mei, Y; Shen, L; Yan, H; Yuan, Z; Zhang, J; Zhang, Y, )	0.92
"Citalopram-treated animals demonstrated no changes in a sucrose test and had elevated body mass."	( The differential effects of chronic imipramine or citalopram administration on physiological and behavioral outcomes in naïve mice. Anokhin, K; Anthony, DC; Dolgov, O; Kubatiev, A; Schroeter, C; Steinbusch, HM; Strekalova, T, 2013)	1.36
"Citalopram treatment had no significant effect on infarct formation or edema 3 days after stroke; however, citalopram-treated mice had better functional recovery than saline-treated controls 3 and 14 days after stroke in the adhesive removal test."	( Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. Espinera, AR; Gu, X; Ogle, ME; Wei, L, 2013)	2.55
"Citalopram treatment for up to 14 weeks."	( SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Drews, MS; Geske, JR; Mrazek, DA; Shiroma, PR, 2014)	2.07
"Escitalopram treatment does not provide an additional benefit either for achieving abstinence, or for the treatment of the cannabis withdrawal syndrome. "	( Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. Bar-Hamburger, R; Bloch, M; Bluvstein, I; Miller, H; Rapoport, E; Schreiber, S; Weinstein, AM, 2014)	1.39
"Citalopram treatment was associated with a larger increase in QTc interval than placebo (difference in week 3 QTc adjusting for baseline QTc: 18.1 ms [95% CI: 6.1, 30.1]; p = 0.004). "	( Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. Devanand, DP; Drye, LT; Frangakis, C; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Spragg, D; Weintraub, D; Yesavage, J, 2014)	2.13
"Escitalopram treatment decreased anxiety-related behaviours in stressed animals, by increasing the time spent in the central part of the arena with respect to saline treated stressed animals, without affecting exploratory related behaviours."	( Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression. Alboni, S; Benatti, C; Blom, JM; Brunello, N; Gandolfi, F; Mendlewicz, J; Tascedda, F, 2014)	1.22
"Citalopram treatment for 5 weeks abolished the increase in anxiety in both sexes, restored the intensity of expression of 5HT1AR in the mPFC in males and increased their expression in the mPFC and DRN in females."	( Sex dependent reduction by prenatal stress of the expression of 5HT1A receptors in the prefrontal cortex and CRF type 2 receptors in the raphe nucleus in rats: reversal by citalopram. Dosoretz-Abittan, L; Shoham, S; Weinstock, M; Zohar, I, 2015)	1.33
"Citalopram treatment changed these behaviors in lactating mice with further reductions in immobility during the FST and decreased marble burying."	( Enhanced responsiveness to selective serotonin reuptake inhibitors during lactation. Benoit, SC; Gregerson, KA; Horseman, ND; Jury, NJ; McCormick, BA, 2015)	1.14
"Escitalopram treatment was associated with beneficial effects compared to placebo and MTO on one-year outcomes on HAMD, MADRS and SOFAS (p-values<0.01)."	( Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015)	0.98
"Escitalopram-treated rats with >20% recovery in the sucrose consumption during the last 2 wk of treatment were defined as escitalopram responders."	( Chronic selective serotonin reuptake inhibition modulates endothelial dysfunction and oxidative state in rat chronic mild stress model of depression. Aalkjaer, C; Bouzinova, EV; Kravtsova, VV; Matchkov, VV; Wiborg, O, 2015)	0.98
"Citalopram-treated subjects showed significantly greater improvement in reappraisal ability than CBT-waitlisted subjects. "	( Emotional Reactivity and Regulation Following Citalopram Therapy in Children and Adolescents with Anxiety Disorders. Apter, A; Benaroya-Milshtein, N; Carthy, T; Valevski, A, 2017)	2.16
"Escitalopram treatment was significantly more efficacious in reducing and treating suicidal ideation than placebo treatment over a 24-week period."	( Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, H; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Yoon, JS, 2016)	1.32
"Escitalopram treatment significantly decreased PAI-1 levels in the serum, but not in the CSF."	( Plasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies. Chen, S; Jiang, H; Li, X; Liang, J; Lu, N; Yuan, Y; Yue, Y; Zhang, Z, 2016)	0.99
"Escitalopram treatment in patients with MNCD-AD or ScVMNCD led to an increase of plasma BDNF concentrations and as a result to a decrease of cognitive, depressive, and anxiety symptom severity."	( Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study. Cherednichenko, NV; Levada, OA; Trailin, AV; Troyan, AS, 2016)	0.99
"Escitalopram and placebo treatment have differential effects on delta-theta and alpha frequency oscillations."	( Escitalopram but not placebo modulates brain rhythmic oscillatory activity in the first week of treatment of Major Depressive Disorder. Cook, IA; Crump, C; Hunter, AM; Jain, FA; Leuchter, AF; Tartter, M, 2017)	1.73
"Escitalopram treatments reduced escape latency, elevated platform crossing times, improved CA1 neuronal damage, increased DA and 5-HT levels in hippocampal and cortical neurons, as well as elevated expression of 5-HT1AR mRNA (P < 0.05)."	( Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia. Guo, K; Pan, Q; Yin, G; Zhu, HX; Zi, XH, 2016)	0.99
"The citalopram treatment produced unexpected results in the FRL rats: 5-HT synthesis was elevated not only in most of the terminal areas, but also in the cell body areas, the DR and MR."	( Acute citalopram has different effects on regional 5-HT synthesis in FSL, FRL, and SDP rats: an autoradiographic evaluation. Diksic, M; Hasegawa, S; Kanemaru, K; Nishi, K, 2008)	1.31
"Escitalopram-treated patients (N = 459) were less likely to discontinue treatment (HR = 0.85, p = 0.012) or switch to another second-generation antidepressant (HR = 0.76, p = 0.006) compared to patients treated with other SSRI/SNRIs (N = 1517). "	( Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Ben-Hamadi, R; Erder, MH; Greenberg, P; Wu, E; Yang, E; Yu, A, 2008)	1.27
"Escitalopram treatment was effective at decreasing escape latency times in all ages tested. "	( Treatment with escitalopram but not desipramine decreases escape latency times in a learned helplessness model using juvenile rats. Anderson, JC; Bylund, DB; El Refaey, H; Happe, HK; Petty, F; Reed, AL, 2009)	1.41
"Escitalopram treatment did not affect the maximum pupil size, but it did statistically significantly decrease the relative amplitude of the pupil light reflex compared to the placebo; this effect was equal in both phenotype groups."	( Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Brosen, K; Damkier, P; Larsen, F; Nielsen, F; Noehr-Jensen, L; Sindrup, SH; Zwisler, ST, 2009)	1.19
"Citalopram treatment of MDD in older patients with heart failure is well-tolerated with low rates of side effects, but was not significantly more effective than placebo in the treatment of depression. "	( A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms. Alves, TC; Andrei, AM; da Silva Telles, RM; Fraguas, R; Iosifescu, DV; Rays, J; Wajngarten, M, 2009)	2.04
"Escitalopram treatment increased cAMP accumulation, and this seemed due to increased coupling between Galpha(s) and adenylyl cyclase."	( Chronic treatment with escitalopram but not R-citalopram translocates Galpha(s) from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound. Rasenick, MM; Zhang, L, 2010)	1.22
"Escitalopram treatment restored some but not all alterations observed in FSL rats after early-life stress."	( Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression. El Khoury, A; Gruber, SH; Mallei, A; Mathé, AA; Musazzi, L; Popoli, M; Racagni, G; Tardito, D, 2010)	0.92
"Citalopram-treated patients with DRI did significantly worse than placebo-treated patients with DRI. "	( Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression. Culang, ME; Devanand, DP; Keilp, JG; Roose, SP; Rutherford, BR; Sneed, JR, 2010)	1.8
"Escitalopram treatment was also associated with higher clinical response (73 vs."	( Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. Despiégel, N; Lam, RW; Lönn, SL, 2010)	1.64
"Escitalopram treatment did not effect the reduced levels of NR2B resulting from depression."	( Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model. Cure, MC; Demirdas, A; Eren, I; Kirbas, A; Sutcu, R; Yilmaz, M; Yilmaz, N, 2011)	1.22
"Citalopram treatment was effective in treating behavioral symptoms, with significant decreases in NPI total score (F[2, 28] = 6.644, p = 0.004), disinhibition (F[2, 28] = 4.030, p = 0.029), irritability (F[2, 28] = 7.497, p = 0.003) and depression (F[2, 28] = 3.467, p = 0.045) scores over the 6 weeks. "	( Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Black, SE; Cappell, J; Chow, T; Herrmann, N; Lanctôt, KL; Tang-Wai, DF, 2012)	1.82
"Escitalopram treatment is generally well tolerated by adolescents, but treatment-emergent agitation, suicidal behavior and manic symptoms should be closely monitored."	( Escitalopram for the treatment of major depressive disorder in youth. Ahn, JH; Patkar, AA, 2011)	1.65
"The citalopram-treated male mice showed altered sexual behavior, specifically a significant reduction in the number of intromissions preceding ejaculation compared with the vehicle-treated mice."	( Early-life citalopram-induced impairments in sexual behavior and the role of androgen receptor. Parhar, IS; Putteeraj, M; Soga, T; Song, KP; Wong, DW, 2012)	1.25
"Escitalopram treatment resulted in statistically significant improvements in PEG scores compared to placebo (mean treatment group difference at 8 weeks of -0.33; 95% CI -0.81 to 0.15; p=0.045)."	( Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Carpenter, JS; Cohen, L; Ensrud, KE; Freeman, EW; Joffe, H; LaCroix, AZ; Larson, J; Newton, KM; Reed, SD; Seguin, RA; Sternfeld, B, 2012)	1.31
"Citalopram-treated subjects showed a greater decrease in Hamilton Depression Rating Scale scores (significant at 2 weeks)."	( Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression. Baethge, C; Bschor, T; Erbe, S; Ising, M; Lewitzka, U; Ritter, D; Uhr, M; Winkelmann, P, 2013)	1.36
"Citalopram treatment was begun at 20 mg/day and increased every 2 weeks by 20 mg/day, absent marked response and limiting side effects, to 60 mg/day."	( Citalopram treatment of compulsive shopping: an open-label study. Bullock, KD; D'Andrea, V; Elliott, MA; Hartston, HJ; Koran, LM, 2002)	2.48
"Citalopram treatment may benefit patients with primary social anxiety disorder and comorbid major depression, and it should be further studied in controlled trials."	( Citalopram treatment of social anxiety disorder with comorbid major depression. Blanco, C; Campeas, R; Lewis-Fernandez, R; Liebowitz, MR; Lin, SH; Marshall, R; Sanchez-Lacay, JA; Schmidt, AB; Schneier, FR; Simpson, HB, 2003)	2.48
"Citalopram treatment did not increase risk of suicide, overdose, seizure, or arrhythmia."	( Overview of the safety of citalopram. Nemeroff, CB, 2003)	1.34
"Citalopram treated subjects significantly lowered systolic and diastolic blood pressures, while sertraline and placebo treated patients significantly lowered only systolic blood pressure reactivity to individualized trauma scripts."	( Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Burgin, C; Jones, DE; Masters, BK; Parker, DE; Potter-Kimball, R; Tucker, P; Wyatt, DB, 2003)	1.25
"Escitalopram-treated subjects had significantly lower depression ratings than those of placebo-treated patients."	( Escitalopram continuation treatment prevents relapse of depressive episodes. Bose, A; Rapaport, MH; Zheng, H, 2004)	1.6
"Citalopram treatment was well tolerated."	( A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Findling, RL; Gutierrez, MM; Heydorn, WE; Jin, J; Robb, AS; Wagner, KD, 2004)	1.31
"Citalopram treatment resulted in significant deactivation (p = 0.001) for the entire group in the superior (t = 4.78) and anterior (t = 4.04) cingulate, right thalamus (t = 4.66) and left hippocampus (t = 3.96). "	( Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. Carey, PD; Harvey, BH; Niehaus, DJ; Seedat, S; Stein, DJ; van der Linden, G; van Heerden, BB; Warwick, J, 2004)	1.98
"Escitalopram treatment was well tolerated and associated with robust response rates in a broadly representative population of depressed outpatients."	( Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Bose, A; Rush, AJ, 2005)	1.61
"Citalopram pretreatment enhanced the right BA47 responses to the No-go condition, but attenuated this response to aversive faces."	( The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Anderson, IM; Deakin, JF; Del-Ben, CM; Delvai, NA; Dolan, M; Elliott, R; McKie, S; Williams, SR, 2005)	1.41
"Citalopram pretreatment prevented the reduction of affiliation behavior and reduced stereotypies after weaning, and both citalopram and reboxetine abolished the increase in activity seen in control monkeys after weaning, but no statistically significant differences were found between groups."	( Psychopharmacology of maternal separation anxiety in vervet monkeys. Brand, L; Daniels, W; Hugo, C; Marais, L; Stein, DJ; Viljoen, F, 2006)	1.06
"Citalopram treatment resulted in elevated behavioural activity in the PCS rats during night, indicative of an improved entrainment to the light-dark cycle, whereas no behavioural effect could be observed in sham rats."	( Sustained citalopram treatment in experimental hepatic encephalopathy: effects on entrainment to the light-dark cycle and melatonin. Ahlner, J; Apelqvist, G; Bengtsson, F; Carlsson, B; Kugelberg, FC, 2006)	1.46
"Escitalopram-treated patients were associated with 14.4% higher first-line treatment success and significantly lower discontinuation rates due to adverse events than were those treated with paroxetine. "	( Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Baldwin, DS; Despiegel, N; Drost, PB; Hemels, ME; Jørgensen, TR; Stein, DJ, 2006)	1.34
"Escitalopram treatment for 12 weeks led to significant improvement of trichotillomania in some patients in this small open-label trial."	( Escitalopram treatment of trichotillomania. Connor, KM; Foust, MS; Gadde, KM; Ryan Wagner, H, 2007)	1.62
"Escitalopram treatment (mean final daily dosage: 12.4+/-5.0 mg) led to a significant reduction (baseline versus end of study) of sick leave (11.0+/-12.8 days versus 5.4+/-11.0 days; p<0.001). "	( Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. Kasper, S; Moser, U; Pjrek, E; Winkler, D, 2007)	1.78
"Citalopram pretreatment blocked MDMA-related reductions in aggressive and exploratory behavior measured in the social interaction and hole-board tests respectively."	( Dissociation of the neurochemical and behavioral toxicology of MDMA ('Ecstasy') by citalopram. Ali, SF; Fraiman, JB; Meyer, JS; Owens, CB; Piper, BJ, 2008)	1.29
"Citalopram treated subjects showed a significant reduction in cocaine-positive urines during treatment compared to placebo treated subjects."	( Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Grabowski, J; Green, CM; Lai, LY; Moeller, FG; Reist, C; Schmitz, JM; Steinberg, JL; Swann, AC, 2007)	2.5
"In citalopram treated subjects, basal glucose and lactate concentrations were higher compared with controls or with the trimipramine treated group."	( Metabolism in adipose tissue in response to citalopram and trimipramine treatment--an in situ microdialysis study. Adler, G; Alt, A; Ditschuneit, HH; Flechtner-Mors, M; Jenkinson, CP, 2008)	1.12
"Escitalopram treatment was associated with improvement on all assessed domains that impair quality of life in panic disorder."	( Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Andersen, HF; Baldwin, DS; Bandelow, B; Dolberg, OT; Stein, DJ, 2007)	1.14
"Only citalopram treatment led to a slight MABP-decreasing effect."	( Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits. Csete, K; Papp, JG; Sas, K; Sztriha, L; Vécseil, L; Vezekényi, Z, 2007)	1.18
"Escitalopram treatment was not significantly different from placebo treatment on the primary efficacy measure, change from baseline to week 12 in MADRS. "	( Escitalopram in the acute treatment of depressed patients aged 60 years or older. Bose, A; Gandhi, C; Li, D, 2008)	1.79
"Citalopram treatment had no substantial effect on cardiovascular (heart rate and blood pressure) or hormonal (cortisol, prolactin and growth hormone) responses to CCK-4."	( Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. Aluoja, A; Bradwejn, J; Podar, T; Shlik, J; Vasar, E; Vasar, V, 1997)	1.41
"Citalopram treatment did not alter the self-rated sedation response to pregnanolone compared to vehicle in either study cycle."	( Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Bäckström, T; Sundström, I, 1998)	2.46
"Citalopram treatment partially reversed p-CPA-induced downregulation of [3H]-ketanserin binding in rat whole neocortex."	( [3H]-ketanserin binding and elevated plus-maze behavior after chronic antidepressant treatment in DSP-4 and P-CPA pretreated rats: evidence for partial involvement of 5-HT2A receptors. Allikmets, L; Matto, V; Skrebuhhova, T, 1999)	1.02
"Citalopram treatment did not alter Bmax and Kd for platelet [3H]paroxetine-binding."	( The effect of citalopram treatment on platelet serotonin function in panic disorders. Aberg-Wistedt, A; Neuger, J; Sinner, B; Stain-Malmgren, R; Wistedt, B, 2000)	1.39
"The citalopram-treated patients in whom AAM developed were significantly older than those in whom it did not (about 10 years, P < 0.001); gender distribution was similar."	( Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients? Barak, Y; Kimhi, R; Weizman, R, 2000)	0.79
"Citalopram treatment had no effect on the pharmacokinetic characteristics of theophylline."	( Effect of citalopram on plasma levels of oral theophylline. Larsen, F; Møller, SE; Pitsiu, M; Rolan, PE, 2000)	1.43
"Citalopram treatment had no effect on serum insulin levels in 15-week-old mice."	( Effect of serotonin reuptake inhibitor on syndrome development in obese hyperglycemic mice (Umeå ob/ob). Lindström, P; Rooth, P; Thrybom, T, 2001)	1.03
"Citalopram treatment also significantly improved depressive symptomatology compared with placebo; however, escitalopram, 10 mg/day, was at least as effective as citalopram, 40 mg/day, at endpoint."	( Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Bose, A; Burke, WJ; Gergel, I, 2002)	1.3
"Treatment with Citalopram appears to have little effect on Aβ generation in fADPSEN1 cells, but our findings suggest that treatment can significantly increase non-amyloidogenic AβPP processing and reduce oxidative stress."	( The effect of citalopram treatment on amyloid-β precursor protein processing and oxidative stress in human hNSC-derived neurons. Aldred, S; Crowe, JA; Dunleavy, C; Elsworthy, RJ; Fisher, E; Hill, EJ; King, MC; Ludlam, A; Parri, HR, 2022)	1.42
"Rats treated with Escitalopram (10 mg/kg) daily for 7 days followed by apomorphine injections (1mg/kg) for next 7 days."	( Depletion of apomorphine induced behavioral sensitization in rats treated with escitalopram. Farhan, M; Parveen, M, 2019)	1.05
"Treatment with citalopram but not desipramine after the pretest swim significantly increased pCREB immunoreactivity only in the dBNST."	( Desipramine and citalopram attenuate pretest swim-induced increases in prodynorphin immunoreactivity in the dorsal bed nucleus of the stria terminalis and the lateral division of the central nucleus of the amygdala in the forced swimming test. Cho, JH; Cho, YH; Choi, SH; Chung, S; Kim, DH; Kim, HJ; Shin, KH, 2014)	1.09
"Treatment with citalopram for agitation in AD needs to be at least 9 weeks in duration to allow sufficient time for full response. "	( Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2015)	1.09
"Treatment with citalopram versus saline was applied via osmotic pump after coronary artery ligation. "	( Early citalopram treatment increases mortality due to left ventricular rupture in mice after myocardial infarction. Ertl, G; Frantz, S; Frey, A; Hofmann, U; Lehmann, M; Lesch, KP; Mathes, D; Pachel, C; Popp, S; Saxon, VM, 2016)	1.27
"Treatment with citalopram (5 and 10 mg/kg, ip) and desipramine (10 and 20 mg/kg, ip) for 5 days significantly improved locomotor activity, anti-anxiety like behavior in all paradigms tasks (mirror chamber, plus maze, zero maze) as compared to control (72 hr sleep-deprived)."	( Possible role of citalopram and desipramine against sleep deprivation-induced anxiety like-behavior alterations and oxidative damage in mice. Garg, R; Kumar, A, 2008)	1.03
"Open treatment with citalopram followed by up to 3 sequential next-step treatments."	( Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Fava, M; Goldberg, JF; Ostacher, M; Perlis, RH; Rush, AJ; Trivedi, MH; Uher, R, 2011)	0.69
"Treatment with citalopram abolished the abnormal amygdala responses to sad faces in currently depressed patients but did not alter responses to fearful faces."	( Increased amygdala responses to sad but not fearful faces in major depression: relation to mood state and pharmacological treatment. Anderson, IM; Arnone, D; Deakin, JF; Downey, D; Elliott, R; Juhasz, G; McKie, S; Thomas, EJ; Williams, SR, 2012)	0.72
"Treatment with citalopram rescued behavior in the forced swim test in hamsters housed in dLAN, but had no effect on hamsters housed in LD."	( Chronic citalopram treatment ameliorates depressive behavior associated with light at night. Bedrosian, TA; Nelson, RJ; Weil, ZM, 2012)	1.15
"Pretreatment with citalopram, a selective 5-HT reuptake inhibitor (2.5 mg kg(-1) i.p.), 40 min prior to CO2 exposure, in Mecp2(-/y) mice resulted in an improvement in CO2 chemosensitivity to wild-type levels."	( Increasing brain serotonin corrects CO2 chemosensitivity in methyl-CpG-binding protein 2 (Mecp2)-deficient mice. Abdala, AP; Bissonnette, JM; Knopp, SJ; Paton, JF; Toward, MA, 2013)	0.71
"Treatment with citalopram resulted in a gradual decline of anxiety symptoms."	( Alexithymia in Noonan syndrome. Egger, JI; Hendrikx, JL; MDoorakkers, MC; Tuinier, S; Van der Burgt, I; Verhoeven, WM, 2004)	0.66
"Treatment with citalopram resulted in significant deactivation in the left medial temporal cortex irrespective of clinical response. "	( Single photon emission computed tomography in posttraumatic stress disorder before and after treatment with a selective serotonin reuptake inhibitor. Hugo, C; Seedat, S; Stein, DJ; van Heerden, B; Van Kradenburg, J; Warwick, J; Zungu-Dirwayi, N, 2004)	0.68
"Treatment with citalopram led to an increase in BDNF mRNA in only one hippocampal region (CA2) after short-term (2 days) treatment, and when combined with exercise, increased BDNF mRNA in the CA4 and dentate gyrus after 2 weeks."	( Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Alejandre, H; Chen, MJ; Garcia, C; Ivy, AS; Russo-Neustadt, AA, 2004)	0.88
"Treatment with citalopram was effective in reversing the behavioral deficits induced by bulbectomy, but did not protect against neurodegeneration."	( Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy. Jarosik, J; Legutko, B; Unsicker, K; von Bohlen Und Halbach, O, 2007)	0.68
"Treatment with citalopram was associated with greater increase in tNO over 12 weeks compared to placebo (P = 0.005). "	( Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. Atar, D; Frasure-Smith, N; Laliberté, MA; Lespérance, F; Malinin, AI; Serebruany, VL; van Zyl, LT, 2009)	0.92
"Treatment with citalopram for 12 weeks in depressed CAD patients is associated with enhanced production of nitric oxide despite the co-administration of commonly prescribed anti-platelet regimens including aspirin and clopidogrel. "	( Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. Atar, D; Frasure-Smith, N; Laliberté, MA; Lespérance, F; Malinin, AI; Serebruany, VL; van Zyl, LT, 2009)	0.92
"The treatment with citalopram or with fluoxetine was confirmed to delay ejaculation, but was significant only for citalopram. "	( The effects of citalopram and fluoxetine on sexual behavior in healthy men: evidence of delayed ejaculation and unaffected sexual desire. A randomized, placebo-controlled, double-blind, double-dummy, parallel group study. Balestrieri, A; Bettica, P; Carani, C; Granata, AR; Madeo, B; Milleri, S; Rochira, V, 2008)	1.03
"Treatment with citalopram by the intravenous or oral route was most successful in anxious or inhibitory depressions, while atypical forms with hypochondriac or obsedant features responded better to infusions."	( [Citalopram (Seropram) in tablet and infusion forms in the treatment of major depression]. Buresová, A; Cesková, E; Kamenická, V; Obrovská, V; Svestka, J; Synek, O, 1993)	1.54
"Treatment with citalopram at 20 or 30 mg, 40 or 60 mg and clomipramine were significantly superior to placebo, judged by the number of patients free of panic attacks in the week prior to the final assessment. "	( The effect of citalopram in panic disorder. Koponen, HJ; Lepola, U; Pedersen, T; Pedersen, V; Wade, AG, 1997)	1.01
"Pretreatment with citalopram at a dose of 1.0 mg/kg shifted the DOM dose response relationship to the left."	( Potentiation of DOM-induced stimulus control by fluoxetine and citalopram: role of pharmacokinetics. Doat, MM; Eckler, JR; Rabin, RA; Winter, JC, 2002)	0.88
"Pretreatment with citalopram (40 mg/kg i.p.) and clomipramine (20 mg/kg i.p.) protected against neuronal destruction of hippocampal CA1 pyramidal cells following 5 min of forebrain ischemia."	( Protective effects of serotonin reuptake inhibitors, citalopram and clomipramine, against hippocampal CA1 neuronal damage following transient ischemia in the gerbil. Kato, H; Kogure, K; Nakata, N, 1992)	0.86

Excerpt	Reference	Relevance
"Orthostatic hypotension, the clinically most important side effect in treatment with tricyclic antidepressants, was investigated in a double-blind study with clomipramine and the selective serotonin reuptake inhibitor citalopram given for 5 weeks."	( Orthostatic side effects of clomipramine and citalopram during treatment for depression. Christensen, P; Gram, LF; Kragh-Sørensen, P; Pedersen, OL; Thomsen, HY, 1985)	0.71
" Spontaneous adverse event reports arising from clinical use have confirmed the safety profile defined during the trials programme."	( The safety and tolerability of citalopram. Muldoon, C, 1996)	0.58
" It is thus suggested that otherwise generally safe central nervous system 5-HT-active drugs may represent a potential hazard in patients with liver failure with or without PSE."	( Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency. Apelqvist, G; Bengtsson, F; Bergqvist, PB; Hjorth, S; Wikell, C, 1997)	0.7
"English-language articles identified through MEDLINE (1985 through 1997), and case reports from the American Association of Poison Control Centers (AAPCC) (1987 through 1996) and United States Food and Drug Administration (FDA) adverse event database (through 1997) that describe findings of fatal and nonfatal overdoses involving SSRIs alone or in combination with other ingestants were reviewed."	( SSRI safety in overdose. Barbey, JT; Roose, SP, 1998)	0.3
" At very high doses (> 75 times the common daily dose), more serious adverse events, including seizures, electrocardiogram (ECG) changes, and decreased consciousness may occur."	( SSRI safety in overdose. Barbey, JT; Roose, SP, 1998)	0.3
" Both treatments were well tolerated with a relatively low incidence of adverse events."	( A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Augusto De Mendonça Lima, C; Eglin, M; Godderis, J; Karlsson, I; Nygaard, H; Simányi, M; Taal, M, 2000)	0.54
"The article focuses on adverse drug reactions (ADR) to selective serotonin reuptake inhibitors (SSRI) concerning libido and sexual behaviour: cases of disinhibition of libido observed at the Psychiatric Hospital of Kilchberg near Zurich are described."	( Disinhibition of libido: an adverse effect of SSRI? Erazo, N; Greil, W; Grohmann, R; Horvath, A; Sassim, N, 2001)	0.31
"Selective serotonin reuptake inhibitors are widely used in the treatment of depressive and obsessive-compulsive disorders because of their low-frequency adverse effects."	( [Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases]. Fiszenson, F; Grob, JJ; Jean Pastor, MJ; Jreissati, M; Richard, MA, )	0.13
"Adverse cutaneous effects of selective serotonin reuptake inhibitors are rare but the knowledge of these reactions is important because toxic epidermal necrolysis and Stevens-Johnson syndrome had been reported during fluoxetine (Prozac(R)) and fluvoxamine (Floxyfral(R)) treatment."	( [Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases]. Fiszenson, F; Grob, JJ; Jean Pastor, MJ; Jreissati, M; Richard, MA, )	0.13
" The age-related differences in the side effect profile may be attributable to altered sensitivity of the serotonergic system."	( Age-related differences in the side effect profile of citalopram. Barak, Y; Levy, D; Swartz, M; Weizman, R, 2003)	0.57
" The available data suggest that citalopram 20-60 mg once daily is safe for patients with depression."	( Overview of the safety of citalopram. Nemeroff, CB, 2003)	0.9
" However, subtle differences in improvements in PTSD symptom clusters, physiologic reactivity, and reported adverse events were identified."	( Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Burgin, C; Jones, DE; Masters, BK; Parker, DE; Potter-Kimball, R; Tucker, P; Wyatt, DB, 2003)	0.53
"The purpose of this study was to determine the frequency of infantile adverse events from exposure through breast-feeding to maternal citalopram therapy."	( Frequency of infant adverse events that are associated with citalopram use during breast-feeding. Ito, S; Lee, A; Woo, J, 2004)	0.77
" Data collection included infant feeding method, medication use, and adverse events."	( Frequency of infant adverse events that are associated with citalopram use during breast-feeding. Ito, S; Lee, A; Woo, J, 2004)	0.57
"There was no statistically significant difference in the rate of adverse events in the three groups (3/31 events, 0/12 events, and 1/31 events in groups 1, 2, and 3, respectively)."	( Frequency of infant adverse events that are associated with citalopram use during breast-feeding. Ito, S; Lee, A; Woo, J, 2004)	0.57
" The reported incidence of treatment-emergent adverse events was somewhat lower with escitalopram than with duloxetine, with the possible exception of sexual dysfunction."	( Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. Hirschfeld, RM; Vornik, LA, 2004)	0.79
"Mirtazapine and nefazadone appear safe in overdose and were associated with minimal features of neurological or cardiovascular toxicity."	( Comparative toxicity of citalopram and the newer antidepressants after overdose. Bateman, DN; Dhaun, N; Good, AM; Kelly, CA; Laing, WJ; Strachan, FE, 2004)	0.63
" The efficacy of two treatments was assessed every 2 weeks during treatment, at the end of study and in 3- and 6-month follow-up after cessation of treatment, using responses to IIEF, IVELT evaluation, mean intercourse satisfaction domain, mean weekly coitus episodes and adverse drug effects."	( Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. Hosseini, SY; Safarinejad, MR, )	0.44
" Their use is frequently associated with dose-limiting adverse effects."	( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I, )	0.13
" For detecting side effect liability (ataxia, sedation, impairment of voluntary motor functions), (1) the rota-rod test, (2) measurement of spontaneous motility, (3) the weight-lifting test and (4) the thiopental sleep test were used."	( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I, )	0.13
"Therapeutic indices calculated from the results of these in vivo experiments for the clinically used muscle relaxants are in agreement with their adverse effect profiles in humans."	( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I, )	0.13
" The safety and tolerability of hypericum extract in comparison to citalopram and placebo was investigated on the basis of CGI, the occurrence of adverse events and the investigation of laboratory parameters and vital signs."	( Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Gastpar, M; Singer, A; Zeller, K, 2006)	0.79
" Significantly more adverse events with "certain", "probable" or "possible" relation to study medication were documented in the citalopram group (hypericum: 17."	( Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Gastpar, M; Singer, A; Zeller, K, 2006)	0.76
" In all, 57 patients (33%) reported at least 1 adverse event, and 7 patients (4%) were withdrawn due to an adverse event."	( Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder. Arbus, C; Schmitt, L; Tonnoir, B, 2006)	0.62
" Adverse events occurring in 10% of patients or more with adjunctive placebo or aripiprazole were akathisia (4."	( The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008)	0.35
" In 9% of patients, RLS was recorded as a side effect related to the administration of AD."	( Restless legs syndrome as side effect of second generation antidepressants. Gallwitz, T; Kirch, MH; Messer, T; Rottach, KG; Schaner, BM; Teufel, LM; Zivotofsky, AZ, 2008)	0.35
" Therefore, the issue of how safe the combination of these 2 treatment modalities is warrants investigation."	( The safety of the electroconvulsive therapy-escitalopram combination. Florakis, A; Markatou, M; Masdrakis, VG; Oulis, P; Papadimitriou, GN; Valamoutopoulos, T, 2008)	0.6
"The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects."	( Adverse effects of propafenone after long-term therapy with the addition of citalopram. Garcia, A, 2008)	0.79
"An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects."	( Adverse effects of propafenone after long-term therapy with the addition of citalopram. Garcia, A, 2008)	0.58
"This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease."	( Adverse effects of propafenone after long-term therapy with the addition of citalopram. Garcia, A, 2008)	0.81
"Escitalopram seems to be less toxic than citalopram after an acute overdose; seizures and tremors were more common with citalopram."	( Comparison of toxicity of acute overdoses with citalopram and escitalopram. Clark, RF; Hayes, BD; Klein-Schwartz, W; Miloradovich, JE; Muller, AA, 2010)	1.34
"The authors sought to identify predictors of self-harm adverse events in treatment-resistant, depressed adolescents during the first 12 weeks of treatment."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
", suicidal and non-suicidal self-injury adverse events were assessed by spontaneous report for the first 181 participants, and by systematic weekly assessment for the last 153 participants."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
"2%), but not serious adverse events (8."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
"Since predictors of suicidal adverse events also predict poor response to treatment, and many of these events occurred early in treatment, improving the speed of response to depression, by targeting of family conflict, suicidal ideation, and drug use may help to reduce their incidence."	( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)	0.35
" Its use has been widely considered both safe and cost effective."	( Parathyroid surgery and methylene blue: a review with guidelines for safe intraoperative use. Delfiner, J; Fernandez, J; Pollack, A; Pollack, G, 2009)	0.35
" It has been shown in many studies to be an effective and safe antidepressant for treating major depressive disorder (MDD)."	( Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Du, B; Fang, MS; Li, LH; Ou, JJ; Shi, JG; Wu, RR; Xie, SP; Xun, GL; Yuan, XQ; Zhang, HG; Zhao, JP, 2011)	0.67
" The adverse events (AEs) were recorded by the investigator."	( Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Du, B; Fang, MS; Li, LH; Ou, JJ; Shi, JG; Wu, RR; Xie, SP; Xun, GL; Yuan, XQ; Zhang, HG; Zhao, JP, 2011)	0.67
"The study suggests that escitalopram 10-20 mg/d are as effective and safe as citalopram 20-40 mg/d in the short-term treatment for Chinese MDD patients."	( Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Du, B; Fang, MS; Li, LH; Ou, JJ; Shi, JG; Wu, RR; Xie, SP; Xun, GL; Yuan, XQ; Zhang, HG; Zhao, JP, 2011)	0.97
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" Twelve (20%) patients had adverse events leading to discontinuation."	( Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study. Crawford, GM; Wade, AG; Yellowlees, A, 2011)	0.64
"An antidepressant's tolerability, generally captured as the frequency and severity of adverse events (AEs), is often as important as its efficacy in determining treatment success."	( Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Ben-Hamadi, R; Dworak, H; Erder, MH; Ramakrishnan, K; Signorovitch, J; Wu, EQ; Yu, AP, 2011)	0.6
"The serotonin toxicity (ST) is a potentially life-threatening adverse drug reaction results from therapeutic drug use, intentional self-poisoning, or inadvertent interactions between drugs."	( Serotonin toxicity: a short review of the literature and two case reports involving citalopram. Bruno, G; Canevelli, M; Lenzi, GL; Piacentini, E; Pietracupa, S; Talarico, G; Tosto, G, 2011)	0.59
"There is a potential risk that 5-HT(1A) receptor blockade combined with blockade of the 5-HT transporter by an SSRI may cause a toxic increase in 5-HT within the synapse, sparking concern for 'serotonin syndrome', a rare but potentially life threatening condition."	( Concomitant blockade of 5-HT(1A) receptor and 5-HT transporter: use of the Hunter Serotonin toxicity criteria in a clinical pharmacology study. Chalon, S; Connell, J; Parks, V; Philipp, AW; Plotka, A; Raje, S; Schechter, LE, 2012)	0.38
"The objective was to assess differences in adverse events between major depressive patients augmented with a second medication and patients switched to an alternative monotherapy after failing first-step treatment with citalopram."	( Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Stürmer, T, )	0.32
"Incidence proportions of any adverse event and specific adverse events were similar between the augment and switch groups."	( Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Stürmer, T, )	0.13
"After adjusting for selection bias inherent in the STAR*D comparison of augment with switch, clinically meaningful differences in the adverse event profiles between these treatment strategies were not observed."	( Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Stürmer, T, )	0.13
"To determine whether distressing adverse events (DAEs) experienced during initial antidepressant treatment are associated with subsequent DAEs after switching to a second antidepressant."	( Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an a Castillo, WC; Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Katz, AJ; Stürmer, T, 2012)	0.57
" Regression models were used to compare the risk of adverse events during second-step treatment between those who reported similar adverse events during first-step treatment and those who did not, while controlling for potential confounders."	( Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an a Castillo, WC; Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Katz, AJ; Stürmer, T, 2012)	0.57
"Patients who experienced DAEs with initial antidepressant treatment were likely to report similar adverse events after switching to an alternative antidepressant, even when subsequent treatment is from a different class of antidepressants."	( Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an a Castillo, WC; Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Katz, AJ; Stürmer, T, 2012)	0.57
"The physicochemical properties of racemates and stereoisomers of medicines can differ significantly, and this may affect the side-effect profile in addition to the pharmacokinetics and intended pharmacology."	( Safety profile of enantiomers vs. racemic mixtures: it's the same? Bagheri, H; Caillet, C; Chauvelot-Moachon, L; Montastruc, JL, 2012)	0.38
"This is a study to investigate the profile of adverse drug reactions of racemic and enantiomeric forms of drugs."	( Safety profile of enantiomers vs. racemic mixtures: it's the same? Bagheri, H; Caillet, C; Chauvelot-Moachon, L; Montastruc, JL, 2012)	0.38
" A case-noncase approach was used to measure the disproportionality of combination between adverse drug reaction (ADR) and exposure to drug."	( Safety profile of enantiomers vs. racemic mixtures: it's the same? Bagheri, H; Caillet, C; Chauvelot-Moachon, L; Montastruc, JL, 2012)	0.38
" While a range of effective antidepressants are now available, failure and relapse rates remain substantial, with intolerable side effect burden the most commonly cited reason for discontinuation."	( Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Åberg, K; Adkins, DE; Bukszár, J; Clark, SL; Hettema, JM; McClay, JL; Souza, RP; van den Oord, EJ, 2012)	0.65
" After 12 months, 16 and 13 major adverse events (death, recurrent ACS, or acute revascularization) were recorded in the escitalopram and placebo group, respectively (NS)."	( Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. Birket-Smith, M; Hanash, JA; Hansen, BH; Hansen, JF; Nielsen, OW; Rasmussen, A, 2012)	0.86
"One-year escitalopram treatment was safe and well tolerated in patients with recent ACS."	( Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial. Birket-Smith, M; Hanash, JA; Hansen, BH; Hansen, JF; Nielsen, OW; Rasmussen, A, 2012)	1.04
"Published data concerning the cardiac effects of citalopram were ascertained, and clinical data were considered separately between adverse effects arising from therapeutic use versus toxicity in the setting of intentional overdose."	( Citalopram and cardiac toxicity. Cooke, MJ; Waring, WS, 2013)	2.09
"Although some cases of MMs have been reported after maternal exposure to ESC during early pregnancy, the rate of these adverse events is substantially in the range of those reported in unexposed women."	( The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review. Bellantuono, C; Bozzi, F; Catena-Dell'Osso, M; Orsolini, L, 2012)	0.72
"The available data seem to support the notion that ESC might be considered safe during pregnancy, in particular as far as MMs is concerned."	( The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review. Bellantuono, C; Bozzi, F; Catena-Dell'Osso, M; Orsolini, L, 2012)	0.72
"To evaluate the risk factors of psychiatric adverse events associated with PEG interferon and ribavirin treatment for chronic hepatitis C and assess the efficacy of escitalopram intervention for these adverse effects."	( [Escitalopram for intervention of psychiatric adverse events during peginterferon-alfa-2a and ribavirin treatment for chronic hepatitis C]. Pan, J; Qi, M; Su, M; Zhang, H; Zhou, B, 2013)	1.21
" Assessment of cardiovascular safety included heart rate, blood pressure (BP), treatment-emergent adverse events (TEAEs) and electrocardiograms (ECGs)."	( The cardiovascular safety profile of escitalopram. Kennedy, SH; Larsen, KG; Reines, E; Thase, ME, 2013)	0.66
" Side effects were assessed using the Udvalg fur Kliniske Undersøgelser side-effect rating scale."	( Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial. Dixon, D; Doré, PM; Garfield, LD; Kristjansson, SD; Lenze, EJ; Lotrich, FE; Nowotny, P; Pollock, BG, 2014)	0.4
"Four significant drug-placebo side-effect differences were found: increased duration of sleep, dry mouth, diarrhea, and diminished sexual desire."	( Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial. Dixon, D; Doré, PM; Garfield, LD; Kristjansson, SD; Lenze, EJ; Lotrich, FE; Nowotny, P; Pollock, BG, 2014)	0.4
"2% (53/88) receiving lisdexamfetamine dimesylate had ≥ 1 treatment-emergent adverse event, the most frequent with lisdexamfetamine dimesylate being dry mouth and headache (both 11."	( A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. Cutler, AJ; Gao, J; Geibel, BB; Lasser, R; Patkar, AA; Richards, C; Sambunaris, A; Trivedi, MH, 2013)	0.58
" On the contrary, no short-term adverse effects in newborns were reported in the 5 studies evaluating the safety of ESC during breastfeeding."	( [The safety profile of escitalopram in pregnancy and breastfeeding]. Bellantuono, C; Bozzi, F; Orsolini, L, )	0.43
"Data coming from published studies and from our cases seem to support the notion that ESC might be considered safe during pregnancy and breastfeeding, particularly as far as MM is concerned."	( [The safety profile of escitalopram in pregnancy and breastfeeding]. Bellantuono, C; Bozzi, F; Orsolini, L, )	0.43
" Adverse effects are common, occur early on in treatment and are reported to be one of the main reasons for discontinuation of antidepressant treatment."	( Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Cowen, P; Crawford, AA; Lewis, G; Lewis, S; Nutt, D; O'Donovan, MC; Peters, TJ; Wiles, N, 2014)	0.4
"To investigate the association between adverse effects occurring in the first 2 weeks of antidepressant treatment and discontinuation by 6 weeks as the outcome."	( Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Cowen, P; Crawford, AA; Lewis, G; Lewis, S; Nutt, D; O'Donovan, MC; Peters, TJ; Wiles, N, 2014)	0.4
"Individuals randomised to reboxetine reported a greater number of adverse effects and were more likely to stop treatment than individuals receiving citalopram."	( Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Cowen, P; Crawford, AA; Lewis, G; Lewis, S; Nutt, D; O'Donovan, MC; Peters, TJ; Wiles, N, 2014)	0.6
"The majority of adverse effects were not individually associated with discontinuation from antidepressant treatment."	( Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Cowen, P; Crawford, AA; Lewis, G; Lewis, S; Nutt, D; O'Donovan, MC; Peters, TJ; Wiles, N, 2014)	0.4
" Safety and tolerability was evaluated by changes in routine laboratory parameters, vital signs, and adverse events reported by the subject and/or observed by the clinician."	( Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Chakraborty, S; Chatterjee, S; Ghosal, MK; Gupta, A; Maity, N; Sil, A, )	0.4
"The results suggest that compounds that indirectly facilitate 5-HT1 A receptor activation, such as citalopram, may be more effective therapeutics than direct 5-HT1 A receptor agonists because they exhibit similar anti-dyskinesia efficacy, while possessing a reduced side effect profile."	( Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats. Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N, 2015)	0.63
" The most common adverse events (≥5% of vilazodone patients, twice the rate of placebo) were diarrhea, nausea, vomiting (vilazodone 40 mg/day only), and insomnia."	( Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Chen, D; Gommoll, C; Khan, A; Mathews, M; Nunez, R, 2015)	0.42
"P450 genotype did not predict total side effect burden (nortriptyline: n = 251, p = 0."	( Exploring the role of drug-metabolising enzymes in antidepressant side effects. Aitchison, KJ; Craig, IW; Dernovšek, MZ; Dobson, RJ; Farmer, AE; Hauser, J; Henigsberg, N; Hodgson, K; Maier, W; McGuffin, P; Mors, O; Placentino, A; Rietschel, M; Souery, D; Tansey, KE; Uher, R, 2015)	0.42
"It has been suggested that the efficacy of antidepressants has been overestimated in clinical trials owing to unblinding of drug treatments by adverse events."	( Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K, 2016)	0.43
"To investigate the association between adverse events and the efficacy of selective serotonin reuptake inhibitors (SSRIs)."	( Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K, 2016)	0.43
" Reporting of adverse events was used as an indicator of tolerability."	( Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K, 2016)	0.43
"Our results do not support, but also do not unequivocally disprove, the hypothesis that adverse events lead to an overestimation of the effect of SSRIs over placebo."	( Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K, 2016)	0.43
"Even though citalopram is commonly used in psychiatry, there are several reports on its toxic effects."	( In vitro and in vivo evaluation of the mechanisms of citalopram-induced hepatotoxicity. Ahmadian, E; Babaei, H; Eftekhari, A; Eghbal, MA; Fard, JK; Mohammadnejad, D; Nayebi, AM, 2017)	1.08
" We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs)."	( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016)	0.43
" Adverse effects and all-cause/specific-cause discontinuation were similar across all comparisons."	( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016)	0.43
"Lamotrigine was superior to placebo in improving unipolar and bipolar depressive symptoms, without causing more frequent adverse effects/discontinuations."	( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016)	0.43
" Nevertheless, there is a dearth of information regarding their potential adverse effects on non-target organisms."	( Multi-biomarker investigation to assess toxicity induced by two antidepressants on Dreissena polymorpha. Binelli, A; Catani, M; Cavazzini, A; de Oliveira, LF; Della Torre, C; Guzzinati, R; Magni, S; Parolini, M, 2017)	0.46
" Quality of life was assessed by Short Form-12 (SF-12) and safety by adverse events, laboratory investigations, vital signs and physical findings."	( Efficacy and safety of escitalopram in treatment of severe depression in Chinese population. Cuili, H; Dong, J; Fang, M; Fang, Y; Li, J; Rui, Q; Shen, X; Si, T; Wang, G; Wang, J; Yang, F; Zhuo, J, 2017)	0.76
" Therefore, we aimed to clarify the toxic effects of CTL on the reproductive system of male rats."	( Citalopram Induces Reproductive Toxicity in Male Rats. Atli, O; Baysal, M; Ilgin, S; Kilic, G; Kilic, V; Korkut, B; Ucarcan, S, 2017)	1.9
" Participants were surveilled for adverse health outcomes."	( Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia. Chiriac, IM; Ettorre, E; Viscogliosi, G, 2017)	0.77
"Citalopram resulted in similar efficacy and less adverse outcomes when compared to 2 atypical antipsychotics for treatment of agitation in NH residents with AD."	( Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia. Chiriac, IM; Ettorre, E; Viscogliosi, G, 2017)	2.21
" Side effect data were available at weeks 2-4, 6 and 9 in three samples."	( Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. Aitchison, KJ; Biernacka, JM; Breen, G; Craig, I; Curtis, C; Fabbri, C; Farmer, A; Hauser, J; Henigsberg, N; Jenkins, G; Lee, SH; Lewis, CM; Lewis, G; Maier, W; McGuffin, P; Mors, O; Newhouse, S; O'Donovan, M; Patel, H; Perlis, RH; Placentino, A; Rietschel, M; Schruers, K; Souery, D; Tansey, KE; Uher, R; Weinshilboum, RM, 2018)	0.48
" Agomelatine was well-tolerated, with a lower incidence of adverse events than escitalopram."	( 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder. Ahokas, A; Bauer, M; Bitter, I; de Bodinat, C; Hӧschl, C; Jarema, M; Khoo, JP; Matharan, S; Mosolov, SN; Olivier, V; Picarel-Blanchot, F; Stein, DJ; Van Ameringen, M; Vavrusova, L, 2018)	0.92
" The rate of adverse effects also showed no significant difference between citalopram and other antidepressants [P > ."	( Efficacy and Safety of Citalopram for the Treatment of Poststroke Depression: A Meta-Analysis. Cui, M; Huang, CY; Wang, F, 2018)	1.02
" The adverse effects of citalopram have no significant difference compared to other antidepressants and those adverse effects are less and mild."	( Efficacy and Safety of Citalopram for the Treatment of Poststroke Depression: A Meta-Analysis. Cui, M; Huang, CY; Wang, F, 2018)	1.1
" Adverse events (AEs) were assessed with the Treatment Emergent Symptom Scale (TESS)."	( A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: A pilot randomized controlled trial at a single-center in China. Chen, H; Chen, R; Lin, F; Lin, Q; Lin, T; Lin, X; Lin, Y; Luo, L; Xiao, Y, 2019)	0.74
" The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache."	( Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Ameele, HVD; Blier, P; Daly, EJ; Drevets, WC; Fava, M; Fedgchin, M; Gaillard, R; Hough, D; Lane, R; Liebowitz, M; Lim, P; Manji, H; Melkote, R; Preskorn, S; Ravindran, A; Singh, JB; Trivedi, M; Vitagliano, D, 2019)	0.51
" Adverse events were reported by 313 patients (bupropion XL, n = 157; escitalopram, n = 156); the most common on-treatment adverse event in both groups was nausea (10."	( Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial. Hu, J; Li, H; Li, Y; Shen, Y; Tan, Y; Wang, Z; Xu, X; Yu, Y; Zhang, H; Zhao, Q; Zhong, J, 2019)	0.98
" Side effects were assessed with the Toronto Side Effect Scale after 2 weeks of treatment with escitalopram."	( Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. Fiori, LM; Foster, JA; Frey, BN; Kennedy, SH; Lam, RW; MacQueen, GM; Milev, R; Müller, DJ; Turecki, G; Yrondi, A, 2020)	0.96
" No significant differences were observed in response rate, remission rate, relapse rate and adverse events, while, the relapse time in riluzole group was longer than placebo group."	( Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. Wang, G; Wang, H; Wu, C; Yao, R; Yuan, M, 2020)	0.56
" Adverse effects were assessed by the Adverse Events Scale."	( The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression. Chen, S; Feng, L; He, J; Luan, X; Wang, Q; Xiao, M, 2021)	0.85
" Both treatments improved BI score, with no statistical difference, and were well tolerated, with few significant differences in treatment-associated adverse events."	( The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression. Chen, S; Feng, L; He, J; Luan, X; Wang, Q; Xiao, M, 2021)	0.85
"Sexual dysfunction is a common adverse effect in selective serotonin reuptake inhibitors users."	( Resolution of Citalopram Sexual Adverse Effects With Low Dose of Cariprazine: A Case Report. Dieci, M; Mansi, G; Trama, A, )	0.49
"Information on rare adverse effects is often limited when a medication is initially approved for marketing."	( Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies. Bhasale, A; Fabbri, A; Hooimeyer, A; McEwin, E; Mintzes, B; Mohammad, A; Perry, L, 2020)	0.56
" Due to many contradictory findings on the adverse effects and toxicities of SSRIs (especially genotoxicities), we reviewed the genotoxic effects of these drugs."	( A Systematic Review on the Genotoxic Effects of Selective Serotonin Reuptake Inhibitors. Abbaszadegan, MR; Ahmadimanesh, M; Hedayati, N; Jamialahmadi, T; Sahebkar, A; Yazdian-Robati, R, 2021)	0.62
" magna was studied to assess the toxic persistence of those pollutants."	( Combined toxicity and toxicity persistence of antidepressants citalopram and mirtazapine to zooplankton Daphnia magna. Chen, J; Guo, R; Li, C; Li, Y; Liu, Y; Ma, Y; Wei, S; Xu, D, 2022)	0.96

Excerpt	Reference	Relevance
" From a clinical point of view, it is of relevance that potency to inhibit the cytochrome P450 isozyme CYP2D6 gradually decreases from paroxetine, fluoxetine, norfluoxetine, desmethylcitalopram, fluvoxamine, and sertraline down to citalopram, explaining to a great extent differences in pharmacokinetic interactions between the SSRIs and tricyclic antidepressants, which are metabolized by this enzyme."	( Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Baumann, P; Rochat, B, 1995)	0.48
" Both the sparteine and the mephenytoin oxidation polymorphism thus appear to contribute partially to the total pharmacokinetic variability of citalopram."	( Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Aaes-Jørgensen, T; Brøsen, K; Gram, LF; Hansen, MG; Overø, KF; Sindrup, SH, 1993)	0.81
" No evidence was seen of a pharmacokinetic interaction between CIT and Li, and this combination was well tolerated."	( A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. Amey, M; Baettig, D; Baumann, P; Jonzier-Perey, M; Kasas, A; Lambert, S; Montaldi, S; Nil, R; Souche, A; Uehlinger, C, 1996)	0.56
" According to a previous in vitro study, this pharmacokinetic interaction occurs on the level of CYP2C19, but also of CYP2D6 and CYP3A4 which, in contrast to CYP1A2, contribute to the N-demethylation of citalopram and which are stereoselectively inhibited by fluvoxamine."	( Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Baumann, P; Bertschy, G; Bondolfi, G; Chautems, C; Rochat, B, 1996)	0.83
" Blood samples for pharmacokinetic analysis were obtained over a 168 h period after warfarin dosing."	( Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Davis, JD; Khan, AZ; Larsen, F; Priskorn, M; Rolan, PE; Sidhu, JS, 1997)	0.58
" Comparable pharmacokinetic variability was noted for (+)-(S)-, (-)-(R)- and rac-citalopram."	( Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Grollier, G; Larsen, F; Poulsen, M; Priskorn, M; Segonzac, A; Sidhu, J, 1997)	0.77
" Serum Cmax and t(max) for citalopram were essentially unaffected by the occurrence of renal or hepatic disease."	( Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Aaes-Jørgensen, T; Joffe, P; Larsen, FS; Pedersen, V; Ring-Larsen, H; Sidhu, J, 1998)	0.88
" They differ, however, in their pharmacokinetic properties."	( Pharmacokinetics of selective serotonin reuptake inhibitors. Härtter, S; Hiemke, C, 2000)	0.31
"To compare the steady-state pharmacokinetics of citalopram after multiple-dose administration in elderly and young subjects, and to correlate pharmacokinetic measurements with tolerability."	( Steady-state pharmacokinetics of citalopram in young and elderly subjects. Abramowitz, W; Gutierrez, M, 2000)	0.84
" However, only half-life was statistically different between the groups, 30% longer in the elderly."	( Steady-state pharmacokinetics of citalopram in young and elderly subjects. Abramowitz, W; Gutierrez, M, 2000)	0.59
"This study was undertaken to compare the pharmacokinetic profiles of oral solution and tablet formulations of citalopram in healthy volunteers."	( Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study. Abramowitz, W; Gutierrez, MM, 2000)	0.75
" The rate and extent of absorption were similar between the 2 formulations, and no statistically significant differences were observed in half-life or oral clearance between formulations."	( Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study. Abramowitz, W; Gutierrez, MM, 2000)	0.54
" The aim of the present study was to determine the acute pharmacodynamic effects of citalopram and venlafaxine, on cognitive and psychomotor performance."	( Serotonin, noradrenaline and cognitive function: a preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Nathan, PJ; Sali, A; Silberstein, RB; Sitaram, G; Stough, C, 2000)	0.53
" The pharmacokinetic profile of citalopram administered alone was essentially identical to that when administered with ketoconazole."	( Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Abramowitz, W; Gutierrez, M, 2001)	0.82
"There were no significant differences between the two groups in any of the pharmacokinetic parameters with the exception of the renal clearance of citalopram, which was significantly lower in the renal failure group than in the control group (1."	( Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Dahlqvist, R; Hägg, S; Spigset, O; Stegmayr, B, 2000)	1.95
" There were no statistically significant differences in any of the digoxin pharmacokinetic parameters (AUC(0-->24), AUC(0-->infinity), Cmax, tmax, t(1/2), CL/F, CLrenal, and Ae(0-->infinity)), and the 90% confidence intervals for treatment differences for the parameters (except for tmax) were all within 80% to 125%."	( Lack of citalopram effect on oral digoxin pharmacokinetics. Larsen, F; Overø, KF; Priskorn, M, 2001)	0.74
" At the pharmacodynamic level there have been a few documented cases of serotonin syndrome with citalopram and moclobemide and buspirone."	( Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Brøsen, K; Naranjo, CA, 2001)	0.76
" DOM brain levels were measured using a GC-MS method both in the presence and absence of citalopram and fluoxetine in order to evaluate the pharmacokinetic contribution to the observed behavioral effect."	( Potentiation of DOM-induced stimulus control by fluoxetine and citalopram: role of pharmacokinetics. Doat, MM; Eckler, JR; Rabin, RA; Winter, JC, 2002)	0.78
"The aim of this study was to investigate the potential for pharmacokinetic interaction between escitalopram and ritonavir after concomitant administration of a single dose of each in healthy young subjects."	( An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Abramowitz, W; Gutierrez, MM; Rosenberg, J, 2003)	0.77
" Blood was collected and plasma was analyzed for the pharmacokinetic parameters (maximum plasma concentration [C(max)], time to C(max) [T(max)], area under the plasma concentration-time curve, plasma elimination half-life, oral clearance, and apparent volume of distribution) of escitalopram, S-DCT, and ritonavir."	( An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Abramowitz, W; Gutierrez, MM; Rosenberg, J, 2003)	0.73
" The pharmacokinetic parameters of ritonavir were also unaffected by coadministration of escitalopram."	( An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Abramowitz, W; Gutierrez, MM; Rosenberg, J, 2003)	0.77
"In general, no pharmacokinetic interaction was observed between escitalopram and ritonavir in the present study."	( An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Abramowitz, W; Gutierrez, MM; Rosenberg, J, 2003)	0.79
" Building on the existing in vitro and in vivo evidence that suggest a minimal effect of citalopram on cytochrome P450 3A4, we hypothesized that therapeutic doses of citalopram (20 mg/d), as compared with fluoxetine (20 mg/d), would cause less impairment in the metabolism of the probe drug alprazolam (1 mg) through inhibition of the cytochrome P450 3A4 isozyme as measured by pharmacokinetic and pharmacodynamic parameters in vivo."	( Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. Hall, J; Herrmann, N; Naranjo, CA; Sproule, BA, 2003)	0.77
" Terminal elimination half-life (t1/2) values of citalopram in poor metabolizers were significantly higher than the values in extensive metabolizers who were either homozygous or heterozygous with CYP2C19*1."	( Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Chen, GL; Chen, XP; He, N; Liu, ZQ; Ouyang, DS; Yu, BN; Zhou, HH, 2003)	0.9
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."	( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004)	0.32
" On the other hand, age and sex had a significant influence on the pharmacokinetic pattern of trazodone, causing higher concentrations in females and in older patients."	( Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Conca, A; König, P; Moll, W; Prapotnik, M; Waschgler, R, 2004)	0.54
" The role of pharmacokinetic (PK) parameters, as well as sensitivity to placebo injections, in influencing the neuroendocrine response to citalopram was then evaluated."	( Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Bies, R; Lotrich, FE; Manuck, SB; Muldoon, MF; Pollock, BG; Smith, GS, 2005)	0.8
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."	( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. Jolivette, LJ; Ward, KW, 2005)	0.33
"In view of the good tolerability of escitalopram, the pharmacokinetic changes observed on co-administration with cimetidine or omeprazole are unlikely to be of clinical concern."	( The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Malling, D; Poulsen, MN; Søgaard, B, 2005)	0.83
" The aim of this study was to explore a fully Bayesian methodology for population pharmacokinetic analysis of data that arose from deliberate self-poisoning with citalopram."	( The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. Duffull, SB; Friberg, LE; Hackett, LP; Isbister, GK, 2005)	0.8
"Integrated in vivo models applying intracerebral microdialysis in conjunction with automated serial blood sampling in conscious, freely moving rodents are an attractive approach for pharmacokinetic (PK) and simultaneous pharmacokinetic/pharmacodynamic (PK/PD) investigations of CNS active drugs within the same animal."	( An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents. Bundgaard, C; Jørgensen, M; Mørk, A, )	0.13
" The elimination half-life of escitalopram is about 27-33 hours and is consistent with once-daily administration."	( The clinical pharmacokinetics of escitalopram. Rao, N, 2007)	0.9
"The average bioavailability and pharmacokinetic parameters of the two citalopram tablets were as follows: peak plasma concentration Cmax was 35."	( Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. Al-Ghazawi, M; Mohsen, M; Najjar, S; Tutunji, M, 2007)	0.81
"Based on the pharmacokinetic and statistical results, it was concluded that Lecital 40 mg tablets of JOSWE is bioequivalent to Cipramil 40 mg tablets of Lundbeck (Denmark)."	( Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. Al-Ghazawi, M; Mohsen, M; Najjar, S; Tutunji, M, 2007)	0.58
" The pharmacokinetic analysis revealed that systemic clearance decreased as a function of dose, which was incorporated in the integrated model."	( Pharmacokinetic modelling of blood-brain barrier transport of escitalopram in rats. Bundgaard, C; Jørgensen, M; Larsen, F, 2007)	0.58
"We sought to determine whether clinical response or tolerance to the Selective Serotonin Reuptake Inhibitor (SSRI) citalopram is associated with genetic polymorphisms in potentially relevant pharmacokinetic enzymes."	( Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. Hamilton, SP; Jenkins, GD; Kraft, JB; McGrath, PJ; Peters, EJ; Reinalda, MS; Slager, SL, 2008)	0.79
" Fifteen polymorphisms from five (CYP2D6, ABCB1, CYP2C19, CYP3A4, and CYP3A5) pharmacokinetic genes were genotyped."	( Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. Hamilton, SP; Jenkins, GD; Kraft, JB; McGrath, PJ; Peters, EJ; Reinalda, MS; Slager, SL, 2008)	0.58
"No genetic polymorphism in the pharmacokinetic genes examined was significantly associated with our response or tolerance phenotypes in both stages."	( Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. Hamilton, SP; Jenkins, GD; Kraft, JB; McGrath, PJ; Peters, EJ; Reinalda, MS; Slager, SL, 2008)	0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Blood samples were collected for pharmacokinetic analysis of ADTs."	( The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K, 2010)	0.36
"The objective of this study was to compare population pharmacokinetic models of escitalopram developed from dosage times recorded by a medication event monitoring system (MEMS) versus the reported times from patients with diagnosed depression."	( The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. Bies, RR; Fagiolini, A; Feng, Y; Florian, J; Frank, E; Gastonguay, MR; Jin, Y; Kepple, G; Kirshner, M; Kupfer, DJ; Pollock, BG, 2009)	0.79
" Blood samples for pharmacokinetic profiling were taken up to 156 h post-dose, and escitalopram plasma concentrations were determined with a validated liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) method."	( Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. Chen, Y; Li, J; Ren, X; Tian, Y; Wang, N; Zhang, ZJ, 2009)	0.83
" The aim of the present pilot study was to compare the pharmacokinetic profiles of brand-name and generic formulations of citalopram and extended-release venlafaxine."	( Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. Batten, LA; Blier, P; Chenu, F; Hébert, C; Ladstaetter, E; Zernig, G, 2009)	0.79
" Validation results and its application to the analysis of plasma samples after oral administration of citalopram in healthy Chinese volunteers demonstrated the method was applicable to pharmacokinetic studies."	( Simultaneous determination of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study. Chen, B; Chen, C; Chen, H; Jiang, T; Lu, Y; Peng, L; Rong, Z; Sun, J; Xie, Y; Xu, Y, 2010)	0.86
" This novel method has been applied to a pharmacokinetic study and to estimate brain-to-plasma ratio of S-CPM in rats."	( A highly sensitive LC-MS/MS method for the determination of S-citalopram in rat plasma: application to a pharmacokinetic study in rats. Giri, S; Husain, R; Mullangi, R; Suresh, PS, 2010)	0.6
"3, first for a population pharmacokinetic (PK) analysis followed by a PKPD analysis."	( Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. Duffull, S; Hackett, LP; Isbister, GK; van Gorp, F, 2012)	0.63
" Blood samples for pharmacokinetic analysis were obtained during a 168-hour period after dosing."	( The perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy men. Nilausen, DØ; van Gerven, J; Zuiker, RG, 2011)	0.61
"The assumed bioequivalence assessment was based on pharmacokinetic and statistical analysis of data from the 29 men who completed the 3 treatments."	( The perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy men. Nilausen, DØ; van Gerven, J; Zuiker, RG, 2011)	0.61
"A sensitive, rapid and simple liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS/MS) method was developed for the quantitative determination of cyclobenzaprine in human plasma, to study the pharmacokinetic behavior of cyclobenzaprine capsule in healthy Chinese volunteers."	( Determination of cyclobenzaprine in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. Chen, X; Jiang, H; Li, D; Peng, K; Qian, Z; Xiang, Y; Zheng, H; Zhou, L, 2012)	0.38
" The half-life of the racemic mixture of citalopram after intragastric administration was increased by about 287%."	( Influence of tobacco smoke on the pharmacokinetics of citalopram and its enantiomers. Florek, E; Jawien, W; Kulza, M; Majcherczyk, J; Piekoszewski, W; Senczuk-Przybylowska, M, 2012)	0.89
"The aim of this study was to compare the pharmacokinetic characteristics of a new and a branded citalopram 20 mg formulation to support the marketing authorization of the test formulation in China."	( Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. Chen, B; Chen, C; Chen, H; Jiang, T; Li, H; Lu, Y; Rong, Z; Shen, Y; Sun, J; Xie, Y; Xu, Y, 2013)	0.84
" Pharmacokinetic parameters were calculated and analysed statistically."	( Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. Chen, B; Chen, C; Chen, H; Jiang, T; Li, H; Lu, Y; Rong, Z; Shen, Y; Sun, J; Xie, Y; Xu, Y, 2013)	0.62
" Both formulations showed similar pharmacokinetic profiles."	( Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. Chen, B; Chen, C; Chen, H; Jiang, T; Li, H; Lu, Y; Rong, Z; Shen, Y; Sun, J; Xie, Y; Xu, Y, 2013)	0.62
" Individual pharmacokinetic parameters cannot be directly estimated if full pharmacokinetic profiles are not available for each subject."	( How to combine non-compartmental analysis with the population pharmacokinetics? A study of tobacco smoke's influence on the bioavailability of racemic citalopram in rats. Florek, E; Jawień, W; Kulza, M; Majcherczyk, J; Piekoszewski, W, 2013)	0.59
" Combining NLME with NCA may therefore be recommended for investigating pharmacokinetic properties of the drug in the sparse designs."	( How to combine non-compartmental analysis with the population pharmacokinetics? A study of tobacco smoke's influence on the bioavailability of racemic citalopram in rats. Florek, E; Jawień, W; Kulza, M; Majcherczyk, J; Piekoszewski, W, 2013)	0.59
" We attempted to establish a population pharmacokinetic (PPK) model of CIT in Chinese healthy subjects, to evaluate the effect of genetic polymorphism on CIT pharmacokinetics and to compare the PPK and non-compartmental (NCA) assays in the estimation of CIT bioequivalence."	( Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. Adeniyi, O; Chen, B; Chen, H; Feng, R; Jiang, T; Li, J; Sun, J; Xu, Y; Yang, W; Zhang, W, 2013)	0.66
"Due to pharmacokinetic interactions, citalopram plasma concentrations are often higher than expected with a given dose."	( Influence of concomitant medications on the total clearance and the risk for supra-therapeutic plasma concentrations of Citalopram. A population-based cohort study. Brandl, R; Haen, E; Hiemke, C; Wenzel-Seifert, K, 2014)	0.88
" We investigated the two-way pharmacokinetic drug-drug interaction and tolerability of concomitant administration of the SSRI citalopram and the HIV-1 integrase inhibitor raltegravir in healthy volunteers."	( Pharmacokinetic drug-drug interaction study between raltegravir and citalopram. Blonk, MI; Burger, DM; Colbers, AP; Hoogtanders, KE; Langemeijer, CC; Schouwenberg, BJ; van Schaik, RH, 2016)	0.88
" Intensive steady-state pharmacokinetic blood sampling was performed."	( Pharmacokinetic drug-drug interaction study between raltegravir and citalopram. Blonk, MI; Burger, DM; Colbers, AP; Hoogtanders, KE; Langemeijer, CC; Schouwenberg, BJ; van Schaik, RH, 2016)	0.67
" A nonlinear mixed effects population pharmacokinetic modeling approach was used to describe the pharmacokinetics of R- and S-citalopram and their primary metabolite (desmethylcitalopram)."	( A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. Akil, A; Avramopoulos, D; Bies, RR; Devanand, DP; Lyketsos, CG; Mintzer, JE; Pollock, BG; Porsteinsson, AP; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016)	0.9
" Serial blood samples for pharmacokinetic analysis were collected and ECG was performed up to 48 h postdose."	( Pharmacokinetics and effect on the corrected QT interval of single-dose escitalopram in healthy elderly compared with younger adults. Cho, JY; Chung, H; Chung, JY; Kim, A; Lim, KS; Park, SI; Yoon, SH; Yu, KS, 2017)	0.69
"The purpose of this study was to identify specific pharmacokinetic (PK) and pharmacodynamics (PD) factors that affect the likelihood of treatment remission with a serotonin norepinephrine reuptake inhibitor (SNRI) in depressed patients whose initial selective serotonin reuptake inhibitor (SSRI) failed."	( Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. Ahmed, AT; Biernacka, JM; Bobo, WV; Frye, MA; Hall-Flavin, DK; Jenkins, G; Kung, S; Rush, AJ; Shinozaki, G; Veldic, M; Wang, L; Weinshilboum, RM, 2019)	0.71
"The aims of this study were to characterize escitalopram pharmacokinetic profile, to identify factors influencing drug exposure, notably drug-drug interactions with antiretrovirals, and to simulate expected exposure under standard dosage regimen."	( Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Eap, CB; Glatard, A; Guidi, M; Marzolini, C, 2019)	1.49
"A population pharmacokinetic analysis was performed using NONMEM."	( Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Eap, CB; Glatard, A; Guidi, M; Marzolini, C, 2019)	1.24
" This analysis aimed to evaluate the ability of physiologically-based pharmacokinetic modelling to predict exposure of CYP2C19 substrates (lansoprazole, (es)citalopram, voriconazole) across Caucasian and East Asian populations."	( Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling. Al-Huniti, N; Higashimori, M; Sharma, P; Xu, H; Yeo, KR; Zhou, D; Zhou, L, 2019)	0.71
" A population pharmacokinetic model that aimed to better characterize maternal and infant exposure to SCIT and its metabolite was developed."	( A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk. Beaufils, E; Bickle Graz, M; Borradori Tolsa, C; Claris, O; Csajka, C; Eap, CB; Epiney, M; Fischer, CJ; Gaucherand, P; Guidi, M; Hascoët, JM; Kassai-Koupai, B; Morisod Harari, M; Nguyen, KA; Panchaud, A; Rothenburger, S; Rouiller, S; Tolsa, JF; Vial, Y; Weisskopf, E, 2020)	0.82
"Fifty-five pregnant women with Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnoses of affective disorders, treated with SSRIs/SNRIs, were recruited and, during the third trimester, their blood samples were collected for pharmacokinetic and pharmacogenetic analyses."	( Correlation between pharmacokinetics and pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Noradrenaline Reuptake Inhibitors and maternal and neonatal outcomes: Results from a naturalistic study in patients with affec Bosi, MF; Cafaro, R; Cetin, I; Clementi, E; Colombo, A; Dell'Osso, B; Di Bernardo, I; Giordano, F; Giorgetti, F; Pileri, P; Varinelli, A; Viganò, CA, 2021)	0.62
" This study thus aimed to develop a population pharmacokinetic (PK)/pharmacodynamic (PD) model to characterize the relationship between escitalopram concentrations and the delayed effect on QT prolongation."	( Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation. Chung, JY; Kim, A; Kim, Y, 2021)	1.05
" In this single-centre, single-blind, randomized, placebo-controlled, sequential design Phase 1 study with the inclusion of two double-blind crossover parts, the pharmacokinetic (PK; blood sampling at regular intervals) and pharmacodynamic (PD; battery of objective and subjective PD tests performed at regular intervals) interactions between daridorexant (50 mg) and citalopram (20 mg, single dose and at steady state) as well as the safety/tolerability in healthy subjects were investigated."	( Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects. Berger, B; Dingemanse, J; Kornberger, R, 2021)	1
"Further pharmacokinetic examination of the interaction between CBD and citalopram/escitalopram is clearly warranted, and clinicians should be vigilant around the possibility of treatment-emergent adverse effects when CBD is introduced to patients taking these antidepressants."	( Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. Amminger, GP; Anderson, LL; Arnold, JC; Berger, M; Doohan, PT; Kevin, RC; McGregor, IS; Oldfield, L, )	1.81
" The validated methods were successfully applied to a pharmacokinetic study in which 20-mg CTP tablets were administered to healthy volunteers, and their plasma levels were monitored over time in a bioequivalence study."	( Selective LC-MS/MS determination of citalopram enantiomers and application to a pharmacokinetic evaluation of generic and reference formulations. Bedor, DCG; Bedor, NCTC; de Castro, WV; de Oliveira, GHO; de Santana, DP; de Sousa, CEM; Leal, LB; Sousa, GD, 2022)	1

Excerpt	Reference	Relevance
" When administered in combination with citalopram, an attenuation of the power density reduction in the 7-15 Hz range in the FF EEG of citalopram alone, was observed."	( Sleep and EEG power spectrum effects of the 5-HT1A antagonist NAN-190 alone and in combination with citalopram. Bjorvatn, B; Bjørkum, AA; Neckelmann, D; Ursin, R, 1996)	0.78
"This 6-week, open-label, multicenter study evaluated the efficacy and safety of quetiapine in combination with citalopram in adult patients (n=25) with ICD-10/DSM-IV unipolar psychotic depression."	( Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Aschauer, H; Hrubos, W; Kasper, S; Konstantinidis, A; Lehofer, M; Nirnberger, G; Windhager, E, 2007)	0.84
" Results of this study support further examination of citalopram in combination with behavioral therapy as a treatment for cocaine dependence."	( Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Grabowski, J; Green, CM; Lai, LY; Moeller, FG; Reist, C; Schmitz, JM; Steinberg, JL; Swann, AC, 2007)	2.03
"A modified solvent microextraction with back extraction method (SME/BE) combined with high performance liquid chromatography and fluorescence detection (HPLC-FD) was developed for the determination of citalopram in human plasma."	( Modified solvent microextraction with back extraction combined with liquid chromatography-fluorescence detection for the determination of citalopram in human plasma. Babanezhad, E; Bagheri, H; Es-haghi, A; Khalilian, F; Rouini, MR, 2008)	0.74
"In patients with medication-resistant major depression we administered in a randomised trial 15 sessions of sham-controlled rTMS over three weeks in combination with 20 mg escitalopram daily."	( Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial. Bech, P; Bretlau, LG; Dissing, S; Lindberg, L; Lunde, M; Undén, M, 2008)	0.77
"High-frequency rTMS over the left cortex is an add-on strategy of clinical significance in combination with escitalopram in patients with major depression resistant to non-tricyclic antidepressants."	( Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial. Bech, P; Bretlau, LG; Dissing, S; Lindberg, L; Lunde, M; Undén, M, 2008)	0.79
"To determine the efficacy of eszopiclone combined with escitalopram oxalate in treating insomnia comorbid with GAD."	( Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Huang, H; Kinrys, G; Krishnan, R; Krystal, A; McCall, WV; Pollack, M; Roach, J; Roth, T; Rubens, R; Schaefer, K, 2008)	0.87
" The aim of this study was to investigate the toxic effects and toxicokinetic parameters of citalopram in an overdose as a single drug and in combination with other drugs."	( Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. Caminada, K; Hunfeld, NG; Jimmink, A; Touw, DJ, 2008)	0.88
"To present an economic model and cost-effectiveness estimates of switching to bupropion compared to combination with bupropion after failure of an SSRI for major depressive disorder (MDD)."	( Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder. Leelahanaj, T, 2010)	0.36
"To assess the early therapeutic and cognitive effect of repetitive transcranial magnetic stimulation (rTMS) combined with antidepressant medication in treatment of first-episode patients with major depression."	( [Repetitive transcranial magnetic stimulation combined with antidepressant medication in treatment of first-episode patients with major depression]. Hu, JB; Hu, SH; Huang, ML; Luo, BY; Qi, HL; Wei, N; Xu, Y; Zhou, WH, 2011)	0.37
"Sixty first-episode depressed inpatients aged 18-45 y, who met the DSM-IV clinical criteria for major depressive episode were randomly assigned to citalopram treatment (20 mg/d) in combination with a two-week period of either rTMS (study group)or sham procedure (control group) on left dorsal-lateral prefrontal cortex (10 Hz, 90% motor threshold)."	( [Repetitive transcranial magnetic stimulation combined with antidepressant medication in treatment of first-episode patients with major depression]. Hu, JB; Hu, SH; Huang, ML; Luo, BY; Qi, HL; Wei, N; Xu, Y; Zhou, WH, 2011)	0.57
"To quantify the importance of drug-drug interactions (DDIs) in the occurrence of adverse drug reactions (ADRs) reported with serotoninergic reuptake inhibitors in a pharmacovigilance database."	( The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Bagheri, H; Bondon-Guitton, E; Bui, E; Durrieu, G; Lapeyre-Mestre, M; Montastruc, F; Montastruc, JL; Schmitt, L; Sommet, A, 2012)	0.38
" This is partly explained by multiple drug use causing drug-drug interactions."	( Serotonin syndrome during treatment with low dose of escitalopram associated with miconazole mucoadhesive tablet: a suspected drug interaction. Baptista, G; Eiden, C; Jeandel, C; Monguillot, P; Philibert, C, 2012)	0.63
"Quetiapine is now used in the treatment of unipolar and bipolar disorders, both alone and in combination with other medications."	( Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission. Blier, P; Chernoloz, O; El Mansari, M, 2012)	0.38
"In a 2-week double-blind study with a 2-week extended antidepressant phase, 60 first-episode young major depressive patients were randomly assigned to citalopram in combination with 2 weeks of either active or sham rTMS treatment."	( Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial. Hu, JB; Hu, SH; Huang, ML; Luo, BY; Wang, SS; Wei, N; Xu, Y; Zhou, WH, 2012)	0.82
" This practice of polypharmacy increases the possibility for drug-drug interactions."	( Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia. Li, M; Sparkman, NL, 2012)	0.66
" This drug combination resulted in marked prolongation of the QT interval that triggered the electrical storm."	( Citalopram and levosulpiride: a dangerous drug combination for QT prolongation. Agosti, S; Bertero, G; Brunelli, C; Burrone, A; Casalino, L; Morelloni, S, 2013)	1.83
"To prospectively assess the efficacy of the selective serotonin inhibitor escitalopram on painful bone metastases, in combination with external beam irradiation."	( Radiotherapy combined with daily escitalopram in patients with painful bone metastasis: clinical evaluation and quality of life measurements. Fotineas, A; Kantzou, I; Kelekis, N; Kouloulias, V; Kouvaris, J; Nikolaou, K; Pantelakos, P; Platoni, K; Rizos, E; Sarris, G; Tolia, M; Zygogianni, A, )	0.64
"Forty-three patients with cancer metastatic to bone and suffering from depression were treated with 3 Dimensional Conformal Radiotherapy (3DCRT) (30 Gy; 3 Gy/fraction, 5 days/week) combined with escitalopram (20 mg/day)."	( Radiotherapy combined with daily escitalopram in patients with painful bone metastasis: clinical evaluation and quality of life measurements. Fotineas, A; Kantzou, I; Kelekis, N; Kouloulias, V; Kouvaris, J; Nikolaou, K; Pantelakos, P; Platoni, K; Rizos, E; Sarris, G; Tolia, M; Zygogianni, A, )	0.6
" In the present study, we have examined the effect of lisdexamfetamine dimesylate (LDX), an amphetamine pro-drug that is approved for the treatment of ADHD on acetylcholine and histamine efflux in pre-frontal cortex and hippocampus alone and in combination with the anti-depressant s-citalopram."	( Effects of lisdexamfetamine alone and in combination with s-citalopram on acetylcholine and histamine efflux in the rat pre-frontal cortex and ventral hippocampus. Folgering, JH; Heins, MS; Hutson, PH, 2015)	0.84
" When treating HIV-infected patients with a selective serotonin reuptake inhibitor (SSRI), potential drug-drug interactions with antiretroviral agents have to be taken into account."	( Pharmacokinetic drug-drug interaction study between raltegravir and citalopram. Blonk, MI; Burger, DM; Colbers, AP; Hoogtanders, KE; Langemeijer, CC; Schouwenberg, BJ; van Schaik, RH, 2016)	0.67
" Subjects received the following treatments: citalopram 20 mg once daily for 2 weeks followed by the combination with raltegravir 400 mg twice daily for 5 days and after a washout period raltegravir 400 mg twice daily for 5 days."	( Pharmacokinetic drug-drug interaction study between raltegravir and citalopram. Blonk, MI; Burger, DM; Colbers, AP; Hoogtanders, KE; Langemeijer, CC; Schouwenberg, BJ; van Schaik, RH, 2016)	0.93
" The present work determines if AE-PG alone or in combination with the selective serotonin reuptake inhibitor, citalopram, has antidepressant-like effects."	( Aqueous Extract of Pomegranate Alone or in Combination with Citalopram Produces Antidepressant-Like Effects in an Animal Model of Menopause: Participation of Estrogen Receptors. Estrada-Camarena, E; García-Viguera, C; González-Trujano, ME; López-Rubalcava, C; Valdés-Sustaita, B, 2017)	0.91
" In 8% of all drug poisoning deaths, lifetime drug-drug interaction was evaluated having a contribution to the fatal outcome."	( Completed suicides of citalopram users-the role of CYP genotypes and adverse drug interactions. Haukka, J; Niemi, M; Ojanperä, I; Palo, JU; Pett, H; Rahikainen, AL; Sajantila, A; Vauhkonen, P, 2019)	0.83
"The aims of this study were to characterize escitalopram pharmacokinetic profile, to identify factors influencing drug exposure, notably drug-drug interactions with antiretrovirals, and to simulate expected exposure under standard dosage regimen."	( Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Eap, CB; Glatard, A; Guidi, M; Marzolini, C, 2019)	1.49
" Therefore we investigated whether there is a drug-drug interaction between tamoxifen and SRIs resulting in a prolonged QTc-interval."	( The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors. Berger, FA; Binkhorst, L; de Groot, NMS; Hussaarts, KGAM; Mathijssen, RHJ; Mathijssen-van Stein, D; Oomen-de Hoop, E; van Alphen, RJ; van Gelder, T; van Leeuwen, RWF, 2019)	0.51
"To investigate the therapeutic effects and safety of BLT combined with escitalopram oxalate (ESC) on insomnia in patients with PSD."	( The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression. Chen, S; Feng, L; He, J; Luan, X; Wang, Q; Xiao, M, 2021)	1.08
"BLT combined with ESC is effective and well tolerated for the treatment of PSD-associated insomnia."	( The therapeutic effects and safety of bright light therapy combined with escitalopram oxalate on insomnia in patients with poststroke depression. Chen, S; Feng, L; He, J; Luan, X; Wang, Q; Xiao, M, 2021)	0.85
" The aim of this study was to investigate the repurposing of escitalopram oxalate and clonazepam drugs individually, and in combination with the antibiotics ciprofloxacin and sulfamethoxazole-trimethoprim, to treat multidrug-resistant (MDR) microorganisms and to evaluate the potential chemical nuclease activity."	( Repurposing of escitalopram oxalate and clonazepam in combination with ciprofloxacin and sulfamethoxazole-trimethoprim for treatment of multidrug-resistant microorganisms and evaluation of the cleavage capacity of plasmid DNA. Bottega, A; Coelho, SS; Foletto, VS; Hörner, R; Lorenzoni, VV; Machado, CS; Mainardi, A; Rampelotto, RF; Rosa, TFD; Serafin, MB, 2021)	1.2

Excerpt	Reference	Relevance
"The absolute bioavailability of citalopram tablets in healthy subjects was 80%."	( Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Aaes-Jørgensen, T; Joffe, P; Larsen, FS; Pedersen, V; Ring-Larsen, H; Sidhu, J, 1998)	0.87
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
" The high bioavailability of citalopram indicates that the switch from intravenous to oral citalopram would prevent a deterioration of symptoms as plasma drug concentrations would be maintained."	( Intravenous antidepressant treatment: focus on citalopram. Kasper, S; Müller-Spahn, F, 2002)	0.86
" An important reason is that, even at equal concentrations, the bioavailability of a drug depends on the interaction of the drug with the blood-brain barrier (BBB)."	( abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. Grauer, MT; Uhr, M, )	0.38
"The aim of this study was to compare the bioavailability of two citalopram formulations (citalopram from Eurofarma Laboratórios Ltda."	( A bioequivalence study of citalopram based on quantification by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Barrientos-Astigarraga, RE; Borges, NC; De Nucci, G; Mendes, FD; Mendes, GD; Pereira, Ados S, 2005)	0.87
" The effect of activated charcoal on clearance and bioavailability was pronounced and resulted in a 72% increase and 22% decrease, respectively."	( The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. Duffull, SB; Friberg, LE; Hackett, LP; Isbister, GK, 2005)	0.61
" The high bioavailability of citalopram permits the use of identical iv and oral doses."	( [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study]. Arbus, C; Schmitt, L; Tonnoir, B, )	0.71
" However, SSRI bioavailability and non-compliance represent major issues, especially in the clinical trials setting."	( Fluorimetric quantitation of citalopram and escitalopram in plasma: developing an express method to monitor compliance in clinical trials. Atar, D; Dragan, A; Dragan, V; Malinin, A; Serebruany, V; van Zyl, L, 2007)	0.63
"The average bioavailability and pharmacokinetic parameters of the two citalopram tablets were as follows: peak plasma concentration Cmax was 35."	( Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. Al-Ghazawi, M; Mohsen, M; Najjar, S; Tutunji, M, 2007)	0.81
" Calculated with AUC(0-120 h), the bioavailability of two formulations was (102."	( [Determination of citalopram in human plasma with LC-MS/MS method and its bioequivalent evaluation]. Cao, XQ; Chen, XY; Zhang, YF; Zhong, DF, 2007)	0.67
" Escitalopram has favourable pharmacokinetics: it is rapidly absorbed, has a bioavailability of 80% and is not affected by food intake."	( The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Altamura, AC; Bareggi, SR; Dell'Osso, B; Mundo, E, 2007)	1.33
"The aim of the present study was to compare the bioavailability of escitalopram (CAS 128196-01-0) from two escitalopram oxalate (CAS 219861-08-2) tablets (escitalopram 10 mg tablet as test preparation and 10 mg tablet commercially available original tablet of the drug as reference preparation) in 20 Chinese healthy male volunteers, aged between 19 and 27."	( Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. Chen, Y; Li, J; Ren, X; Tian, Y; Wang, N; Zhang, ZJ, 2009)	0.84
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" Selected derivatives showed good oral bioavailability (>30%) and brain penetration (B/B > 4) in rats associated with high in vitro potency and selectivity at SERT, NET, and DAT."	( 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. Arban, R; Benedetti, R; Bertani, B; Bettati, M; Bettelini, L; Bonanomi, G; Braggio, S; Cavanni, P; Checchia, A; Davalli, S; Di Fabio, R; Fazzolari, E; Fontana, S; Marchioro, C; Micheli, F; Minick, D; Negri, M; Oliosi, B; Read, KD; Sartori, I; Tarsi, L; Tedesco, G; Terreni, S; Visentini, F; Zocchi, A; Zonzini, L, 2010)	0.36
" Excellent bioavailability and brain penetration are associated with this series of 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4."	( 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. Andreotti, D; Arban, R; Benedetti, R; Bertani, B; Bettati, M; Bettelini, L; Bonanomi, G; Braggio, S; Carletti, R; Cavanni, P; Checchia, A; Corsi, M; Di Fabio, R; Fazzolari, E; Fontana, S; Marchioro, C; Merlo-Pich, E; Micheli, F; Negri, M; Oliosi, B; Ratti, E; Read, KD; Roscic, M; Sartori, I; Spada, S; Tarsi, L; Tedesco, G; Terreni, S; Visentini, F; Zocchi, A; Zonzini, L, 2010)	0.36
"The aim of this study was to compare the bioavailability of orodispersible and conventional immediate-release (IR) escitalopram tablets."	( The perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy men. Nilausen, DØ; van Gerven, J; Zuiker, RG, 2011)	0.82
" However, few studies have assessed the bioavailability of pharmaceuticals to fish in natural waters."	( Bioavailability of pharmaceuticals in waters close to wastewater treatment plants: use of fish bile for exposure assessment. Brozinski, JM; Kronberg, L; Lahti, M; Oikari, A; Segner, H, 2012)	0.38
"Decreasing the bioavailability of serotonin (5-HT) by inhibiting its biosynthesis may represent a useful adjunctive treatment of pulmonary hypertension (PH)."	( Inhibition of gut- and lung-derived serotonin attenuates pulmonary hypertension in mice. Abid, S; Adnot, S; Amsellem, V; Chevarin, C; Dubois-Randé, JL; Gary-Bobo, G; Hamon, M; Houssaini, A; Marcos, E; Mouraret, N; Tissot, CM; Wan, F, 2012)	0.38
" Functional polymorphisms of ABCB1 may influence central nervous system bioavailability of antidepressants subject to efflux."	( ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Berk, M; Bousman, CA; Byron, K; Ng, CH; Singh, AB, 2012)	0.67
"The inhibitory effects of escitalopram on erectile and vascular function were not accompanied by a change in endothelial nitric oxide synthase, neuronal nitric oxide synthase, inducible nitric oxide synthase expression, or endothelial nitric oxide synthase activity, suggesting that the inhibitory effect is caused by a decrease in nitric oxide bioavailability mediated by increased NADPH oxidase and reactive oxygen species production."	( Chronic escitalopram treatment induces erectile dysfunction by decreasing nitric oxide bioavailability mediated by increased nicotinamide adenine dinucleotide phosphate oxidase activity and reactive oxygen species production. Gokce, A; Hellstrom, WJ; Kadowitz, PJ; Kassan, M; Lasker, GF; Mandava, SH; Matrougui, K; Serefoglu, EC; Sikka, SC, 2013)	1.09
" In contrast MAOi antidepressants, that also increase extracellular serotonin bioavailability have little or no effects on this condition."	( Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs. Beaulieu, JM; Chahine, M; Poulin, H; Thériault, O, 2015)	0.42
" Several models for the absorption rate were explored (e."	( A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats. Bender, DM; Bies, RR; Eastwood, B; Jackson, K; Lowe, S; Swanson, S; Velez de Mendizabal, N, 2015)	0.72
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"This study compared the bioequivalence of two formulations of escitalopram oxalate 20 mg tablets in terms of bioavailability and tolerability in healthy Chinese male and female subjects."	( Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions. Hu, W; Huo, H; Li, Q; Sui, Y; Tang, Y, 2020)	1.02
" 1-H-benzotriazole, carbamazepine, citalopram, lamotrigine, sucralose, tramadol, and venlafaxine (>80 % frequency of appearance in effluents) were assessed with respect to their bioavailability in soil as part of different scenarios of irrigation with reclaimed water following a qualitative approach."	( Multiclass target analysis of contaminants of emerging concern including transformation products, soil bioavailability assessment and retrospective screening as tools to evaluate risks associated with reclaimed water reuse. Beretsou, VG; Fatta-Kassinos, D; Lundy, L; Manoli, K; Michael, C; Nika, MC; Revitt, DM; Sui, Q; Thomaidis, NS, 2022)	1

Excerpt	Relevance	Reference
" Dose-response effects of fluoxetine and desipramine on displacement of [3H]imipramine binding in forebrain regions indicate that the ligand labels predominantly high capacity, low affinity binding sites."	( Autoradiographic characterization of [3H]imipramine and [3H]citalopram binding in rat and human brain: species differences and relationships to serotonin innervation patterns. Breese, GR; Duncan, GE; Kaldas, RS; Kirkman, JA; Little, KY; Stumpf, WE, 1992)	0.53
"The aim of the present study was to compare cardiovascular and/or cardiotoxic effects of eight anti-depressants (imipramine, chlorimipramine, amitriptyline, nortriptyline , doxepin, maprotiline, mianserin and citalopram) in anaesthetized cats after oral dosing and in conscious rabbits after intravenous infusion."	( Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels. Boeck, V; Fredricson Overø, K; Jørgensen, A, 1984)	0.67
" In the present study we determined the time-course and dose-response effects of 6-MeO-THbetaC for blockade of AGS."	( Effects of 6-methoxy-1,2,3,4-tetrahydro-beta-carboline (6-MeO-THbetaC) on audiogenic seizures in DBA/2J mice. Buckholtz, NS; Sparks, DL, 1980)	0.26
" In a double-blind, placebo-controlled study 22 patients with fibromyalgia were randomized to treatment with citalopram for 4 weeks at a dosage of 20 mg a day while 21 received placebo."	( A randomized controlled trial of citalopram in the treatment of fibromyalgia. Danneskiold-Samstøe, B; Nørregaard, J; Volkmann, H, 1995)	0.78
" Metanalysis of the placebo controlled results with citalopram demonstrated that the dose-response curves based on log odds ratios showed a very flat curve across the 20-60 mg range and that 20 mg appeared therefore to be the minimum effective dose."	( Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram. Montgomery, SA, 1995)	0.77
"Optimal dosing schedules for an antidepressant drug can only be established during clinical studies in depressed patients."	( The optimal dosing regimen for citalopram--a meta-analysis of nine placebo-controlled studies. Montgomery, SA; Pedersen, V; Rasmussen, C; Rioux, P; Tanghøj, P, 1994)	0.57
" The time course and dose-response relationships for this effect were examined after treatment with two representative antidepressant drugs (imipramine and citalopram) and electriconvulsive shock (ECS)."	( Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. Layer, RT; Nowak, G; Paul, IA; Popik, P; Skolnick, P, 1994)	0.49
" Citalopram, as in a prior dose-response study, reduced REM sleep."	( Sleep and EEG power spectrum effects of the 5-HT1A antagonist NAN-190 alone and in combination with citalopram. Bjorvatn, B; Bjørkum, AA; Neckelmann, D; Ursin, R, 1996)	1.42
" The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition."	( Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Meier, E; Sánchez, C, 1997)	0.56
" In the first set, the aim of the experiments was to investigate the dose-response effect of selective serotonin re-uptake inhibitor (SSRI) citalopram on rat exploratory behaviour in the elevated plus-maze."	( The effects of cholecystokinin A and B receptor antagonists, devazepide and L 365260, on citalopram-induced decrease of exploratory behaviour in rat. Allikmets, L; Harro, J; Matto, V, 1996)	0.72
"Twelve subjects received a single 25 mg dose of racemic warfarin either alone or on Day 15 of a 21-day oral dosing regimen of 40 mg citalopram daily."	( Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Davis, JD; Khan, AZ; Larsen, F; Priskorn, M; Rolan, PE; Sidhu, JS, 1997)	0.79
" Ratings were completed every 2 weeks for 12 weeks, during which time dosage was increased to a maximum of 60 mg daily (mean dose 36."	( Use of the selective serotonin reuptake inhibitor citalopram in treatment of trichotillomania. Bouwer, C; Maud, CM; Stein, DJ, 1997)	0.55
" Enantiomeric (S/R) serum concentration ratios for citalopram were always less than unity and were constant during the steady-state dosing interval."	( Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Grollier, G; Larsen, F; Poulsen, M; Priskorn, M; Segonzac, A; Sidhu, J, 1997)	0.8
"No reduction of citalopram dosage is warranted in patients with moderately impaired renal function."	( Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Aaes-Jørgensen, T; Joffe, P; Larsen, FS; Pedersen, V; Ring-Larsen, H; Sidhu, J, 1998)	0.93
" One group (N = 17 completers) was administered citalopram continuously at a constant dosage (20+/-10 mg/day) throughout the menstrual cycle."	( Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? Andersch, B; Bengtsson, F; Dagnell, I; Eriksson, E; Sundblad, C; Wikander, I; Zylberstein, D, 1998)	2
"Patients in this double-blind, parallel-group trial were assigned to 1 of 3 fixed dosage ranges of citalopram (10 or 15 mg/day, 20 or 30 mg/day, or 40 or 60 mg/day), 1 dosage range of clomipramine (60 or 90 mg/day), or placebo."	( A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. Frazer, J; Koponen, HJ; Lehto, HJ; Leinonen, EV; Lepola, UM; Pedersen, T; Penttinen, JT; Sjödin, I; Wade, AG, 1998)	0.78
" Analysis of the difference in the number of patients in different treatment groups remaining in the study (perhaps the best measure of long-term efficacy) also demonstrated that the patients treated with citalopram in dosage ranges of 20 or 30 mg/day and 40 or 60 mg/day had better response than placebo-treated patients (p < ."	( A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. Frazer, J; Koponen, HJ; Lehto, HJ; Leinonen, EV; Lepola, UM; Pedersen, T; Penttinen, JT; Sjödin, I; Wade, AG, 1998)	0.75
"Citalopram in the dosage range of 20 to 60 mg/day is effective, well tolerated, and safe in the long-term treatment of patients who have panic disorder."	( A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. Frazer, J; Koponen, HJ; Lehto, HJ; Leinonen, EV; Lepola, UM; Pedersen, T; Penttinen, JT; Sjödin, I; Wade, AG, 1998)	2.01
" In Experiment I, rats were treated with MDMA using several dosing protocols (2."	( (+) 3,4-methylenedioxymethamphetamine ('ecstasy') transiently increases striatal 5-HT1B binding sites without altering 5-HT1B mRNA in rat brain. McEvoy, C; Neumaier, JF; Sexton, TJ, 1999)	0.3
" In summary, the drug components after chronic dosing correlated well between the periphery and the brain, but not with the brain monoamine concentrations."	( Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats. Ahlner, J; Apelqvist, G; Bengtsson, F; Bergqvist, PB; Carlsson, B; Hjorth, S; Kugelberg, FC; Wikell, C, )	0.34
"Citalopram dosing to steady state did not inhibit or induce the metabolism of theophylline in this population of healthy volunteers."	( Effect of citalopram on plasma levels of oral theophylline. Larsen, F; Møller, SE; Pitsiu, M; Rolan, PE, 2000)	2.15
"Citalopram tablets fulfill most dosing needs in the treatment of depression, but some patients may have difficulty swallowing tablets and thus may be less likely to comply with their medication regimen."	( Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study. Abramowitz, W; Gutierrez, MM, 2000)	1.98
" Furthermore, no adjustment of citalopram dosage should be necessary in most patients who receive the drug in combination with a CYP3A4 inhibitor."	( Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Abramowitz, W; Gutierrez, M, 2001)	0.83
" Citalopram was started in a daily dosage of 20 mg that was kept unchanged for 6 weeks."	( Citalopram in mentally retarded patients with depression: a long-term clinical investigation. Jacobs, GA; Tuinier, S; van den Berg, YW; Veendrik-Meekes, MJ; Verhoeven, WM, 2001)	2.66
" Since the flexible dosing started after Week 4, analysis of 4-week data ensured that the patients received fixed doses of 10 mg/day escitalopram (155 patients), 20 mg/day citalopram (160 patients), or placebo (154 patients)."	( Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Loft, H; Montgomery, SA; Papp, M; Reines, EH; Sánchez, C, 2001)	1.24
" However, patients may require dosage adjustment for tolerability of this combination."	( Methylphenidate augmentation of citalopram in elderly depressed patients. Kumar, A; Lavretsky, H, 2001)	0.59
"Selective serotonin reuptake inhibitors are commonly used to treat major depression; however, the percentage of serotonin (5-HT) transporter (5-HTT) sites occupied during clinical dosing is unknown."	( Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Ginovart, N; Goulding, V; Hood, K; Houle, S; Hussey, D; Meyer, JH; Wilson, AA, 2001)	0.56
" Thirty men with an intravaginal ejaculation latency time (IELT) less than 1 minute were randomly assigned to receive paroxetine (20 mg/day) and citalopram (20 mg/day) for 5 weeks, after taking half the dosage in the first week."	( SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. Olivier, B; Waldinger, MD; Zwinderman, AH, 2001)	0.73
" Dosage adjustments were made as the physicians deemed clinically necessary."	( An open-label trial of citalopram for major depression in patients with hepatitis C. Gleason, OC; Isbell, MD; Philipsen, MA; Yates, WR, 2002)	0.63
" This raises the important question of whether once-weekly enteric-coated fluoxetine, 90 mg, is effective for maintenance of response in patients whose depressive symptoms have responded to daily dosing with selective serotonin reuptake inhibitors (SSRIs) such as citalopram, paroxetine, or sertraline."	( Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Brown, EB; Gonzales, JS; Miner, CM; Munir, R, 2002)	0.78
" A 58-year-old man experienced priapism several hours after inadvertently taking three tablets of citalopram 20 mg, which he had mistaken for aspirin, in addition to his usual dosage of 20 mg twice/day."	( Citalopram-induced priapism. Brown, WC; Dent, LA; Murney, JD, 2002)	1.97
" Dosage was regulated individually over a period of 4 weeks."	( Citalopram treatment for impulsive aggression in children and adolescents: an open pilot study. Armenteros, JL; Lewis, JE, 2002)	1.76
" A placebo-controlled study of citalopram, the most selective SSRI, demonstrated that half-cycle dosing (luteal phase) was effective for DSM-IV-defined premenstrual dysphoric disorder (PMDD), a severe form of PMS."	( Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. Auletto, R; Freeman, EW; Jabara, S; Sondheimer, SJ, 2002)	2.04
"001) in both half-cycle and full-cycle dosing groups."	( Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. Auletto, R; Freeman, EW; Jabara, S; Sondheimer, SJ, 2002)	1.76
"Among the many problems in interpreting dose-response studies with antidepressants are the psychometric problems in the identification of true antidepressive effect versus true adverse drug effect."	( Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Andersen, HF; Bech, P; Overø, K; Tanghøj, P, 2002)	1.76
"This study is a re-examination of a dose-response trial with citalopram in order to examine the explanatory ability of using strict psychometric dimensions to measure the wanted and unwanted drug effects of different doses compared to placebo."	( Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Andersen, HF; Bech, P; Overø, K; Tanghøj, P, 2002)	2
"This psychometric re-examination of a citalopram dose-response trial has shown that the pure antidepressive or antianxiety effects can be observed after 6 weeks of therapy even in a dose of 10 mg daily."	( Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Andersen, HF; Bech, P; Overø, K; Tanghøj, P, 2002)	2.03
"An 87-year-old Filipino man was admitted to the hospital reporting malaise, confusion, dizziness, and falls approximately 3 weeks following an increase in his citalopram dosage from 10 to 20 mg/d."	( Citalopram-associated SIADH. Barclay, TS; Lee, AJ, 2002)	1.95
" Citalopram dosing began at 20 mg/day and could be titrated to 60 mg/day."	( Naturalistic study of the early psychiatric use of citalopram in the United States. Bose, A; Heydorn, WE; Rush, AJ, 2002)	1.48
" A comparison of citalopram and fluoxetine pharmacokinetics in the same animal and at the same dosage (1 mg/kg) showed that citalopram SERT occupancy and plasma half-lives were 9 times and 14 times shorter, respectively, than those of fluoxetine and norfluoxetine."	( [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Ginovart, N; Houle, S; Hussey, D; Meyer, JH; Wilson, AA, 2003)	0.66
"30) with coexisting obsessive-compulsive disorder (OCD) and depression were treated for 6 weeks with citalopram (10-60 mg; mean dosage after 6 weeks--25."	( [Clinical efficacy of citalopram in patients with obsessive-compulsive disorder]. Jakitowicz, J; Nowicki, Z; Wiśniewski, G, )	0.66
" In conclusion, the CIT enantiomers were shown for the first time to be stereoselectively metabolized after single-dose administration to rats, as previously shown in steady-state dosing studies in humans and rats."	( Stereoselective single-dose kinetics of citalopram and its metabolites in rats. Ahlner, J; Bengtsson, F; Carlsson, B; Kugelberg, FC, 2003)	0.59
"The AUC of S-, but not R-(CT) was found to be significantly higher in PM of mephenytoin compared to EMs, PMs may need a lower dosage of CT."	( Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Bertilsson, L; Gustafsson, LL; Herrlin, K; Tybring, G; Widén, J; Yasui-Furukori, N, 2003)	0.68
" In the present study we report, for the first time, on an interaction between R-citalopram and escitalopram after repeated dosing in a rat chronic mild stress (CMS) model of depression."	( R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Gruca, P; Papp, M; Sánchez, C, 2003)	1.27
"The present study was conducted to investigate whether a single oral dosage of 20 mg of the selective serotonin reuptake inhibitor citalopram could be used as a tool to stimulate hormone secretion in neuroendocrine challenge paradigms."	( Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests. Henning, J; Netter, P, 2002)	0.84
" Citalopram was started at a dosage of 20 mg/day; the dosage was increased to a maximum of 60 mg/day by the third week, on the basis of clinical need and tolerability."	( Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. Bareggi, SR; Bellodi, L; Bianchi, L; Cavallaro, R; Gervasoni, M; Siliprandi, F, 2004)	2.68
" In addition, a dose-response relationship could be seen for escitalopram and citalopram with increasing 5-HT transport inhibition observed with increasing dose."	( Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique. Corley, KM; Hobby, HM; Rausch, JL, 2004)	0.88
" Outpatients (18 years or older) who met DSM-IV criteria for GAD, with baseline Hamilton Rating Scale for Anxiety (HAMA) scores > or = 18, were randomly assigned to double blind treatment with escitalopram (10 mg/day for the first 4 weeks and then flexibly dosed from 10-20 mg/day) or placebo for 8 weeks, following a 1-week, single-blind, placebo lead-in period."	( Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Bose, A; Davidson, JR; Korotzer, A; Zheng, H, 2004)	1.23
" Multiple SSRI dosing ranges were evaluated in autistic patients of different ages with various functional impairments."	( Treating functional impairment of autism with selective serotonin-reuptake inhibitors. Eichner, SF; Jones, JR; Moore, ML, 2004)	0.32
" The dosing is convenient, and the drug is safe and well tolerated due to a mild profile of side-effects and favorable pharmacokinetic properties."	( [Escitalopram--second generation of serotonin transporter inhibitors?]. Borkowska, AB; Rybakowski, J, )	0.75
"In continuation of a previous psychometric analysis of dose-response data for citalopram in depression, the corresponding study data for escitalopram is of interest, since escitalopram is the active enantiomer of citalopram and because citalopram was used as the active control."	( Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Andersen, HF; Bech, P; Cialdella, P; Pedersen, AG; Tanghøj, P, 2004)	1.27
" Two weeks after the increase of the dosage of sertraline, the patient developed a full-blown SS, which resolved completely after the discontinuation of the drug."	( Repetition of serotonin syndrome after reexposure to SSRI--a case report. Modestin, J; Tomaselli, G, 2004)	0.32
"A rat model was used to study if postmortem redistribution of the S- and R-enantiomers of citalopram (CIT) and its metabolites demethylcitalopram (DCIT) and didemethylcitalopram (DDCIT) occurs after three different subcutaneous dosing procedures with racemic CIT."	( Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats. Ahlner, J; Bengtsson, F; Carlsson, B; Druid, H; Kugelberg, FC, )	0.61
" Initially, dose-response experiments were performed with intrahippocampal perfusions of GBR-12909 and citalopram, respectively, selective dopamine and serotonin re-uptake blockers."	( Anticonvulsant action of GBR-12909 and citalopram against acute experimentally induced limbic seizures. Clinckers, R; Ebinger, G; Meurs, A; Michotte, Y; Smolders, I, 2004)	0.81
" The immediate and early effect of SSRI use on platelets might be an increase be an in tendency for thrombosis, whereas the late effect after repeated dosing might be an increase in tendency to bleed, as suggested by previous literature."	( Venous thromboembolism and escitalopram. Anil Yağcioğlu, AE; Ertugrul, A; Kurne, A; Yazici, KM, )	0.42
" This is especially important, however, for a drug that is pivotal to a patient's well-being; its therapeutic effect should be carefully monitored when any new drug is added or a change in the dosage of a concurrent drug is made."	( Exacerbation of panic disorder with rifampin therapy in a patient receiving citalopram. Argo, TR; Carnahan, RM; Kukoyi, O, 2005)	0.56
"Twenty-seven women meeting DSM-IV criteria for PMDD were randomly assigned in a double-blind manner to luteal phase (N = 13) or symptom-onset (N = 14) dosing of escitalopram (10-20 mg/day) for 3 consecutive menstrual cycles."	( A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. Ferdousi, T; Freeman, EW; Lin, H; Sammel, MD; Sondheimer, SJ, 2005)	0.76
"Premenstrual dysphoric disorder improved significantly with either luteal phase or symptom-onset dosing of escitalopram."	( A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. Ferdousi, T; Freeman, EW; Lin, H; Sammel, MD; Sondheimer, SJ, 2005)	0.77
" Each subject was scanned twice: with and without pre-treatment with the SSRI citalopram in various dosage regimens."	( Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study. Ell, PJ; Erlandsson, K; Lucas, R; Lui, D; Mu, S; Sivananthan, T; Spezzi, A; Townsend, CE; Warrington, S, 2005)	0.56
" Following recovery, the animals were orally dosed at light onset with either desipramine (20 mg/kg), fluoxetine (10 mg/kg), citalopram (10 or 40 mg/kg) or vehicle in a cross-over design."	( Antidepressants and REM sleep in Wistar-Kyoto and Sprague-Dawley rats. Hutson, PH; Ivarsson, M; Paterson, LM, 2005)	0.53
" The clinical investigator graded the veracity of the patients' dosing history on a 5-point ordinal scale."	( The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. Duffull, SB; Friberg, LE; Hackett, LP; Isbister, GK, 2005)	0.61
" Escitalopram was prescribed in a dosage of 10 mg/day for 2-months."	( [Depressive disorders in panic attack patients and their correction with escitalopram]. Cherednichenko, NV; Levada, OA, )	0.98
" Here, we compare the efficacy and safety of citalopram, with its S-enantiomer escitalopram at half dosage as to citalopram, in elderly patients who have panic attacks."	( New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. Alvano, A; Malaguarnera, M; Raffaele, R; Rampello, L; Vecchio, I, 2006)	0.83
"Patients (6-17 years old) with major depressive disorder were randomized to receive 8 weeks of double-blind flexibly dosed treatment with escitalopram (10-20 mg/day; n = 131) or placebo (n = 133)."	( A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. Findling, RL; Jonas, J; Saikali, K; Ventura, D; Wagner, KD, 2006)	0.78
"The objective of this double-blind, randomised, placebo-controlled, multicentre clinical study was to demonstrate the non-inferiority and safety of the hypericum extract STW3-VI in a once-daily dosage regime in the treatment of moderate depression."	( Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Gastpar, M; Singer, A; Zeller, K, 2006)	0.56
"To determine if voluntary prescription change forms for antidepressant drugs could induce dosing changes and reduce the cost of antidepressant therapy in a Medicaid population."	( Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program. Hamer, AM; Hartung, DM; Haxby, DG; Ketchum, KL; Pollack, DA, )	0.13
"The present study has addressed the question of what is more important for the occurrence of adaptive changes observed in the organism treated with antidepressant drugs: a daily dosing of the drug or the period of time necessary for the plastic events to develop."	( Delayed effects of antidepressant drugs in rats. Dziedzicka-Wasylewska, M; Faron-Górecka, A; Kuśmider, M, 2006)	0.33
" Results reveal a clear dose-response relationship in both sexes."	( S-Citalopram in neuroendocrine challenge-tests: serotonergic responsivity in healthy male and female human participants. Bausch, S; Hennig, J; Iffland, J; Kuepper, Y; Reuter, M, 2006)	1.06
" Potential predictors examined were type of disorder, location of study, dosing regimen, number of treatment arms, gender of patients, and duration and severity of disorder."	( Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. Baldwin, DS; Bandelow, B; Despiegel, N; Dolberg, OT; Stein, DJ, 2006)	0.54
" The dosage was reduced and yawning disappeared some hours later."	( Do your patients suffer from excessive yawning? Gutiérrez-Alvarez, AM, 2007)	0.34
" dosing of a novel MCHR1 antagonist, N-[3-(1-{[4-(3,4-difluorophenoxy)-phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847), in three mouse models predictive of antidepressant/anxiolytic-like activity: novelty suppressed feeding (NSF) in 129S6/SvEvTac mice and light/dark paradigm (L/D) and forced swim test (FST) in BALB/cJ mice."	( Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocam Craig, DA; David, DJ; Dong, D; Gerald, CP; Hegde, LG; Hen, R; Holick, KA; Klemenhagen, KC; Marzabadi, MR; Mendez, I; Ping, XI; Santarelli, L; Saxe, MD; Swanson, CJ; Zhong, H, 2007)	0.34
" The treatment was conducted as a monotherapy during 6 weeks, with citalopram dosage of 20 mg/day."	( [An electrophysiological study of the rehabilitation of cognitive functions during the treatment of patients with panic disorders]. Golubev, VL; Gordeev, SA; Posokhov, SI; Riabokon', IV; Tabeeva, GR; Veĭn, AM, 2006)	0.57
"This trial was conducted to compare the efficacy and tolerability of a fixed dose of escitalopram 10 mg/day with sertraline optimally dosed within its recommended dose range (50-200 mg/day) for the treatment of major depressive disorder."	( Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Armstrong, EP; Haim Erder, M; Skrepnek, GH; Ventura, D, 2007)	1.28
" At week 8, the mean sertraline dosage was 144 mg/day (median = 150 mg/day)."	( Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Armstrong, EP; Haim Erder, M; Skrepnek, GH; Ventura, D, 2007)	1.06
"No differences in efficacy were observed for fixed-dose escitalopram 10 mg/day and sertraline flexibly dosed from 50-200 mg/day."	( Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Armstrong, EP; Haim Erder, M; Skrepnek, GH; Ventura, D, 2007)	1.31
" Patients were treated with open-label escitalopram at a dosage of 10 to 20 mg per day."	( Escitalopram in seasonal affective disorder: results of an open trial. Kasper, S; Pjrek, E; Praschak-Rieder, N; Stastny, J; Willeit, M; Winkler, D, 2007)	1.33
" Adolescents, elderly individuals and patients with hepatic impairment do not have clinically relevant differences in pharmacokinetics compared with healthy young adults, implying that adjustment of the dosage is not necessary in these patient groups."	( The clinical pharmacokinetics of escitalopram. Rao, N, 2007)	0.62
" The dosage was increased to 10 mg daily two weeks later."	( Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities. Brahm, NC; Brown, RC; McElwain, DL, 2007)	0.34
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."	( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A, )	0.13
"The efficacy and tolerability of symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD) was evaluated in an open trial."	( Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series. Ravindran, AV; Ravindran, LN; Steiner, M; Woods, SA, 2007)	0.88
" CD1 mice were dosed either acutely or chronically with either antidepressants or 5-HT receptor subtype selective antagonists."	( Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists. Hutson, PH; Murray, F, 2007)	0.34
" Dosage adjustments were made within 2 weeks, depending on the tolerability of the patient."	( Obsessive-compulsive disorder: an open-label pilot trial of escitalopram. da Silva Prado, H; de Oliveira, IR; Galvão-de Almeida, A; Góis, CR; Leckman, JF; Miranda-Scippa, AM; Quarantini, LC; Rosário, MC; Santos-Jesus, R, 2007)	0.58
"56)% were shown after administration of citalopram in a dosage of 4 mg x kg."	( Imaging the availability of serotonin transporter in rat brain with 123I-ADAM and small-animal SPECT. Chang, CJ; Chen, CC; Hwang, LC; Jan, ML; Kao, HC; Lee, SY; Liu, HH, 2007)	0.61
" The model may be applied for preclinical evaluations or predictions of escitalopram concentration-time courses in plasma as well as at the target site in the CNS for various dosing scenarios."	( Pharmacokinetic modelling of blood-brain barrier transport of escitalopram in rats. Bundgaard, C; Jørgensen, M; Larsen, F, 2007)	0.81
"Nondepressed outpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition PG received flexibly dosed escitalopram in a prospective, 10-week, open-label trial after a 2-week observation period."	( An open-label trial of escitalopram in the treatment of pathological gambling. Allen, J; Black, DW; Forbush, KT; Shaw, M, )	0.64
" The results are discussed in the light of dosage issues and subtypes of serotonergic receptors."	( Divergent effects of increased serotonergic activity on psychophysiological parameters of human attention. Glenthøj, BY; Jensen, K; Oranje, B; Wienberg, M, 2008)	0.35
" Participants received flexible doses of citalopram for up to 14 weeks, with dosage adjustments based on routine clinical assessments."	( Ethnicity/race and outcome in the treatment of depression: results from STAR*D. Alpert, JE; Castro, DB; Gaynes, BN; Gonzalez, J; Lesser, IM; Luther, JF; Rush, AJ; Trivedi, M; Wisniewski, SR, 2007)	0.61
"Simple, accurate, precise, and sensitive ultraviolet spectrophotometric and reversed-phase high-performance liquid chromatographic (RP-HPLC) methods for simultaneous estimation of escitalopram oxalate (ESC) and clonazepam (CLO) in combined tablet dosage form have been developed and validated."	( Spectrophotometric and reversed-phase high-performance liquid chromatographic methods for simultaneous determination of escitalopram oxalate and clonazepam in combined tablet dosage form. Dhavale, ND; Gandhi, SV; Jadhav, VY; Sabnis, SS, )	0.53
" Participants were adult outpatients who, following 8 weeks of monotherapy with an adequate dosing regimen of an SSRI other than citalopram and had not responded, met the diagnostic criteria for depression as described in the Diagnostic and statistical manual of mental disorders, fourth edition, and had a score > or =20 on the 21-item Hamilton Rating Scale for Depression (HAM-D21)."	( Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Jiang, Q; Lenox-Smith, AJ, 2008)	0.83
"Selective serotonin reuptake inhibitors were found to be effective in treating premenstrual symptoms, with continuous dosing regimens favored for effectiveness."	( Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Aperi, J; Borenstein, J; Jones, JB; Karne, A; Shah, NR; Shemtov, R, 2008)	0.35
"Despite the typically chronic course of OCD, many patients with OCD responded to the Esciatolpram at the dosage of twenty milligram per day."	( Escitalopram in the treatment of obsessive-compulsive disorder: a double blind placebo control trial. Ahmad, S; Hotiana, UA; Khan, MN, )	0.85
" Participants received citalopram for up to 14 weeks, with dosage adjustments based on routine clinical assessments."	( Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D. Alpert, J; Cook, I; Epstein, M; Flores, D; Gonzalez, C; Lesser, I; Luther, J; Rosales, A; Rush, AJ; Sciolla, A; Trivedi, M; Wisniewski, S; Zisook, S, 2008)	0.66
" The clinical assessment was carried out at baseline (t0) and at the 4th (t1), 12th (t2), 24th (t3), 36th (t4), and 48th (t5) week by means of the Yale-Brown Obsessive Compulsive Scale, Hamilton Rating Scale for Depression, Clinical Global Impression scale, and the Dosage Record and Treatment Emergent Symptom Scale."	( Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. Carlini, M; Catena Dell'osso, M; Consoli, G; Golia, F; Marazziti, D; Mungai, F; Pfanner, C; Presta, S, 2008)	0.61
" Escitalopram and aripiprazole were flexibly dosed for 7 weeks, with maximum dosages of 20 and 30 mg/d, respectively."	( An open study of aripiprazole and escitalopram for psychotic major depressive disorder. Denninger, JW; Dording, C; Fava, M; Hilliker, S; Homberger, C; Matthews, JD; Park, L; Rooney, K; Siefert, C; Sklarsky, K; van Nieuwenhuizen, AO, 2009)	1.25
"The objective of this study was to compare population pharmacokinetic models of escitalopram developed from dosage times recorded by a medication event monitoring system (MEMS) versus the reported times from patients with diagnosed depression."	( The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. Bies, RR; Fagiolini, A; Feng, Y; Florian, J; Frank, E; Gastonguay, MR; Jin, Y; Kepple, G; Kirshner, M; Kupfer, DJ; Pollock, BG, 2009)	0.79
"In a multicentre part-randomised open-label design (the Genome Based Therapeutic Drugs for Depression (GENDEP) study) 811 adults with moderate to severe unipolar depression were allocated to flexible dosage escitalopram or nortriptyline for 12 weeks."	( Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Aitchison, KJ; Barreto, M; Dmitrzak-Weglarz, M; Elkin, A; Farmer, A; Giovannini, C; Hauser, J; Henigsberg, N; Jorgensen, L; Kalember, P; Landau, S; Maier, W; Marusic, A; McGuffin, P; Mors, O; Petrovic, A; Placentino, A; Rietschel, M; Schmael, C; Souery, D; Uher, R; Zobel, A, 2009)	0.84
" A selective serotonergic drug (citalopram) or a placebo was administered using a mean dosage of 10 mg/day in combination with physiotherapy."	( A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. Acler, M; Fiaschi, A; Manganotti, P; Robol, E, 2009)	0.64
" Despite similar medication dosing and time at exit dose, the efficacy participants tolerated citalopram better."	( Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Fava, M; Gaynes, BN; Lavori, PW; Luther, JF; McGrath, PJ; Nierenberg, AA; Rush, AJ; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2009)	0.57
" A pooled analysis suggests that build-up of the R-enantiomer after repeated citalopram dosing may lead to increased inhibition of S-enantiomer occupancy of SERT."	( Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Asenbaum, S; Attarbaschi-Steiner, T; Dudczak, R; Holik, A; Kasper, S; Klein, N; Lanzenberger, R; Mossaheb, N; Sacher, J; Spindelegger, C, 2009)	0.79
"Citalopram was delivered using measurement-based care and flexible dosing with the aim of achieving symptom remission."	( Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. Balasubramani, GK; Fava, M; Friedman, ES; Gilmer, W; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2009)	2.01
" The mean (SD) maximum dosage of citalopram hydrobromide was 16."	( Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Anagnostou, E; Bregman, JD; Donnelly, CL; Dukes, K; Hirtz, D; Hollander, E; King, BH; McCracken, JT; Ritz, L; Scahill, L; Sikich, L; Sullivan, L; Wagner, A, 2009)	0.96
"To report the successful use of high dose insulin (HDI) in previously unreported insulin dosing ranges in a patient with severe myocardial toxicity due to an amitriptyline and citalopram overdose."	( High dose insulin in toxic cardiogenic shock. Engebretsen, KM; Holger, JS; Marini, JJ, 2009)	0.55
" A total of 796 adult patients with major depressive disorder who were treated with a flexible dosage of escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP) were included in the sample and provided data on suicidal ideation."	( Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Aitchison, KJ; Bonvicini, C; Craig, I; Farmer, AE; Gray, J; Gupta, B; Hauser, J; Henigsberg, N; Huezo-Diaz, P; Jorgensen, L; Kalember, P; Kapelski, P; Lewis, CM; Maier, W; Marusic, A; McGuffin, P; Mors, O; Perroud, N; Petrovic, A; Placentino, A; Rietschel, M; Schulze, TG; Smith, R; Souery, D; Uher, R; Zobel, A, 2009)	0.57
" Phase 1 was a 6-week lead-in with open-label sertraline flexibly dosed to 100 mg (or escitalopram equivalent) to prospectively define treatment refractoriness (lack of remission)."	( Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. Hoge, EA; Lebeau, RT; Moshier, SJ; Otto, MW; Pollack, MH; Simon, NM; Thompson, EH; Worthington, JJ; Zalta, AK, 2009)	0.58
"In a multicentre part-randomised open-label study, 811 adult patients with moderate to severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for 12 weeks."	( Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. Aitchison, KJ; Campbell, D; Elkin, A; Farmer, AE; Giovannini, C; Gray, J; Gunasinghe, C; Gupta, B; Hauser, J; Henigsberg, N; Jorgensen, L; Maier, W; Marusic, A; McGuffin, P; Mors, O; Perroud, N; Placentino, A; Rietschel, M; Souery, D; Strohmaier, J; Szczepankiewicz, A; Uher, R; Zobel, A, 2009)	0.8
"0 mg/kg) attenuated the priming effects of cocaine, shifting the cocaine dose-response function rightward and downward."	( Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms. Platt, DM; Rowlett, JK; Rüedi-Bettschen, D; Spealman, RD, 2010)	0.36
"It is important that variations in drug metabolism during pregnancy be considered as these changes may necessitate a dosage adjustment to ensure that therapeutic failure does not occur during pregnancy."	( Changes in antidepressant metabolism in pregnancy evidenced by metabolic ratios in hair: a novel approach. Baumer, C; Koren, G; O'Brien, L; Sachs, H; Thieme, D, 2010)	0.36
" Citalopram alone produced predominantly saline-appropriate responding, but when administered before cocaine, citalopram dose-dependently shifted the cocaine dose-response curve leftward."	( Citalopram enhances cocaine's subjective effects in rats. Hiranita, T; Katz, JL; Soto, PL, 2009)	2.71
"Our results suggest that the genetic polymorphisms in CYP2C19 may be influencing S-CIT serum concentrations, and that specific CYP2D6 polymorphisms may be predicting patient treatment outcomes based on gene dosage analyses."	( Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Chen, CY; Fang, CK; Hsiao, MC; Lin, KM; Liu, SC; Liu, YL; Lu, ML; Lu, SC; Shen, WW; Tang, HS; Tsai, MH; Wu, CS, 2010)	0.58
" Treatment dropout was defined as missing seven consecutive buprenorphine dosing days."	( Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. Anderson, BJ; Cioe, PA; Friedmann, PD; Herman, DS; Kettavong, M; Stein, MD; Tellioglu, T, 2010)	0.36
" Patients randomly received flexible dosing of citalopram or placebo augmentation of their antipsychotic medication."	( Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response. Fellows, I; Golshan, S; Kasckow, J; Meeks, T; Solorzano, E; Zisook, S, 2010)	0.62
"we related medication choice and dosage range to outcomes of treatment as reflected by discharge rates and suicidality."	( Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team. Agius, M; Gardner, J; Liu, K; Zaman, R, 2010)	0.36
" Regarding Dose Ranges, we note that wheras many patients had their dosage titrated upwards from the starting dose, most did not have the dosage titrated to the highest dose of the relevant medication."	( Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team. Agius, M; Gardner, J; Liu, K; Zaman, R, 2010)	0.36
"Nineteen healthy volunteers underwent a gastric barostat, gastric emptying and/or a drinking test after dosing with either placebo or citalopram (20 mg intravenously)."	( The effects of acute citalopram dosing on gastric motor function and nutrient tolerance in healthy volunteers. Casteels, C; Janssen, P; Tack, J; Van Oudenhove, L; Verbeke, K; Vos, R, 2011)	0.89
"Among 811 adults with moderate-to-severe depression, melancholic, atypical, anxious and anxious-somatizing depression subtypes established at baseline were evaluated as predictors of outcome of treatment with flexible dosage of the SSRI escitalopram or the tricyclic antidepressant nortriptyline."	( Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. Aitchison, KJ; Dernovsek, MZ; Farmer, A; Hauser, J; Henigsberg, N; Kalember, P; Maier, W; McGuffin, P; Mendlewicz, J; Mors, O; Placentino, A; Rietschel, M; Souery, D; Uher, R; Zobel, A, 2011)	0.77
" Patients on higher dosage of antidepressant have higher risk of having FSD."	( Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine. Asmidar, D; Guan, NC; Hod, R; Sidi, H, 2012)	0.6
" Trials of citalopram and escitalopram were associated with reports of persistent nausea and gastric reflux unresolved by changes in dosing schedule or positioning."	( Antidepressant-mediated gastroesophageal reflux disease. Brahm, NC; Kelly-Rehm, MC, 2011)	0.76
" Despite therapeutic doses, a significant number of patients had serum concentrations less than 50 ng/mL, and these were associated with an unfavorable treatment outcome; therapeutic drug monitoring is recommended to optimize dosing citalopram in the early phase of treatment."	( Association between citalopram serum levels and clinical improvement of patients with major depression. Boland, K; Dragicevic, A; Fric, M; Hiemke, C; Laux, G; Müller, MJ; Ostad Haji, E; Rao, ML; Tadić, A; Wagner, S, 2011)	0.88
"We tested nine symptom dimensions derived from a previously published factor analysis of depression rating scales as predictors of outcome in 811 adults with moderate to severe depression treated with flexibly dosed escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP)."	( Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Aitchison, KJ; Bajs, M; Dernovsek, MZ; Farmer, A; Hauser, J; Henigsberg, N; Maier, W; McGuffin, P; Mors, O; Perlis, RH; Rietschel, M; Souery, D; Uher, R; Zobel, A, 2012)	0.56
" Although perturbation of the serotonin system during neonatal life has been implicated in the long-term behavioral effects of neonatal antidepressant exposure, dose-response studies were necessary to confirm that inhibition of the serotonin transporter during the neonatal period is sufficient to produce impairments in sexual behavior."	( Dose-dependent effects of neonatal SSRI exposure on adult behavior in the rat. Harris, SS; Lin, RC; Maciag, D; Paul, IA; Simpson, KL, 2012)	0.38
" Moderate to high antidepressant dosage is another significant predictor of HSD in depressed women treated with SSRIs."	( Hypoactive sexual desire among depressed female patients treated with selective serotonin reuptake inhibitors: a comparison between escitalopram and fluoxetine. Asmidar, D; Guan, NC; Hod, R; Jaafar, NR; Sidi, H, 2012)	0.58
"99) and escitalopram dosage (r = -0."	( An integrative assessment of the psychophysiologic alterations in young women with recurrent major depressive disorder. Chang, JS; Choi, HM; Ha, K; Ha, TH; Her, JY; Park, T; Yi, SH; Yoo, CS, 2012)	0.78
" Citalopram dose-response was evaluated."	( Comparison of citalopram and other selective serotonin reuptake inhibitor ingestions in children. Benson, BE; Klein-Schwartz, W; Lee, SC; Litovitz, T, 2012)	1.65
"In clinical practice, indication and dosage of citalopram and other SSRIs should be carefully monitored."	( Citalopram-induced subacute cutaneous lupus erythematosus -- first case and review concerning photosensitivity in selective serotonin reuptake inhibitors. Conrad, R; Geiser, F; Röhrs, S, )	1.83
" Escitalopram was started at 10 mg/d with a dosage increase to 20 mg/d after 4 weeks; placebo dosing was identical."	( Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial. Gadde, KM; Gang, CH; Griffing, GT; Vander Wal, JS, 2012)	1.72
" Quantitative proteomic analyses were undertaken on hippocampal tissue from a study design that used two inbred mouse strains, two depressogenic protocols and a control condition, (maternal separation, chronic mild stress, control), two antidepressant drugs and two dosing protocols."	( Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains. Aitchinson, KJ; Binder, E; Campbell, J; Craig, I; Davies, M; Keers, R; Kuhn, K; Malki, K; McGuffin, P; Paya-Cano, J; Schalkwyk, LC; Selzer, S; Sluyter, F; Uher, R; Ward, M, 2012)	0.38
" The aim of this study was to describe characteristics of dosing history in participants with depression receiving once daily escitalopram."	( Adherence to escitalopram treatment in depression: a study of electronically compiled dosing histories in the 'Depression: the search for phenotypes' study. Anderton, J; Bies, RR; Buttenfield, J; Fagiolini, A; Frank, E; Jin, Y; Kepple, G; Kupfer, DJ; Lange, AC; Pollock, BG; Rucci, P; Vrijens, B; Wessels, AM, 2012)	0.94
" Escitalopram and other SSRIs decrease the HPA axis response to the DST, beeing the aim of this study validate the DST as a surrogate marker of central serotonergic activity in the treatment with escitalopram and its application to the calculation of the dosage regimens."	( Therapeutic monitoring of escitalopram by dexamethasone suppression test. Lozano-Ortiz, R; Marin-Lacasa, R; Orea-Ramón, B; Pascual-Garcia, A; Santacruz-Abion, MJ; Sebastian-Perez, F, )	1.05
"The objective of the current study was to develop a validated, specific stability-indicating reversed-phase liquid chromatographic (LC) method for the quantitative determination of escitalopram oxalate and clonazepam and their related substances in bulk drugs and pharmaceutical dosage forms in the presence of degradation products."	( Stability-indicating RP-HPLC method for the simultaneous determination of escitalopram oxalate and clonazepam. Gadapayale, KK; Kakde, MG; Kakde, RB; Satone, DD, 2013)	0.81
" Dosed in vivo, escitalopram had little impact on the occurrence of activity onsets in rats given access to running wheels, whether the drug was given acutely or sub-chronically."	( The effects of combining serotonin reuptake inhibition and 5-HT7 receptor blockade on circadian rhythm regulation in rodents. Sánchez, C; Sprouse, J; Westrich, L, 2013)	0.72
"Cassette dosed plasma and brain samples from nine compounds were extracted using a protein precipitation method."	( High-throughput liquid chromatography/mass spectrometry method for the quantitation of small molecules using accurate mass technologies in supporting discovery drug screening. Dean, B; Deshmukh, G; Ding, X; Ghobarah, H; Hop, CE; Jaochico, A; Liederer, BM; Liu, X; Zhang, X, 2013)	0.39
"To make an informed benefit-risk evaluation of a drug, a range of doses needs to be evaluated and its dose-response and exposure-response relationships for safety and effectiveness assessed during drug development (International Conference on Harmonisation E4)."	( Is this the dose for you?: the role of modeling. Bhattaram, A; Huang, SM; Mehrotra, N; Wang, Y, 2013)	0.39
"25 mg/day; escitalopram dosage remained at 10 mg/day."	( Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. Franco-Chaves, JA; Luckenbaugh, DA; Mallinger, AG; Martinez, PE; Mateus, CF; Zarate, CA, 2013)	0.76
" Cox regression models, adjusted for demographic and clinical characteristics, were used to examine associations of antidepressant dosing with ventricular arrhythmia and cardiac, noncardiac, and all-cause mortality."	( Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Blow, FC; Bohnert, AS; Ganoczy, D; Kales, HC; Nallamothu, BK; Pfeiffer, PN; Zivin, K, 2013)	0.64
"The data taken together indicate that TDM-guided dosing of citalopram has the potential to be cost effective by reducing the length of hospitalization."	( Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopram. Boland, K; Dragicevic, A; Fric, M; Hiemke, C; Laux, G; Mann, K; Müller, MJ; Ostad Haji, E; Rao, ML, 2013)	0.85
"Decomposed bone and plasma samples of rats exposed to amitriptyline (AMI) and citalopram (CIT) under different dosing patterns were analyzed."	( Discrimination between patterns of drug exposure by toxicological analysis of decomposed skeletal tissues. Part II: Amitriptyline and citalopram. Cornthwaite, HM; Watterson, JH, 2013)	0.82
"Adolescents (12-17 years) who completed an 8-week randomized, double-blind, flexible-dose, placebo-controlled, lead-in study of escitalopram 10-20 mg versus placebo could enroll in a 16-24-week, multisite extension trial; patients maintained the same lead-in randomization (escitalopram or placebo) and dosage (escitalopram 10 or 20 mg/day, or placebo) during the extension."	( Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial. Bose, A; Findling, RL; Robb, A, 2013)	1.32
"12-week trial of flexibly dosed citalopram."	( Structural imaging in late-life depression: association with mood and cognitive responses to antidepressant treatment. Kraut, MA; Lyman, CH; Marano, CM; Munro, CA; Smith, GS; Workman, CI, 2015)	0.7
" Here, the in vivo effects of dosing with duloxetine 60 mg once daily for 11 days in healthy subjects were assessed in 2 studies: (1) centrally (n = 11), by measuring concentrations of 5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylglycol (DHPG), and NE in cerebrospinal fluid, and (2) versus escitalopram 20 mg/d (n = 32) in a 2-period crossover study by assessing the ΔDHPG/ΔNE ratio in plasma during orthostatic testing and by pharmacokinetic/pharmacodynamic modeling of reuptake inhibition using subjects' serum in cell lines expressing cloned human 5-HTT or NET."	( Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. Chappell, JC; Dean, RA; Detke, MJ; Eisenhofer, G; Haber, H; Iyengar, S; Knadler, MP; Lachno, DR; Lobo, ED; Mitchell, MI; Nemeroff, CB; Owens, MJ; Pangallo, B, 2014)	0.58
"Two hundred forty-five outpatients aged 18-65 having non-psychotic, non-bipolar major depression were randomly assigned to double-blind treatment with bupropion or escitalopram or the combination dosed to a maximum of bupropion 450 mg/d and/or escitalopram 40 mg/d for 12 weeks."	( Combination antidepressant therapy for major depressive disorder: speed and probability of remission. Amat, J; Bergeron, R; Blier, P; Blondeau, C; Chen, Y; Deliyannides, DA; Hellerstein, D; Laberge, L; McGrath, PJ; Norris, S; O'Shea, D; Pilowsky, DJ; Stewart, JW; Tessier, P; Withers, A, 2014)	0.6
" Dosage began at 10 mg per day with planned titration to 30 mg per day over 3 weeks based on response and tolerability."	( Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2014)	0.8
"Among patients with probable Alzheimer disease and agitation who were receiving psychosocial intervention, the addition of citalopram compared with placebo significantly reduced agitation and caregiver distress; however, cognitive and cardiac adverse effects of citalopram may limit its practical application at the dosage of 30 mg per day."	( Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2014)	1.01
" Glycaemia values returned to normality only after suspension of escitalopram, despite antidiabetic dosage increase."	( A case report on escitalopram-induced hyperglycaemia in a diabetic patient. Brasesco, PC; Fucile, C; Leone, S; Martelli, A; Mattioli, F; Milano, G; Zuccoli, ML, 2013)	0.95
" The proposed method is used to determine the citalopram in tablet dosage forms."	( Spectrophotometric determination of citalopram hydrobromide in tablet dosage form using chloranil. Ansari, TM; Raza, A, 2014)	0.94
"While preliminary, our findings comprise the first pharmacogenetic study demonstrating an effect of the 5-HTTLPR 'S' allele load on escitalopram-induced changes in amygdala activity during emotional processing, consistent with a 5-HTT expression dosage model."	( The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: preliminary findings from a randomised, crossover fMRI study. Bryant, RA; Das, P; Dobson-Stone, C; Felmingham, KL; Kemp, AH; Malhi, GS; Nathan, PJ; Outhred, T, 2014)	0.84
" In healthy human volunteers, citalopram's effects on Aβ production and Aβ concentrations in cerebrospinal fluid (CSF) were measured prospectively using stable isotope labeling kinetics, with CSF sampling during acute dosing of citalopram."	( An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Bateman, RJ; Chott, R; Cirrito, JR; Ficker, WD; Fisher, JR; Frederiksen, C; Grzelak, MV; Jasielec, MS; Lee, JM; Mintun, MA; Morris, JC; Sheline, YI; Swarm, R; West, T; Xiong, C; Yan, P; Yarasheski, K, 2014)	0.69
" Whether similar observations would occur after repeated administration of such compounds in an attempt to simulate dosing in humans, or be compromised by dopaminergic-mediated adverse effects warrants further investigation."	( Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain. Coudoré, F; Gardier, AM; Guiard, BP; Hache, G; Munro, G; Nguyen, TH; Peters, D; Quesseveur, G, 2015)	0.42
" However, therapeutic efficacy and treatment success is often variable, requiring changes in dosing regimens or drug selection."	( The development and validation of a turbulent flow-liquid chromatography-tandem mass spectrometric method for the simultaneous quantification of citalopram, sertraline, bupropion and hydroxybupropion in serum. Clarke, W; Jannetto, PJ; Johnson-Davis, KL; Langman, LJ; Marzinke, MA; Moskowitz, J; Petrides, AK, 2014)	0.6
" The selective serotonin reuptake inhibitor (SSRI) antidepressants reduce REM sleep time and increase REM latency after acute dosing in normal condition and even during REM rebound following RD."	( Chronic escitalopram treatment attenuated the accelerated rapid eye movement sleep transitions after selective rapid eye movement sleep deprivation: a model-based analysis using Markov chains. Bagdy, G; Gyertyán, I; Kátai, Z; Kitka, T; Kostyalik, D; Tóthfalusi, L; Vas, S, 2014)	0.8
"In this sample where antidepressant dosage is titrated using clinical judgement, P450 genotypes do not explain differences between patients in side effects with antidepressants."	( Exploring the role of drug-metabolising enzymes in antidepressant side effects. Aitchison, KJ; Craig, IW; Dernovšek, MZ; Dobson, RJ; Farmer, AE; Hauser, J; Henigsberg, N; Hodgson, K; Maier, W; McGuffin, P; Mors, O; Placentino, A; Rietschel, M; Souery, D; Tansey, KE; Uher, R, 2015)	0.42
" Present findings may have implications for escitalopram dosage and side effect profile in younger MDD patients."	( Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123 I]β-CIT SPECT study. Bartenstein, P; Brendel, M; Cumming, P; Karch, S; Koch, W; la Fougère, C; Pogarell, O; Rominger, A; Tatsch, K; Xiong, G; Zach, C, 2015)	0.89
"An accurate, selective and sensitive spectrofluorimetric method was developed for the determination of citalopram hydrobromide in commercial dosage forms."	( Utility of eosin Y as a complexing reagent for the determination of citalopram hydrobromide in commercial dosage forms by fluorescence spectrophotometry. Al-Badaei, M; Al-Fazari, A; Al-Mahrazi, R; Azmi, SN, 2015)	0.87
" We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d."	( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015)	0.42
" In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34."	( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015)	0.42
" Treatment for both groups started at baseline, and patients received either 12 weeks of individual CBT or 12 weeks of escitalopram with flexible dosing (10 to 20 mg)."	( Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder: Implications for mechanisms of change. Alpert, JE; Baer, L; Cardoos, A; Cohen, M; Farabaugh, A; Fava, M; Fisher, L; Holt, D; Huz, I; Nyer, M; Shapero, BG, 2015)	0.86
" Nevertheless, a maximum citalopram dosage of 20 mg in high risk patients (e."	( Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study. Aarts, N; Hofman, A; Kors, JA; Maljuric, NM; Niemeijer, MN; Noordam, R; Stricker, BH; van den Berg, ME; Visser, LE, 2015)	0.72
" For citalopram, analyses were additionally restricted to a maximum dosage of 20 mg in participants aged 60 years and older."	( Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study. Aarts, N; Hofman, A; Kors, JA; Maljuric, NM; Niemeijer, MN; Noordam, R; Stricker, BH; van den Berg, ME; Visser, LE, 2015)	0.93
" This result remained similar in the analysis comprising participants aged 60 years and older with a maximum prescribed daily dosage of 20 mg citalopram."	( Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study. Aarts, N; Hofman, A; Kors, JA; Maljuric, NM; Niemeijer, MN; Noordam, R; Stricker, BH; van den Berg, ME; Visser, LE, 2015)	0.62
" Although candidates for elective Roux-en-Y gastric bypass (RYGB) surgery may be treated with escitalopram, drug dosing strategies are typically not adjusted postoperatively."	( Decreased Escitalopram Concentrations Post-Roux-en-Y Gastric Bypass Surgery. Clarke, W; Coughlin, JW; Magnuson, TH; Marzinke, MA; Petrides, AK; Reinblatt, SP; Schweitzer, MA; Steele, K, 2015)	1.01
" Similarly, dosing trajectory was not significantly associated with genotype groups."	( Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism. Bishop, JR; Cook, EH; Gibbons, RD; Guter, SJ; Hur, K; Jacob, S; Mosconi, MW; Najjar, F; Owley, T; Sweeney, JA, 2015)	0.42
" CYP2C19 encodes the primary enzyme responsible for escitalopram metabolism and we investigated whether polymorphisms in CYP2C19 were related to symptoms and dosing in a pharmacogenetic study of ASD."	( Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Bishop, JR; Cook, EH; Guter, SJ; Jacob, S; Mosconi, MW; Najjar, F; Owley, T; Rubin, LH, 2015)	1.39
" Further studies should evaluate whether repeated dosing of SSRIs, or as combined with specific interventions, is required to elicit significant benefit of these agents on lower limb function poststroke."	( Increased Lower Limb Spasticity but Not Strength or Function Following a Single-Dose Serotonin Reuptake Inhibitor in Chronic Stroke. Gourab, K; Hornby, TG; Schmit, BD, 2015)	0.42
" The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder."	( Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016)	0.43
" Endpoint and tolerability analyses were analyzed using meta-regression and stratified subgroup analysis by predefined SSRI dose categories in order to assess the effect of SSRI dosing on the efficacy and tolerability of SSRIs for major depressive disorder."	( Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016)	0.43
" Food and Drug Administration (FDA) on the risk of suicidality among children associated with use of antidepressants, but the warning's effect on dosing of antidepressants has not been evaluated."	( Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning. Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A, 2016)	0.43
"The proportion of commercially insured children initiating an SSRI with a low dose was higher after the 2004 FDA warning on the risk of suicidality among children, suggesting improved prescribing practices surrounding SSRI dosing among children."	( Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning. Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A, 2016)	0.43
"In this double-blind parallel-group multicenter trial of 186 patients with Alzheimer's disease and clinically significant agitation, participants were randomly assigned to receive citalopram or placebo for 9 weeks, with the dosage titrated to 30 mg/day over the first 3 weeks."	( Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Devanand, DP; Drye, LT; Frangakis, C; Lyketsos, CG; Marano, CM; Mintzer, J; Mulsant, BH; Munro, CA; Newell, JA; Pawluczyk, S; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rein, L; Rosenberg, PB; Schneider, LS; Shade, D; Weintraub, D; Yesavage, J, 2016)	0.9
" These results indicate that higher doses of these drugs could lead to greater QT prolongation in a dose-response manner."	( A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. Cho, JY; Chung, H; Chung, JY; Jang, IJ; Kim, A; Lee, H; Lim, KS; Yoon, SH; Yu, KS, 2016)	0.65
"While dosage constraints must be considered because of citalopram's adverse effect profile, this agent's overall therapeutic effects in patients with Alzheimer's disease and agitation, in addition to efficacy for agitation/aggression, included reductions in the frequency of irritability, anxiety, and delusions; among patients who had these symptoms at week 9, they included a reduction in the severity of hallucinations but an increase in the severity of sleep/nighttime behavior disorders."	( Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. Devanand, DP; Drye, LT; Frangakis, C; Leonpacher, AK; Lyketsos, CG; Makino, KM; Mintzer, JE; Munro, CA; Newell, JA; Peters, ME; Pollock, BG; Porsteinsson, AP; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016)	1.07
" All drugs showed maximum occupancy at 4h after dosing and then decreasing occupancies with time."	( Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB. Arakawa, R; Kim, W; Ogawa, K; Okubo, Y; Sakayori, T; Tateno, A, 2016)	0.43
"Eligible participants were randomised 1 : 1 to treatment with either placebo (one capsule) or 20 mg of citalopram per day for 48 weeks, with the clinical option at 4 weeks to increase the daily dosage to 40 mg of citalopram or two placebo capsules for the remainder of the study."	( Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. Baldwin, D; Barnes, TR; Costelloe, C; Craig, TK; Crawford, M; Geddes, J; Ismail, S; Keown, P; Killaspy, H; Kiss, N; Kumar, M; Leeson, VC; Lewis, G; Lewis, S; Osborn, D; Pathak, R; Paton, C; Simon, J; Taylor, S, 2016)	0.65
" All-cause hospitalizations or deaths were found to significantly increase after dosage reductions (adjusted hazard ratio=4."	( Outcomes of Citalopram Dosage Risk Mitigation in a Veteran Population. Adabag, S; Cunningham, F; Dieperink, E; Nelson, D; Rector, TS, 2016)	0.81
" In contrast, among doses above these, there was no indication of a dose-response relationship."	( A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Eriksson, E; Hieronymus, F; Nilsson, S, 2016)	0.43
" These data reveal age- and genotype-dependent shifts in the dose-response for escitalopram to produce antidepressant-like effects, which vary with SERT expression, and may contribute to the limited therapeutic response to SSRIs in juveniles and adolescents."	( Ontogeny of SERT Expression and Antidepressant-like Response to Escitalopram in Wild-Type and SERT Mutant Mice. Daws, LC; Gould, GG; Koek, W; Mitchell, NC, 2016)	0.9
" To this aim, we exploited the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) data set, selected a subpopulation of 591 patients with an overlapping clinical history and analyzed treatment outcome according to dosage -20 or 40 mg per day of citalopram."	( Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR*D study. Branchi, I; Chiarotti, F; Giuliani, A; Viglione, A, 2017)	2.08
"Although the favourable characteristics of escitalopram as being the most selective serotonin reuptake inhibitor and having an increased therapeutic efficacy via binding on an additional allosteric binding site of the serotonin transporter, its dosing regimen has not yet been optimized for its use in dogs."	( Estimation of the optimal dosing regimen of escitalopram in dogs: A dose occupancy study with [11C]DASB. Baeken, C; De Vos, F; Dobbeleir, A; Dockx, R; Goethals, I; Peremans, K; Polis, I; Sadones, N; Saunders, J; Taylor, O; Van Laeken, N; Vlerick, L, 2017)	0.97
"The median daily dosage of citalopram was 20mg (Q1: 10mg, Q3: 20mg; range 10-40mg)."	( Pregnancy exposure to citalopram - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. Goecke, TW; Gründer, G; Janssen, G; Paulzen, M; Schoretsanitis, G; Stickeler, E; Stingl, JC, 2017)	1.07
"This randomized, double-blind, placebo-controlled study evaluated dose-response relationships of lisdexamfetamine dimesylate when used as augmentation for major depressive disorder in individuals exhibiting inadequate responses to antidepressant monotherapy."	( A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. Dauphin, M; Geibel, B; Iosifescu, DV; Mago, R; Reynolds, J; Richards, C; Sarkis, E, 2017)	0.46
"For Montgomery-Åsberg Depression Rating Scale total score change, no significant dose-responses were observed for any candidate dose-response curve (all p>0."	( A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy. Dauphin, M; Geibel, B; Iosifescu, DV; Mago, R; Reynolds, J; Richards, C; Sarkis, E, 2017)	0.46
"To assess the risk of headache associated with commonly prescribed antidepressant medications and to examine the impact of medication class, pharmacodynamics and dosage on risk of headache."	( Meta-analysis: Second generation antidepressants and headache. Bloch, MH; Olten, B; Telang, S; Walton, C, 2018)	0.48
"The small number of studies that examined side effects within fixed-dose trials may have limited the power to examine the association between medication dosing and risk of headache."	( Meta-analysis: Second generation antidepressants and headache. Bloch, MH; Olten, B; Telang, S; Walton, C, 2018)	0.48
" However, gamma activity during active and passive wakefulness (AW and PW, respectively) was not influenced by either acute or chronic dosing of escitalopram."	( Acute and chronic escitalopram alter EEG gamma oscillations differently: relevance to therapeutic effects. Bagdy, G; Bogáthy, E; Kátai, Z; Kostyalik, D; Papp, N; Vas, S, 2018)	1
" Serum concentration of citalopram and daily dosage correlated positively while daily dosage and mother milk concentration did not (rho = 0."	( Antidepressants in breast milk; comparative analysis of excretion ratios. Augustin, M; Franz, C; Gründer, G; Paulzen, M; Saßmannshausen, H; Schoretsanitis, G, 2019)	0.82
"The present study involved segmental testing of hair in two clinical cases with known dosage histories."	( Segmental Hair Analysis-Interpretation of the Time of Drug Intake in Two Patients Undergoing Drug Treatment. Johansen, SS; Linnet, K; Nielsen, MKK; Wang, X, 2019)	0.51
" Rats were chronically dosed with respectively clomipramine, citalopram, or midazolam."	( Distribution of clomipramine, citalopram, midazolam, and metabolites in skeletal tissue after chronic dosing in rats. Cuypers, E; Somers, T; Vandenbosch, M, 2019)	1.04
"Although the US Food and Drug Administration (FDA) recommended upper limits for citalopram dosing in older adults due to risk of corrected-QT (QTc) prolongation, which was adopted, and extended to escitalopram by Health Canada, the scientific basis is unclear."	( Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting. Brown, HK; Crépeau-Gendron, G; Koh, S; Madan, R; Mah, L; Shorey, C; Szabuniewicz, C; Veinish, S, 2019)	1.06
"We reviewed electronic health records at a university-affiliated geriatric health care center, over a 7-year period, to identify patients prescribed citalopram and escitalopram, who had an ECG within 90 days of initiation or dosage change."	( Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting. Brown, HK; Crépeau-Gendron, G; Koh, S; Madan, R; Mah, L; Shorey, C; Szabuniewicz, C; Veinish, S, 2019)	1.04
" This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray."	( Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E, 2019)	0.51
"The aims of this study were to characterize escitalopram pharmacokinetic profile, to identify factors influencing drug exposure, notably drug-drug interactions with antiretrovirals, and to simulate expected exposure under standard dosage regimen."	( Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Eap, CB; Glatard, A; Guidi, M; Marzolini, C, 2019)	1.49
"The variability in escitalopram disposition is large and poorly explained by demographic, clinical and environmental covariates, thus suggesting a role for dosage individualization based on therapeutic drug monitoring in case of poor clinical response."	( Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. Alves Saldanha, S; Buclin, T; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Eap, CB; Glatard, A; Guidi, M; Marzolini, C, 2019)	1.55
" This conditioned geotaxis was reduced by the administration of citalopram in a linear dose-response curve and ethanol at the low concentration."	( Design and development of a robotic predator as a stimulus in conditioned place aversion for the study of the effect of ethanol and citalopram in zebrafish. Clément, RJG; Macrì, S; Porfiri, M, 2020)	1
" Reduction in the magnitude of the excitatory post-synaptic currents by endogenous 5-HT was interpolated in the dose-response curve elicited by exogenous 5-HT, yielding that citalopram raised the extracellular 5-HT concentration to 823 nM."	( Citalopram reduces glutamatergic synaptic transmission in the auditory cortex via activation of 5-HT1A receptors. Aguilar-Magaña, D; Atzori, M; Canto-Bustos, M; Cervantes-Ramírez, V; Góngora-Alfaro, JL; Pérez-Padilla, EA; Pineda, JC; Salgado, H, 2019)	2.15
" We investigated the dosage assumptions of 1 unit per day, and 1 DDD per day, versus actual prescribed dosage under different handling of gaps and overlaps of prescriptions."	( Methods for constructing treatment episodes and impact on exposure-outcome associations. Andersen, M; Bahmanyar, S; Brandt, L; Linder, M; Mavros, P; Myers, D; Pazzagli, L, 2020)	0.56
"Fifty-eight patients with MDD (DSM-V) and Hamilton Depression Rating Scale (HAM-D) score ≥ 19 were randomized to receive either 400 mg twice daily L-Carnosine or placebo in addition to citalopram (maximum dosage of 40 mg/day) for six weeks in a randomized double-blind, and placebo-controlled study."	( L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. Akhondzadeh, S; Aqamolaei, A; Araminia, B; Ardebili, ME; Ghaffari, S; Mortazavi, SH; Mortezaei, A; Naderi, S; Sahebolzamani, E; Shalbafan, M; Shariati, B; Shirazi, E, 2020)	0.75
" Some symptoms appeared whilst I reduced the antidepressant dosage steadily: these were mild and resolved swiftly, but a few were quite puzzling."	( A personal account of reducing and stopping antidepressant treatment. Baldwin, DS, 2020)	0.56
" To evaluate the effects of GPR139 pharmacological activation on sleep, rats were orally dosed with the selective GPR139 agonist JNJ-63533054 (3-30 mg/kg)."	( Putative role of GPR139 on sleep modulation using pharmacological and genetic rodent models. Bonaventure, P; Dugovic, C; Dvorak, C; Liu, C; Lord, B; Lovenberg, T; Wang, L; White, A; Yun, S, 2020)	0.56
" A sensitive, efficient and rapid assay was selected satisfactorily and applied for simultaneous determination of citalopram and tadalafil either in their pure forms, in tablet dosage forms or in spiked human plasma."	( Simultaneous determination of citalopram and tadalafil by the second derivative synchronous fluorescence method in biological fluids; application of Box-Behnken optimization design. Abdel-Fattah, A; Abdel-Raoof, AM; Eissa, MS; Hasan, MA; Madkour, AW, 2021)	1.12
"Application of capillary electrophoresis (CE) has become a rapidly growing analytical technique for the estimation of drugs in pharmaceutical dosage forms and biological fluids."	( Capillary Electrophoresis Method for Determination of Escitalopram Oxalate in Urine Samples and Different Dosage Forms. Arlı, G; Atkoşar, Z; Badulla, WFS; Dal Poçan, AG, 2020)	0.8
"Escitalopram significantly reduced Aβ in mice, similar to previous findings in humans treated with acute dosing of an SSRI."	( Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Cirrito, JR; Davis, TA; Doherty, BM; Gardiner, WD; King, D; Lee, JM; Sheline, YI; Wallace, CE; Yan, P; Yuede, CM, 2020)	1.66
"Participants with GAD and coprescribed benzodiazepines were treated with a lower mean dosage of escitalopram and were less likely to complete the trial; there was no difference in adherence or treatment response."	( Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes. Altmann, H; Blumberger, DM; Gebara, MA; Karp, JF; Lenze, EJ; Mulsant, BH; Reynolds, CF; Stahl, ST, 2020)	0.78
"We observed a linear dose-response profile with respect to geotaxis, with increasing Citalopram concentrations reducing the tendency to swim near the bottom of the tank."	( Acute Citalopram administration modulates anxiety in response to the context associated with a robotic stimulus in zebrafish. Karakaya, M; Macrì, S; Porfiri, M; Scaramuzzi, A, 2021)	1.33
" Dosing strategies, discontinuation considerations, and side effects are discussed."	( The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia. Chen, A; Cloutier, A; Copeli, F; Metzger, E; Osser, DN, 2021)	0.62
"Since several recent meta-analyses report a dose-response relationship for the antidepressant effect of the selective serotonin reuptake inhibitors (SSRIs), we investigated how these drugs are dosed in clinical practice."	( Low SSRI dosing in clinical practice-a register-based longitudinal study. Eriksson, E; Hieronymus, F; Lisinski, A; Wallerstedt, SM, 2021)	0.62
" The lack of consensus regarding effective dosing of SSRIs may have contributed to this state of affairs."	( Low SSRI dosing in clinical practice-a register-based longitudinal study. Eriksson, E; Hieronymus, F; Lisinski, A; Wallerstedt, SM, 2021)	0.62
" Toxicokinetic and toxicodynamic submodels were used to dynamically simulate the chemical uptake and elimination, as well as dose-response relationships for hypothetical physiological modes of action and survival over time."	( Making Sense of Life-History Effects of the Antidepressant Citalopram in the Copepod Nitocra spinipes Using a Bioenergetics Model. De Schamphelaere, KAC; Koch, J, 2021)	0.86
" Study durations ranged from 8 to 16 weeks and MPH dosing ranged from 5 to 90 mg per day."	( Methylphenidate use in geriatric depression: A systematic review. Britt, RB; Brown, JN; Kahlon, CH; Smith, KR, 2021)	0.62
" Citalopram enhanced and prolonged the facilitation induced by anodal tDCS regardless of the dosage while turning cathodal tDCS-induced excitability diminution into facilitation."	( Dosage-Dependent Impact of Acute Serotonin Enhancement on Transcranial Direct Current Stimulation Effects. Ghanavati, E; Kuo, MF; Melo, L; Mosayebi-Samani, M; Nitsche, MA, 2021)	1.53
" The proportion of patients dosed above the new limit decreased from 8 to 1% in patients ≤ 65 years and from 46 to 23% in patients > 65 years old for citalopram versus 14-5% and 47-31% for escitalopram."	( Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data. Bleich, S; Bridler, R; de Bardeci, M; Greil, W; Grohmann, R; Hasler, G; Kasper, S; Köberle, U; Rüther, E; Seifert, J; Stassen, H; Toto, S; Willms, J, 2023)	1.4
" At 60 postnatal days (PD), male Wistar rats were treated chronically (16 days) with MOD at 30 or 60 mg/kg, with MOD+CIT at four dosage combinations administered to four groups (30MOD + CIT3, 30MOD + CIT5, 60MOD + CIT3, 60MOD + CIT5 mg/kg), or with a vehicle."	( Modafinil acquires reinforcing effects when combined with citalopram. Juárez, J; Yepez, JE, 2022)	0.97
" Dose-response effects were not investigated because dosage instructions were not available."	( Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults. Aakjaer, M; Andersen, M; De Bruin, ML; Werther, SK, 2022)	1
" On the other hand, a non-significant dosage of orexin-1 reversed the antidepressant effect of citalopram in the normal and REM sleep-deprived animals."	( Synergistic antidepressant effects of citalopram and SB-334867 in the REM sleep-deprived mice: Possible role of BDNF. Alibeik, H; Bananej, M; Khakpai, F; Saadati, N; Zarrindast, MR, 2022)	1.21
" The specific recommendation on daily dosage seems to have been better implemented than the broadly formulated contraindication of QTc-prolonging co-medication."	( [Effect of the direct healthcare professional communication on citalopram and escitalopram drug utilization for inpatient treatment of anxiety disorders]. Belz, M; Degner, D; Greil, W; Grohmann, R; Köberle, U, 2022)	0.96
" The ratio could be a valuable alternative to genotyping in personalized dosing of escitalopram and possibly other CYP2C19 substrates."	( Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers. Faraj, P; Hermansen, A; Hole, K; Molden, E, 2022)	1.27
" Genotype-guided dosing and drug selection have been implemented at several sites, including Vanderbilt University Medical Center, where clinical decision support (CDS) based on pharmacogenetic results went live for selective serotonin reuptake inhibitors in 2020 for both adult and pediatric patients."	( Pediatric considerations for pharmacogenetic selective serotonin reuptake inhibitors clinical decision support. Liu, M; Maxwell-Horn, AC; Rossow, KM; Saucier, LA; Van Driest, SL, 2023)	0.91
" This guideline updates and expands the 2015 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and SSRI dosing and summarizes the impact of CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes on antidepressant dosing, efficacy, and tolerability."	( Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Bell, GC; Bishop, JR; Bousman, CA; Brown, JT; Caudle, KE; Gaedigk, A; Hicks, JK; Klein, TE; Leeder, JS; Mueller, DJ; Ramsey, LB; Ruaño, G; Sangkuhl, K; Scott, SA; Singh, AB; Stevenson, JM; Strawn, JR; Tsermpini, EE, 2023)	0.91
" However, it is important to acknowledge certain limitations of our research, such as the use of a single depression induction model and limited dosing regimens."	( Vitamins C and D Exhibit Similar Antidepressant Effects to Escitalopram Mediated by NOx and FKBPL in a Stress-Induced Mice Model. Aljabali, AAA; Alqudah, A; Altaber, S; Gammoh, O; Ibrahim, A; Qnais, E; Tambuwala, MM, 2023)	1.15
" It has a narrow therapeutic window and can cause severe toxicity and mortality if the dosage exceeds the safe level."	( Toward Personalized Treatment of Depression: An Affordable Citalopram Test based on a Solid-Contact Potentiometric Electrode for at-Home Monitoring of the Antidepressant Dosage. Amirghasemi, F; Chen, R; Ma, H; Mousavi, MPS; Ong, V; Tran, A, 2023)	1.15
" Binding of inhibitors to the allosteric site of human SERT (hSERT) impedes the dissociation of antidepressants bound at the central site and may enhance the efficacy of such antidepressants to potentially reduce their dosage and side effects."	( Dynamic extracellular vestibule of human SERT: Unveiling druggable potential with high-affinity allosteric inhibitors. Abramyan, AM; Bang-Andersen, B; Bundgaard, C; Loland, CJ; Plenge, P; Salomon, K; Shi, L; Wang, L, 2023)	0.91

Class	Description
2-benzofurans
nitrile	A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
cyclic ether	Any ether in which the oxygen atom forms part of a ring.
tertiary amino compound	A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Citalopram Action Pathway	37	24
Citalopram Metabolism Pathway	7	15
Serotonin transporter activity	0	3

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	1.0610	0.1000	20.8793	79.4328	AID588453; AID588456
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	14.1254	0.0112	12.4002	100.0000	AID1030
EWS/FLI fusion protein	Homo sapiens (human)	Potency	16.6996	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259256
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	35.9932	0.0355	20.9770	89.1251	AID504332
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	20.5962	0.0126	2.4518	25.0177	AID485313
D(1A) dopamine receptor	Homo sapiens (human)	Potency	15.8489	0.0224	5.9449	22.3872	AID488983
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	1.1220	0.1259	12.2344	35.4813	AID1458
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	10.0000	0.0096	10.5250	35.4813	AID1479145
Ataxin-2	Homo sapiens (human)	Potency	35.4813	0.0119	12.2221	68.7989	AID588378
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	37.9330	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 22 member 1	Homo sapiens (human)	IC50 (µMol)	18.8000	0.2100	5.5537	10.0000	AID386625
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Sodium-dependent noradrenaline transporter	Mus musculus (house mouse)	Ki	1.0000	0.0120	0.0905	0.2900	AID134216
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.2970	0.0001	1.0076	8.7800	AID625218
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	Ki	0.1560	0.0000	0.8871	10.0000	AID625218
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	IC50 (µMol)	2.1960	0.0004	1.8773	10.0000	AID625207
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	Ki	2.1780	0.0032	2.2887	9.3160	AID625207
Tryptophan 5-hydroxylase 1	Rattus norvegicus (Norway rat)	Ki	16.5400	0.0005	0.0914	0.4900	AID64517
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	16.6754	0.0000	1.6129	10.0000	AID625171
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	Ki	13.6618	0.0004	2.0337	8.6606	AID625171
Aldo-keto reductase family 1 member B1	Bos taurus (cattle)	Ki	0.0044	0.0004	0.0018	0.0044	AID408801
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Ki	50.1187	0.0001	0.7396	10.0000	AID4411
Acetylcholinesterase	Homo sapiens (human)	IC50 (µMol)	73.3000	0.0000	0.9332	10.0000	AID1738334
Aromatase	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0018	0.0018	1.8564	6.2000	AID179069
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	2.1960	0.0008	1.5416	20.0000	AID625207
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Ki	336.1227	0.0003	1.4656	10.0000	AID147725; AID625207; AID731396
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	41.0000	0.0007	0.9774	9.7000	AID179076
Alpha-1D adrenergic receptor	Homo sapiens (human)	IC50 (µMol)	3.2890	0.0002	0.7568	8.8970	AID625200
Alpha-1D adrenergic receptor	Homo sapiens (human)	Ki	1.6170	0.0000	0.3609	10.0000	AID625200
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	IC50 (µMol)	0.2970	0.0001	1.0302	9.0000	AID625218
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	Ki	0.1560	0.0001	0.9549	10.0000	AID625218
Sodium-dependent serotonin transporter	Homo sapiens (human)	IC50 (µMol)	0.0227	0.0001	0.8645	8.7096	AID1058858; AID1434653; AID1495956; AID1659263; AID1738335; AID1783170; AID1824583; AID576813; AID625222
Sodium-dependent serotonin transporter	Homo sapiens (human)	Ki	0.0118	0.0000	0.7048	8.1930	AID1718178; AID204199; AID361595; AID361596; AID408801; AID408802; AID625222; AID731395
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0027	0.0003	0.8197	8.4900	AID1059389; AID179069; AID471630
Histamine H1 receptor	Homo sapiens (human)	IC50 (µMol)	3.1940	0.0000	0.4436	5.1768	AID625269
Histamine H1 receptor	Homo sapiens (human)	Ki	0.3710	0.0000	0.5110	10.0000	AID625269
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	IC50 (µMol)	1.8390	0.0001	1.1873	8.9125	AID625217
5-hydroxytryptamine receptor 2B	Homo sapiens (human)	Ki	1.1710	0.0003	0.7693	10.0000	AID625217
5-hydroxytryptamine receptor 7	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	18.8000	2.0300	5.5313	9.9000	AID386625
Sodium-dependent dopamine transporter	Homo sapiens (human)	Ki	508.2700	0.0002	1.1115	8.0280	AID64517; AID731394
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	5.4349	0.0009	1.9014	10.0000	AID1054122; AID161281; AID243151; AID408340; AID576612; AID625171
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	Ki	13.6618	0.0021	1.8407	10.0000	AID625171
Sigma intracellular receptor 2	Rattus norvegicus (Norway rat)	Ki	5.4100	0.0024	1.1050	9.3000	AID1718151
Sodium-dependent serotonin transporter	Mus musculus (house mouse)	Ki	0.0029	0.0004	0.5957	4.1000	AID134217
Sodium-dependent dopamine transporter	Mus musculus (house mouse)	Ki	10.0000	0.4040	0.6873	1.0350	AID134215
Nuclear receptor subfamily 3 group C member 3	Bos taurus (cattle)	IC50 (µMol)	16.6754	0.1048	2.8398	8.3173	AID625171
Nuclear receptor subfamily 3 group C member 3	Bos taurus (cattle)	Ki	13.6618	0.0858	2.9542	8.6606	AID625171
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	IC50 (µMol)	0.3980	0.0003	0.7028	5.3660	AID625223
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Ki	0.1670	0.0000	0.4901	10.0000	AID625223
Sigma non-opioid intracellular receptor 1	Rattus norvegicus (Norway rat)	Ki	0.2920	0.0003	0.2671	5.0700	AID1718165
Transporter	Rattus norvegicus (Norway rat)	IC50 (µMol)	8.8000	0.0008	1.9562	8.8000	AID179081
Transporter	Rattus norvegicus (Norway rat)	Ki	6.1900	0.0001	0.8667	10.0000	AID147725
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium-dependent serotonin transporter	Homo sapiens (human)	EC50 (µMol)	8.7000	0.0011	2.3883	8.7000	AID1434655
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
retinoid metabolic process	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
prostaglandin metabolic process	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
retinol metabolic process	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
acetylcholine catabolic process in synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
regulation of receptor recycling	Acetylcholinesterase	Homo sapiens (human)
osteoblast development	Acetylcholinesterase	Homo sapiens (human)
acetylcholine catabolic process	Acetylcholinesterase	Homo sapiens (human)
cell adhesion	Acetylcholinesterase	Homo sapiens (human)
nervous system development	Acetylcholinesterase	Homo sapiens (human)
synapse assembly	Acetylcholinesterase	Homo sapiens (human)
receptor internalization	Acetylcholinesterase	Homo sapiens (human)
negative regulation of synaptic transmission, cholinergic	Acetylcholinesterase	Homo sapiens (human)
amyloid precursor protein metabolic process	Acetylcholinesterase	Homo sapiens (human)
positive regulation of protein secretion	Acetylcholinesterase	Homo sapiens (human)
retina development in camera-type eye	Acetylcholinesterase	Homo sapiens (human)
acetylcholine receptor signaling pathway	Acetylcholinesterase	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Acetylcholinesterase	Homo sapiens (human)
monoamine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
chemical synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
response to pain	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuron cellular homeostasis	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Alpha-1D adrenergic receptor	Homo sapiens (human)
neuron-glial cell signaling	Alpha-1D adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-1D adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Alpha-1D adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-1D adrenergic receptor	Homo sapiens (human)
behavioral fear response	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
locomotory behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
feeding behavior	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
cGMP-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of nervous system process	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of appetite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
regulation of corticotropin-releasing hormone secretion	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of fat cell differentiation	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of calcium-mediated signaling	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
monoamine transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to hypoxia	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to nutrient	Sodium-dependent serotonin transporter	Homo sapiens (human)
memory	Sodium-dependent serotonin transporter	Homo sapiens (human)
circadian rhythm	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to toxic substance	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of gene expression	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of serotonin secretion	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Sodium-dependent serotonin transporter	Homo sapiens (human)
response to estradiol	Sodium-dependent serotonin transporter	Homo sapiens (human)
social behavior	Sodium-dependent serotonin transporter	Homo sapiens (human)
vasoconstriction	Sodium-dependent serotonin transporter	Homo sapiens (human)
sperm ejaculation	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of neuron differentiation	Sodium-dependent serotonin transporter	Homo sapiens (human)
positive regulation of cell cycle	Sodium-dependent serotonin transporter	Homo sapiens (human)
negative regulation of organ growth	Sodium-dependent serotonin transporter	Homo sapiens (human)
behavioral response to cocaine	Sodium-dependent serotonin transporter	Homo sapiens (human)
enteric nervous system development	Sodium-dependent serotonin transporter	Homo sapiens (human)
brain morphogenesis	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin uptake	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane depolarization	Sodium-dependent serotonin transporter	Homo sapiens (human)
platelet aggregation	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to retinoic acid	Sodium-dependent serotonin transporter	Homo sapiens (human)
cellular response to cGMP	Sodium-dependent serotonin transporter	Homo sapiens (human)
regulation of thalamus size	Sodium-dependent serotonin transporter	Homo sapiens (human)
conditioned place preference	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent serotonin transporter	Homo sapiens (human)
inflammatory response	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
memory	Histamine H1 receptor	Homo sapiens (human)
visual learning	Histamine H1 receptor	Homo sapiens (human)
regulation of vascular permeability	Histamine H1 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Histamine H1 receptor	Homo sapiens (human)
regulation of synaptic plasticity	Histamine H1 receptor	Homo sapiens (human)
cellular response to histamine	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H1 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H1 receptor	Homo sapiens (human)
neural crest cell migration	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of cytokine production	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of endothelial cell proliferation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled receptor internalization	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
heart morphogenesis	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cardiac muscle hypertrophy	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
intracellular calcium ion homeostasis	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
activation of phospholipase C activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of cell population proliferation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
response to xenobiotic stimulus	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neural crest cell differentiation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
intestine smooth muscle contraction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
phosphorylation	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
calcium-mediated signaling	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cGMP-mediated signaling	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
vasoconstriction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
negative regulation of apoptotic process	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of MAP kinase activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
embryonic morphogenesis	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
regulation of behavior	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of nitric-oxide synthase activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
release of sequestered calcium ion into cytosol	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of cell division	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein kinase C signaling	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cellular response to temperature stimulus	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin receptor signaling pathway	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
chemical synaptic transmission	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
monoamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
lactation	Sodium-dependent dopamine transporter	Homo sapiens (human)
sensory perception of smell	Sodium-dependent dopamine transporter	Homo sapiens (human)
locomotory behavior	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to xenobiotic stimulus	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to iron ion	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
adenohypophysis development	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to nicotine	Sodium-dependent dopamine transporter	Homo sapiens (human)
positive regulation of multicellular organism growth	Sodium-dependent dopamine transporter	Homo sapiens (human)
regulation of dopamine metabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cocaine	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine biosynthetic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine catabolic process	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to ethanol	Sodium-dependent dopamine transporter	Homo sapiens (human)
cognition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake involved in synaptic transmission	Sodium-dependent dopamine transporter	Homo sapiens (human)
response to cAMP	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
prepulse inhibition	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine uptake	Sodium-dependent dopamine transporter	Homo sapiens (human)
hyaloid vascular plexus regression	Sodium-dependent dopamine transporter	Homo sapiens (human)
amino acid transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
sodium ion transmembrane transport	Sodium-dependent dopamine transporter	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
lipid transport	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nervous system development	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
regulation of neuron apoptotic process	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein homotrimerization	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
retinal dehydrogenase activity	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
prostaglandin H2 endoperoxidase reductase activity	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
allyl-alcohol dehydrogenase activity	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
glycerol dehydrogenase [NADP+] activity	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
all-trans-retinol dehydrogenase (NADP+) activity	Aldo-keto reductase family 1 member B1	Bos taurus (cattle)
amyloid-beta binding	Acetylcholinesterase	Homo sapiens (human)
acetylcholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
cholinesterase activity	Acetylcholinesterase	Homo sapiens (human)
protein binding	Acetylcholinesterase	Homo sapiens (human)
collagen binding	Acetylcholinesterase	Homo sapiens (human)
hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
serine hydrolase activity	Acetylcholinesterase	Homo sapiens (human)
acetylcholine binding	Acetylcholinesterase	Homo sapiens (human)
protein homodimerization activity	Acetylcholinesterase	Homo sapiens (human)
laminin binding	Acetylcholinesterase	Homo sapiens (human)
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
identical protein binding	Alpha-1D adrenergic receptor	Homo sapiens (human)
alpha1-adrenergic receptor activity	Alpha-1D adrenergic receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
integrin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoatomic cation channel activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin:sodium:chloride symporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
antiporter activity	Sodium-dependent serotonin transporter	Homo sapiens (human)
syntaxin-1 binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
cocaine binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
sodium ion binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
identical protein binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
nitric-oxide synthase binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
actin filament binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonin binding	Sodium-dependent serotonin transporter	Homo sapiens (human)
histamine receptor activity	Histamine H1 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H1 receptor	Homo sapiens (human)
neurotransmitter receptor activity	Histamine H1 receptor	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G-protein alpha-subunit binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
GTPase activator activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
protease binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
signaling receptor binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopamine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
amine binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein-containing complex binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
protein phosphatase 2A binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
heterocyclic compound binding	Sodium-dependent dopamine transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent dopamine transporter	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
G protein-coupled opioid receptor activity	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein binding	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular region	Acetylcholinesterase	Homo sapiens (human)
basement membrane	Acetylcholinesterase	Homo sapiens (human)
extracellular space	Acetylcholinesterase	Homo sapiens (human)
nucleus	Acetylcholinesterase	Homo sapiens (human)
Golgi apparatus	Acetylcholinesterase	Homo sapiens (human)
plasma membrane	Acetylcholinesterase	Homo sapiens (human)
cell surface	Acetylcholinesterase	Homo sapiens (human)
membrane	Acetylcholinesterase	Homo sapiens (human)
neuromuscular junction	Acetylcholinesterase	Homo sapiens (human)
synaptic cleft	Acetylcholinesterase	Homo sapiens (human)
synapse	Acetylcholinesterase	Homo sapiens (human)
perinuclear region of cytoplasm	Acetylcholinesterase	Homo sapiens (human)
side of membrane	Acetylcholinesterase	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-1D adrenergic receptor	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
focal adhesion	Sodium-dependent serotonin transporter	Homo sapiens (human)
endosome membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
endomembrane system	Sodium-dependent serotonin transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
membrane raft	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
serotonergic synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
synapse	Sodium-dependent serotonin transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent serotonin transporter	Homo sapiens (human)
neuron projection	Sodium-dependent serotonin transporter	Homo sapiens (human)
cytosol	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
synapse	Histamine H1 receptor	Homo sapiens (human)
dendrite	Histamine H1 receptor	Homo sapiens (human)
plasma membrane	Histamine H1 receptor	Homo sapiens (human)
nucleoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
cytoplasm	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2B	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
cytoplasm	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
cell surface	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuron projection	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon terminus	Sodium-dependent dopamine transporter	Homo sapiens (human)
membrane raft	Sodium-dependent dopamine transporter	Homo sapiens (human)
postsynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
dopaminergic synapse	Sodium-dependent dopamine transporter	Homo sapiens (human)
flotillin complex	Sodium-dependent dopamine transporter	Homo sapiens (human)
axon	Sodium-dependent dopamine transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent dopamine transporter	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nuclear envelope	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear inner membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear outer membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
lipid droplet	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytosol	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
growth cone	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytoplasmic vesicle	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
anchoring junction	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID309940	Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 1.62 mM/kg, ip after 24 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID471630	Inhibition of [3H]5-HT reuptake at rat SERT expressed in HEK293 cells after 2 mins by liquid scintillation counting	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents.
AID1220557	Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1220559	Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID230538	Relative binding affinity for serotonin and dopamine transporters	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1220555	Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID132117	Tested in vivo for head twitches antagonizing activity in mice	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID1718178	Inhibition of SERT (unknown origin)	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID361596	Displacement of [3H]paroxetine from human SERT expressed in HEK293 cells	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.
AID1220560	Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID714086	Increase in DOPAC level in Sprague-Dawley rat striatum at 25 umol/kg, sc by HPLC analysis relative to saline-treated control	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID29811	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID540214	Clearance in rat after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID112283	Antagonistic activity against tetrabenazine-induced ptosis in mice	1985	Journal of medicinal chemistry, Dec, Volume: 28, Issue:12	3-Phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake.
AID714091	Reduction in spontaneous locomotor activity in Sprague-Dawley rat at 25 umol/kg, sc measured after 15 to 60 mins relative to saline-treated control	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID309946	Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 19.42 mM/kg, ip after 24 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1458667	Anxiolytic-like activity in Swiss albino mouse assessed as suppression of movement administered for 30 mins by four-plate test	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID311933	Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID309937	Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 6.47 mM/kg, ip after 20 mins	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID26362	Ionization constant (pKa)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID161281	Inhibition of human Potassium channel HERG expressed in mammalian cells	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID499950	Selectivity ratio of Ki for NET in rat brain frontal cortex to Ki for SERT in rat brain stem	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588208	Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset	2010	Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5	Predicting phospholipidosis using machine learning.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1269157	Antidepressant-like activity in Swiss albino mouse assessed as reduction in immobility time at 1.25 mg/kg, ip dosed 30 mins before test measured after 6 mins by forced swim test	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT(7) receptor selectivity versus multireceptor profile.
AID539464	Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1274950	Antidepressant activity in C57BL/6J mouse assessed as average force at 10 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 0.281 +/- 0.018 to 0.359 +/- 0.027 N)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1274957	Antidepressant activity in C57BL/6J mouse assessed as number of events at 10 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 1325.1 +/- 77.8 to 1773.4 +/- 109.9 No_unit)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID309938	Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 12.94 mM/kg, ip after 20 mins	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1274951	Antidepressant activity in C57BL/6J mouse assessed as average force at 20 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 0.281 +/- 0.018 to 0.359 +/- 0.027 N)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID8002	Observed volume of distribution	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID204703	Inhibition of [3H]citalopram binding to Serotonin transporter of rat cerebral cortex	2000	Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14	Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1552842	Antidepressant activity in ip dosed C57BL6/J mouse as total time of immobile by tail suspension test relative to control	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu
AID1209418	AUC(0 to infinity) in Sprague-Dawley rat brain at 10 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID408340	Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique	2008	Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11	Support vector machines classification of hERG liabilities based on atom types.
AID643383	Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
AID239085	Displacement of [3H]GBR-12935 from dopamine transporter of rat caudate-putamen	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Synthesis and monoamine transporter affinity of new 2beta-carbomethoxy-3beta-[4-(substituted thiophenyl)]phenyltropanes: discovery of a selective SERT antagonist with picomolar potency.
AID1824583	Inhibition of SERT (unknown origin) in HEK293 cells assessed as inhibition of 5-HT reuptake by spectrophotometric analysis	2022	European journal of medicinal chemistry, Feb-05, Volume: 229	The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
AID1209350	Ratio of unbound brain concentration to drug level in cerebrospinal fluid in Sprague-Dawley rat at 10 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID408801	Displacement of [3H]citalopram from human SERT expressed in HEK293 cells	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.
AID576612	Inhibition of human ERG	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID239125	Displacement of [3H]paroxetine from serotonin transporter of rat cerebral cortex	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Synthesis and monoamine transporter affinity of new 2beta-carbomethoxy-3beta-[4-(substituted thiophenyl)]phenyltropanes: discovery of a selective SERT antagonist with picomolar potency.
AID64517	In vitro binding affinity against human dopamine transporter in dog kidney cell line by using [125I]RTI-55 radioligand	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.
AID1552839	Anti-anxiety activity in C57BL/6J mouse assessed as increase in total time spent in open arms at 15 mg/kg, ip treated for 15 mins by elevated zero maze assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1718165	Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in Sprague-Dawley rat brain membranes by scintillation counting method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID411793	Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
AID179081	Inhibition of noradrenaline uptake in rat synaptosomal fraction	1985	Journal of medicinal chemistry, Dec, Volume: 28, Issue:12	3-Phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake.
AID1274945	Toxicity in ip dosed C57BL/6J mouse assessed as effect on spontaneous locomotory activity at MED measured over 1 min 15 secs	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29359	Ionization constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1274968	Antidepressant activity in ip dosed albino Swiss mouse assessed as decrease in immobility time by forced swim test	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1269159	Toxicity in Swiss albino mouse assessed as effect on spontaneous locomotor activity at 1.25 mg/kg, ip dosed 30 mins before test measured after 2 to 6 mins	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT(7) receptor selectivity versus multireceptor profile.
AID540217	Volume of distribution at steady state in dog after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID309935	Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 3.24 mM/kg, ip after 20 mins	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1738337	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jul-15, Volume: 198	Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease.
AID134217	Tested in vitro for serotonin(5-HT) neuronal uptake inhibition	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID1274940	Antidepressant activity in ip dosed C57BL/6J mouse assessed as reduction in immobility time of mouse by tail suspension test	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID395324	Lipophilicity, log D at pH 7.4 by liquid chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID781328	pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID499949	Displacement of [3H]WIN-35428 from DAT in rat caudate-putamen by scintillation counting	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.
AID1659263	Antagonist activity at SERT receptor (unknown origin) by fluorescence based assay	2020	Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8	Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychotics.
AID134216	Tested in vitro for norepinephrine (NE) neuronal uptake inhibition	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID1274942	Anxiolytic activity in ip dosed albino Swiss mouse assessed as increase in number of shocks accepted measured over 1 min, 15 secs by four plates test	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID243151	Inhibitory concentration against potassium channel HERG	2005	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11	A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID309936	Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 4.86 mM/kg, ip after 20 mins	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID408252	Inhibition of [3H]dopamine reuptake at human NET expressed in african green monkey COS7 cells at 100 nM	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies.
AID309950	Selectivity ratio of ED50 for 5-HT reuptake in mouse to ED50 for norepinephrine reuptake in mouse	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540231	Dose normalised AUC in dog after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1434655	Inhibition of [3H]-S-citalopram dissociation from SERT allosteric modulator site (S2) (unknown origin) expressed in African green monkey COS1 cell membranes by scintillation counting method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	X-ray structure based evaluation of analogs of citalopram: Compounds with increased affinity and selectivity compared with R-citalopram for the allosteric site (S2) on hSERT.
AID309941	Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 3.24 mM/kg, ip after 24 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID499948	Displacement of [3H]nisoxetine from NET in rat frontal cortex by scintillation counting	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.
AID712521	Displacement of [3H]5-carboxamidotryptamine to human 5HT1A expressed in HEK293 cells by filter binding assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID179069	Inhibition of 5-HT uptake in rat synaptosomal fraction	1985	Journal of medicinal chemistry, Dec, Volume: 28, Issue:12	3-Phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake.
AID7783	Unbound fraction (plasma)	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID540218	Clearance in monkey after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1274943	Toxicity in ip dosed C57BL/6J mouse assessed as effect on spontaneous locomotory activity at MED measured over 6 mins	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1274941	Antidepressant activity in ip dosed Wistar rat assessed as reduction in immobility time of rat by forced swim test	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID309948	Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced intraperitoneally dosed mouse head twitch after 20 mins	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID540233	Dose normalised AUC in human after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID540232	Dose normalised AUC in monkey after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1207630	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	2012	Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID298031	Lipophilicity, log D at pH7.4	2007	Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19	High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1274964	Antidepressant activity in C57BL/6J mouse assessed as immobility time at 10 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 160.7 +/- 12 to 170.6 +/- 9 sec)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID1434650	Selectivity ratio of EC50 for inhibition of [3H]-S-citalopram dissociation from SERT allosteric modulator site (S2) (unknown origin) expressed in African green monkey COS1 cell membranes to IC50 for [3H]5-HT uptake by SERT primary site (S1) (unknown origi	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	X-ray structure based evaluation of analogs of citalopram: Compounds with increased affinity and selectivity compared with R-citalopram for the allosteric site (S2) on hSERT.
AID1209410	AUC(0 to 7 hrs) in Sprague-Dawley rat brain at 10 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID688847	Octanol-phosphate buffered saline partition coefficient, log K of the compound	2011	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24	Fluorescent reporters of monoamine transporter distribution and function.
AID1274952	Antidepressant activity in C57BL/6J mouse assessed as average force at 40 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 0.281 +/- 0.018 to 0.359 +/- 0.027 N)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID309934	Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 1.62 mM/kg, ip after 20 mins	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID395327	Dissociation constant, pKa by capillary electrophoresis	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID298032	Acid dissociation constant, pKa of the compound	2007	Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19	High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID723164	Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 1.25 mg/kg, ip measured during last 4 mins of a 6 mins test session by forced swim test	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID731396	Inhibition of [3H]dopamine uptake at human NET expressed in COS7 cells after 5 mins by beta-counting	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID681144	TP_TRANSPORTER: cell accumulation of calcein in L-MDR1 cells	2003	The Journal of pharmacology and experimental therapeutics, Apr, Volume: 305, Issue:1	Inhibition of P-glycoprotein by newer antidepressants.
AID731394	Inhibition of [3H]dopamine uptake at human DAT expressed in COS7 cells after 3 mins by beta-counting	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID309939	Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 25.89 mM/kg, ip after 20 mins	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID499947	Displacement of [3H]citalopram from SERT in rat brain stem by scintillation counting	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.
AID1209377	AUC(0 to 7 hrs) in Sprague-Dawley rat plasma at 10 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID50341	Maximal activatory effect against human carbonic anhydrase I (hCA I)	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID540221	Volume of distribution at steady state in human after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1059389	Displacement of [3H]paroxetine from SERT in rat cortical membranes after 6 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Synthesis, docking and pharmacological evaluation of novel homo- and hetero-bis 3-piperazinylpropylindole derivatives at SERT and 5-HT1A receptor.
AID50343	Maximal activatory effect against human carbonic anhydrase I (hCA I) at a concentration of 1 uM	2003	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16	Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II.
AID714081	Decrease in 5-HIAA level in Sprague-Dawley rat striatum at 25 umol/kg, sc by HPLC analysis relative to saline-treated control	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID1552838	Anti-anxiety activity in C57BL/6J mouse assessed as increase in total number of open arm entries at 15 mg/kg, ip treated for 15 mins by elevated zero maze assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu
AID576813	Inhibition of [3H]-serotonin reuptake at human SERT expressed in HEK293 cells after 15 to 20 mins by fluorescence neurotransmitter transporter assay	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.
AID179076	Inhibition of dopamine uptake in rat synaptosomal fraction	1985	Journal of medicinal chemistry, Dec, Volume: 28, Issue:12	3-Phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake.
AID1274965	Antidepressant activity in C57BL/6J mouse assessed as immobility time at 20 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 160.7 +/- 12 to 170.6 +/- 9 sec)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID499951	Selectivity ratio of Ki for DAT in rat caudate-putamen to Ki for SERT in rat brain stem	2010	Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16	Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.
AID1783170	Inhibition of human wild type SERT expressed in COS7 cells assessed as inhibition of [3H]5HT uptake measured for 40 hrs by scintillation counting analysis	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine.
AID1718151	Displacement of [3H]DTG from sigma 2 receptor in Sprague-Dawley rat brain membranes in presence of (+)-pentazocine by scintillation counting method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID204199	Inhibition of [125I]RTI-55 binding to human serotonin transporter expressed in human embryonic kidney cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.
AID1458659	Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time administered for 30 mins measured last 4 mins of 6 mins test by forced swimming test	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1274944	Toxicity in ip dosed Wistar rat assessed as effect on spontaneous locomotory activity at MED measured over 2 to 6 mins	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID4411	Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
AID309942	Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 4.86 mM/kg, ip after 24 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1738334	Inhibition of human plasma AChE using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition and measured after 10 mins by Ellman's method	2020	European journal of medicinal chemistry, Jul-15, Volume: 198	Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1209386	AUC(0 to infinity) in Sprague-Dawley rat plasma at 10 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID243060	Selectivity for inhibition of serotonin and dopamine transporters	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Synthesis and monoamine transporter affinity of new 2beta-carbomethoxy-3beta-[4-(substituted thiophenyl)]phenyltropanes: discovery of a selective SERT antagonist with picomolar potency.
AID112281	Compound was tested for antagonistic activity against 5-HTP-induced potentiation in mice	1985	Journal of medicinal chemistry, Dec, Volume: 28, Issue:12	3-Phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID243422	log (1/Km) value for human liver microsome cytochrome P450 3A4	2005	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18	Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID1209334	Ratio of drug level in brain to plasma in Sprague-Dawley rat at 10 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1220558	Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID361595	Displacement of [3H]citalopram from human SERT expressed in HEK293 cells	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	3-(4-(6-Fluoroalkoxy-3,4-dihydroisoquinoline-2(1H)-yl)cyclohexyl)-1H-indole-5-carbonitriles for SERT imaging: chemical synthesis, evaluation in vitro and radiofluorination.
AID243077	Selectivity for inhibition of serotonin and norepinephrine transporters	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Synthesis and monoamine transporter affinity of new 2beta-carbomethoxy-3beta-[4-(substituted thiophenyl)]phenyltropanes: discovery of a selective SERT antagonist with picomolar potency.
AID540219	Volume of distribution at steady state in monkey after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1738335	Displacement of [3H]paroxetine from human SERT expressed in human HEK293 cells incubated for 30 mins by liquid scintillation counting analysis	2020	European journal of medicinal chemistry, Jul-15, Volume: 198	Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID395325	Lipophilicity, log P by microemulsion electrokinetic chromatography	2009	Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6	Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID491771	Potentiation of 5-hydroxytryptophan-induced stereotypic behavior in mouse at 10 mg/kg, po administered 2 hrs before 5-hydroxytryptophan challenge measured for 30 mins	2010	Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13	6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1453904	Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 1.25 mg/kg, ip for 30 mins measured last 4 mins of 6 mins test by forced swim test relative to control
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1495956	Inhibition of SERT (unknown origin) expressed in HEK293 cells assessed as reduction in 5-HT uptake incubated for 30 mins	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID147725	In vitro binding affinity against human norepinephrine transporter in human embryonic kidney cell line by using [3H]-nisoxatine radioligand	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1220554	Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID309947	Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 25.89 mM/kg, ip after 24 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1434653	Inhibition of [3H]5-HT uptake by SERT primary site (S1) (unknown origin) expressed in African green monkey COS1 cells after 10 mins by TopCount scintillation counting method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	X-ray structure based evaluation of analogs of citalopram: Compounds with increased affinity and selectivity compared with R-citalopram for the allosteric site (S2) on hSERT.
AID462725	Potentiation of 5-hydroxytryptophan-induced stereotpic behavior in CD1 mouse at 10 mg/kg, po administered 120 mins before 5HTP challenge measured for 30 mins	2010	Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6	1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1458668	Toxicity in Swiss albino mouse assessed as effect on spontaneous locomotory activity measuring number of areas crossed administered for 30 mins measured every 2 mins up to 6 mins	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID540216	Clearance in dog after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1220556	Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Species independence in brain tissue binding using brain homogenates.
AID1209342	Ratio of drug level in cerebrospinal fluid to unbound plasma concentration in Sprague-Dawley rat at 10 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID576805	Cytotoxicity against human chemoresistant DG75 cells expressing SERT assessed as decrease in cell viability 10 or 50 uM after 72 hrs Alamar blue assay	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.
AID540237	Phospholipidosis-positive literature compound observed in rat
AID179990	Tested in vivo for serotonin syndrome antagonizing activity in rat	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID1129361	Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1209394	AUC(0 to 7 hrs) in Sprague-Dawley rat cerebrospinal fluid at 10 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1458670	Toxicity in CD-1 mouse assessed as effect on spontaneous locomotory activity by measuring number of areas crossed administered for 30 mins measured every 1 min for first 5 mins	2017	Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1054122	Inhibition of human ERG	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Polypharmacology - foe or friend?
AID1274970	Toxicity in ip dosed albino Swiss mouse assessed as effect on spontaneous locomotory activity at MED measured over 2 to 6 mins	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1058858	Inhibition of SERT (unknown origin) assessed as inhibition of serotonin uptake	2013	Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23	Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites.
AID408802	Displacement of [3H]paroxetine from human SERT expressed in HEK293 cells	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1738336	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jul-15, Volume: 198	Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1274958	Antidepressant activity in C57BL/6J mouse assessed as number of events at 20 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 1325.1 +/- 77.8 to 1773.4 +/- 109.9 No_unit)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1274966	Antidepressant activity in C57BL/6J mouse assessed as immobility time at 40 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 160.7 +/- 12 to 170.6 +/- 9 sec)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540215	Volume of distribution at steady state in rat after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID714104	Increase in DOPAC level in sc dosed Sprague-Dawley rat striatum by HPLC analysis	2012	Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22	Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
AID309949	Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in intraperitoneally dosed mouse after 24 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID576815	Inhibition of [3H]-serotonin reuptake at human SERT expressed in HEK293 cells at 1 uM after 15 to 20 mins by fluorescence neurotransmitter transporter assay	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.
AID723163	Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 2.5 mg/kg, ip measured during last 4 mins of a 6 mins test session by forced swim test	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID1274959	Antidepressant activity in C57BL/6J mouse assessed as number of events at 40 mg/kg, ip measured over 6 mins by tail suspension test (Rvb = 1325.1 +/- 77.8 to 1773.4 +/- 109.9 No_unit)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID408251	Inhibition of [3H]5-hydroxytryptamine reuptake at human SERT expressed in african green monkey COS7 cells at 100 nM	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies.
AID311934	Dissociation constant, pKa of the compound	2008	Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2	Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID239218	Displacement of [3H]nisoxetine from norepinephrine transporter of rat cerebral cortex	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Synthesis and monoamine transporter affinity of new 2beta-carbomethoxy-3beta-[4-(substituted thiophenyl)]phenyltropanes: discovery of a selective SERT antagonist with picomolar potency.
AID309944	Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 9.71 mM/kg, ip after 24 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID576811	Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 48 hrs neutral red dye assay	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.
AID576803	Cytotoxicity against human SH-SY5Y cells expressing human SERT assessed as decrease in cell viability after 48 hrs neutral red dye assay	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.
AID1209402	AUC(0 to infinity) in Sprague-Dawley rat cerebrospinal fluid at 10 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID134215	Tested in vitro for dopamine(DA) neuronal uptake inhibition	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID1059388	Displacement of [3H]8-OH-DPAT from human 5-HT1A receptor expressed in HEK293 cells	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Synthesis, docking and pharmacological evaluation of novel homo- and hetero-bis 3-piperazinylpropylindole derivatives at SERT and 5-HT1A receptor.
AID309943	Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 6.47 mM/kg, ip after 24 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1552840	Anti-anxiety activity in C57BL/6J mouse assessed as reduction in number of marbles buried at 15 mg/kg, ip treated for 15 mins by marble burying assay	2019	Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18	Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu
AID712520	Inhibition of SERT-mediated [3H]5HT uptake in rat synaptosomes by scintillation counting	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID576812	Cytotoxicity against human HEK293 cells expressing human SERT assessed as decrease in cell viability after 48 hrs neutral red dye assay	2011	Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3	Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID712522	Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by filter binding assay	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
AID386625	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID731395	Inhibition of [3H]5-HT uptake at human SERT expressed in COS7 cells after 3 mins by beta-counting	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter.
AID540230	Dose normalised AUC in rat after po administration	2005	Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2	Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID309945	Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 12.94 mM/kg, ip after 24 hrs	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID723165	Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 5 mg/kg, ip measured during last 4 mins of a 6 mins test session by forced swim test	2013	European journal of medicinal chemistry, Feb, Volume: 60	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
AID540220	Clearance in human after iv administration	2005	Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7	Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1209358	Ratio of unbound drug level in brain to plasma in Sprague-Dawley rat at 10 mg/kg, sc by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11	An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346943	Human SERT (Monoamine transporter subfamily)	2008	Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12	Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter.
AID1346971	Human NET (Monoamine transporter subfamily)	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	149 (2.97)	18.7374
1990's	514 (10.24)	18.2507
2000's	1740 (34.68)	29.6817
2010's	2173 (43.30)	24.3611
2020's	442 (8.81)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,424 (26.63%)	5.53%
Reviews	344 (6.43%)	6.00%
Case Studies	677 (12.66%)	4.05%
Observational	26 (0.49%)	0.25%
Other	2,877 (53.80%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (247)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effects of Mood Symptoms Treatment on Quality of Life and Motor Function in de Novo Parkinson's Disease Patients [NCT04590612]		30 participants (Anticipated)	Interventional	2021-01-31	Not yet recruiting
Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder [NCT01109030]	Phase 2/Phase 3	50 participants (Actual)	Interventional	2010-04-30	Completed
Randomized, 2-way Crossover, Bioequivalence Study of Citalopram Hydrobromide 40 mg Tablets and Celexa 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fed Conditions [NCT01149980]	Phase 1	24 participants (Actual)	Interventional	2003-10-31	Completed
Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia [NCT01300364]	Phase 4	249 participants (Anticipated)	Interventional	2008-11-30	Recruiting
Antidepressant Effect of Escitalopram: Delay of Onset. Clinical Randomized Double-blinded Study With Three Parallel Treatment Groups (Escitalopram 20mg vs Escitalopram 30mg vs Escitalopram 20 mg + Pindolol 15 mg/Day [NCT01219686]	Phase 2/Phase 3	18 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to Recruitment difficulties)
Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Patients With Anorexia Nervosa: a Single-center Study. [NCT05795283]		123 participants (Anticipated)	Observational	2022-08-01	Recruiting
Pharmacodynamics of Intravenous Citalopram in the Elderly: a Functional Magnetic Resonance Imaging Analysis [NCT01216449]		29 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to loss of funding)
A Single-center, Single-blind, Randomized, Placebo-controlled, Sequential Design Phase 1 Study With the Inclusion of Two Double-blind Nested Crossover Parts to Investigate the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Fe [NCT03907215]	Phase 1	24 participants (Actual)	Interventional	2019-04-09	Completed
Chinese Longitudinal and Systematic Study of Bioplar Disorder [NCT05480150]		10,000 participants (Anticipated)	Interventional	2021-11-01	Recruiting
Fase III Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode [NCT02532660]	Phase 3	111 participants (Actual)	Interventional	2018-07-02	Terminated(stopped due to Recruitment difficulties due to monocentric study)
Microbiome of Depression &Amp; Treatment Response to Citalopram: A Feasibility Study [NCT02330068]		34 participants (Actual)	Observational	2014-12-31	Completed
A New System for Diagnosis and Treatment of Gastroesophageal Refulx Diseases : Based on Endoscopy, pH Parameter, Impedence Parameter, High Resolution Manometry and Psychology [NCT03600974]		200 participants (Anticipated)	Observational	2019-02-01	Not yet recruiting
[NCT00149825]	Phase 2	30 participants (Actual)	Interventional	2004-06-30	Completed
The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression [NCT04156425]		180 participants (Anticipated)	Interventional	2020-07-01	Not yet recruiting
Effect of Citalopram on Fasting and Postprandial Lower Esophageal Sphincter Function in Healthy Subjects: a Double-blind, Placebo-controlled, Randomized, Cross-over Study [NCT03746691]	Phase 4	19 participants (Actual)	Interventional	2017-02-01	Completed
Escitalopram and Language Intervention for Subacute Aphasia (ELISA) [NCT03843463]	Phase 2	88 participants (Anticipated)	Interventional	2021-07-18	Recruiting
International Committee of Medical Journal Editors [NCT02179268]	Phase 3	203 participants (Actual)	Interventional	2012-03-31	Completed
The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms [NCT04336228]	Phase 4	48 participants (Anticipated)	Interventional	2020-04-01	Recruiting
A Phase I, Open-label, Randomized, 3-way Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Escitalopram at Steady-state [NCT01090700]	Phase 1	20 participants (Actual)	Interventional	2010-05-31	Completed
Predictors of Depression Treatment Response Following an Acute Coronary Syndrome [NCT01099592]	Phase 4	7 participants (Actual)	Interventional	2010-11-30	Terminated(stopped due to inability to recruit)
Comprehensive Acupuncture for Depressive Disorder With Comorbid Psychogenic Pain: Randomized Controlled Study [NCT03282110]	Early Phase 1	60 participants (Anticipated)	Interventional	2017-11-30	Not yet recruiting
A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of TC-5214 in the Treatment of MDD With Subjects Who Are Partial Responders or Non-Responders to Citalopram Therapy [NCT00692445]	Phase 2	574 participants (Actual)	Interventional	2008-06-30	Completed
Auricular Concha Electro-acupuncture for the Treatment of Mild to Moderate Depression: A Randomized Controlled Trial [NCT03607331]	Early Phase 1	106 participants (Anticipated)	Interventional	2018-09-17	Recruiting
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants [NCT03511118]		1,600 participants (Anticipated)	Observational	2018-10-04	Recruiting
Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin [NCT02092974]	Phase 1	40 participants (Actual)	Interventional	2014-04-30	Completed
A Single Dose, Randomized, Placebo Controlled Phase I Study on the Effects of BI 1358894 on Functional MRI Measurements in an Emotional Processing Paradigm in Patients With Major Depressive Disorder [NCT03854578]	Phase 1	73 participants (Actual)	Interventional	2019-03-12	Completed
Combining SSRIs and TDCS to Enhance Motor Recovery After Stroke [NCT05041582]	Phase 3	80 participants (Anticipated)	Interventional	2021-09-01	Not yet recruiting
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene [NCT02237937]	Phase 4	80 participants (Anticipated)	Interventional	2011-09-30	Recruiting
A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD) [NCT00271596]	Phase 2	33 participants (Actual)	Interventional	2005-11-30	Completed
Effects of a 14-day Combined Antidepressant and Behavioural Intervention on Emotional Cognition in Healthy Volunteers Experiencing Low Mood [NCT05627154]		135 participants (Anticipated)	Interventional	2021-05-28	Recruiting
A New Biomarker-Based Approach Towards Developing Improved Treatment for Major Depressive Disorder (MDD) Based Upon Targeting Monoamine Oxidase A (MAO-A) [NCT02269540]	Early Phase 1	10 participants (Actual)	Interventional	2014-10-31	Completed
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury [NCT02320240]		3,255,526 participants (Actual)	Observational	2013-06-30	Completed
A Single Center, Randomized, Double-blind, Parallel-design Study to Investigate the Safety and Tolerability of RO4995819 in Combination With Citalopram Following Oral Administration in Healthy Volunteers [NCT01367756]	Phase 1	32 participants (Actual)	Interventional	2011-05-31	Completed
Randomized, 2-way Crossover, Bioequivalence Study of Citalopram Hydrobromide 40 mg Tablets and Celexa 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fasting Conditions [NCT01149967]	Phase 1	24 participants (Actual)	Interventional	2003-10-31	Completed
Unraveling Impaired Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes: a Series of Experiments Targeting Brain Neurotransmission [NCT01154647]		70 participants (Anticipated)	Interventional	2010-09-30	Not yet recruiting
Pilot Study of Treatment of Depression in Refractory Asthma [NCT01153165]		40 participants (Anticipated)	Interventional	2010-11-30	Recruiting
Adherence to Antidepressant Treatment in Subjects With Depression [NCT03388164]	Phase 2	23 participants (Actual)	Interventional	2018-01-01	Terminated(stopped due to The study was terminated early based on the planned interim analysis that did not meet criteria for continuation.)
Citalopram Titration in Early Non-responder Patients With Major Depressive Disorders: a Pilot Study (CRY-MOOD) [NCT03899285]	Phase 2	8 participants (Actual)	Interventional	2018-01-08	Completed
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]	Phase 4	104 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Difficulties in recruiting)
A Pilot Study Utilizing Escitalopram to Address Cognitive Dysfunction in Glioma Patients [NCT03728673]	Phase 2	20 participants (Anticipated)	Interventional	2019-03-06	Recruiting
Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT. [NCT00594269]	Phase 4	149 participants (Actual)	Interventional	2008-08-31	Completed
A Randomized Clinical Trial of Response to Psychopharmacotherapy According to Multimodal Serum Biomarkers in Depressive Patients [NCT06054321]		400 participants (Anticipated)	Interventional	2022-08-03	Recruiting
Stress and Inflammation in the Pathophysiology of Late Life Depression [NCT02389465]	Phase 4	119 participants (Actual)	Interventional	2014-08-31	Completed
Citalopram for Sx/Util in Acute Coronary Syndrome Patients [NCT01667744]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2016-01-01	Withdrawn(stopped due to unfunded)
TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode [NCT00666757]	Phase 4	750 participants (Actual)	Interventional	2008-05-31	Completed
A Randomized Double-blind Parallel Innovator-Controlled Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram Oxalate Tablets in the Treatment of Chinese Patients With Depression [NCT00866593]	Phase 2/Phase 3	260 participants (Actual)	Interventional	2009-03-31	Completed
"(The Role of the Glutamatergic Neurotransmission in Post- Partum Depression: an Integrated Molecular-pharmaco-imaging Study)" [NCT06131255]		15 participants (Anticipated)	Observational	2024-01-01	Not yet recruiting
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Assess Safety and Effectiveness of Liposom in Enhance and Speed up Response With Citalopram in Elderly Patients Suffering From Major Depressive Disorder (MDD) [NCT04975724]	Phase 4	150 participants (Anticipated)	Interventional	2019-04-18	Recruiting
Pentoxifylline as a New Adjuvant in Adult Patients With Major Depressive Disorder: Randomized, Double Blind, Placebo Controlled Trial. [NCT03554447]		80 participants (Actual)	Interventional	2015-04-20	Completed
Etude Comparative Monocentrique, randomisée, en Cross-over, en Double Aveugle, Contre Placebo, de l'Action du Citalopram Sur Les paramètres Cognitifs de la Motivation [NCT02113943]	Phase 2	24 participants (Actual)	Interventional	2014-04-30	Completed
Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study [NCT04806230]		81 participants (Actual)	Observational	2011-04-01	Completed
A Randomized, Single Dose, Open Label, Bioequivalence Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Und [NCT00940238]	Phase 1	0 participants	Interventional		Completed
Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning [NCT00935246]		202 participants (Anticipated)	Interventional	2008-12-31	Active, not recruiting
Assessment of PACAP-BDNF Signaling System Involvement in Etiology and Treatment of Major Depression [NCT00944996]		100 participants (Actual)	Interventional	2009-06-30	Completed
Predicting Alcoholics' Treatment Responses to an SSRI [NCT00249405]	Phase 2	200 participants (Anticipated)	Interventional	2005-02-28	Completed
Acute Neurophysiologic Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD) [NCT04846829]	Early Phase 1	30 participants (Anticipated)	Interventional	2017-04-24	Active, not recruiting
Cognitive Flexibility and Its Correlation to Sleep and Neuroplasticity In The Course Of Depression During Different Treatments [NCT00993876]		45 participants (Actual)	Interventional	2005-08-31	Completed
Individually Randomised, Placebo-controlled, Parallel Arm RCT With 12-month Follow-up to Establish the Clinical and Cost Effectiveness of the Antidepressant Citalopram in the Management of Negative Symptoms of Schizophrenia [NCT01032083]	Phase 4	62 participants (Actual)	Interventional	2011-07-31	Completed
Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder [NCT00220701]	Phase 4	36 participants (Actual)	Interventional	2002-06-30	Completed
Proton Pump Inhibitor (PPI's) and Selective Serotonin Reuptake Inhibitor Therapy (SSRI's) for the Management of Non Cardiac Chest Pain (NCCP) [NCT02825342]	Phase 4	60 participants (Actual)	Interventional	2014-03-31	Terminated(stopped due to Primary endpoint was reached.)
The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives [NCT02028026]	Phase 4	0 participants (Actual)	Interventional	2013-04-30	Withdrawn(stopped due to Inability to recruit eligible subjects)
A Randomized, Single Dose, Open Label, Bioequivalence Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in [NCT00939835]	Phase 1	0 participants	Interventional		Completed
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram [NCT00562861]	Phase 2/Phase 3	119 participants (Actual)	Interventional	2007-11-30	Completed
Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram [NCT00613470]	Phase 1	927 participants (Actual)	Interventional	2005-03-31	Completed
The Objective of This Study Was to Investigate the Bioequivalence of Mylan's Escitalopram Oxalate 20 mg Tablets to Forest's Lexapro® 20 mg Tablets Following a Single, Oral 20 mg (1 x 20 mg) Dose Administered Under Fasting Conditions. [NCT00648570]	Phase 1	37 participants (Actual)	Interventional	2004-08-31	Completed
Randomised Clinical Trial Comparing Early Medication Change (EMC) Strategy With Treatment as Usual (TAU) in Patients With Major Depressive Disorder - the EMC Trial [NCT00974155]	Phase 4	889 participants (Actual)	Interventional	2009-09-30	Completed
Effects of 3 Months of SSRI-Treatment on Metabolism and HPA-axis in Young Men Born With Low Birth Weight - a Randomized, Double Blinded and Placebo-controlled Trial [NCT00971815]		60 participants (Actual)	Interventional	2009-05-31	Completed
N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder [NCT00977353]	Phase 2	40 participants (Actual)	Interventional	2009-04-30	Completed
Single Dose Crossover Comparative Bioavailability Study of Citalopram 40 mg Tablets in Healthy Male Volunteers/Fasting State [NCT00865085]	Phase 1	28 participants (Actual)	Interventional	2003-06-30	Completed
A Relative Bioavailability of 10 mg Citalopram Hydrobromide Tablets Under Fasting Conditions [NCT00865943]	Phase 1	26 participants (Actual)	Interventional	2003-07-31	Completed
Combining Antidepressants to Hasten Remission From Depression [NCT00519428]	Phase 4	245 participants (Actual)	Interventional	2007-08-31	Completed
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms [NCT06049797]		1,000 participants (Anticipated)	Observational	2023-11-15	Recruiting
A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder [NCT04476030]	Phase 3	440 participants (Actual)	Interventional	2020-11-09	Completed
A Controlled Trial of Citalopram Added to Methylphenidate in Youth With Severe Mood Dysregulation [NCT00794040]	Phase 2	103 participants (Actual)	Interventional	2008-11-17	Completed
Behavioral Insomnia Therapy For Those With Insomnia and Depression [NCT00620789]		477 participants (Anticipated)	Interventional	2008-03-31	Recruiting
Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change [NCT00834834]	Phase 4	84 participants (Actual)	Interventional	2009-03-31	Completed
Phase IIa Proof of Concept Study of Pipamperone/Citalopram (PipCit) Versus Citalopram in the Treatment of Major Depressive Disorder (MDD) [NCT00672659]	Phase 2	165 participants (Actual)	Interventional	2008-02-29	Completed
Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study of Escitalopram in Combination With Two Fixed Doses of Gaboxadol Compared to Escitalopram in Major Depressive Disorder [NCT00807248]	Phase 2	490 participants (Actual)	Interventional	2008-11-30	Completed
Human Cerebral Blood Flow and Serotonin [NCT05957094]		15 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects [NCT04097288]	Phase 1	24 participants (Actual)	Interventional	2019-09-17	Completed
Phase II Study Using Nexalin Therapy for the Treatment of Depressive Symptoms Associated With Mild to Moderate Depression Episodes [NCT00774813]	Phase 2	120 participants (Actual)	Interventional	2007-10-31	Completed
Single-Dose Food In Vivo Bioequivalence Study of Escitalopram Oxalate Tablets (20 mg; Mylan) to Lexapro® Tablets (20 mg; Forest) in Healthy Volunteers [NCT00648661]	Phase 1	35 participants (Actual)	Interventional	2004-09-30	Completed
A Multimodal Technology-assisted Intervention for the Management of Menopause After Cancer: The Menopause After Cancer Study [NCT04766229]	Phase 2	205 participants (Actual)	Interventional	2021-06-21	Completed
Examination of the Pharmacokinetic Properties of Two Generic Antidepressants and Their Respective Brand Preparations in Healthy Male Volunteers [NCT00676039]	Phase 1	18 participants (Actual)	Interventional	2007-11-30	Completed
Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder [NCT00813735]	Phase 4	60 participants (Actual)	Interventional	2006-09-30	Completed
[NCT00217828]		0 participants	Interventional	2002-03-31	Completed
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness [NCT00817011]		1,000 participants (Anticipated)	Interventional	2006-04-30	Recruiting
[NCT00838305]		13 participants (Actual)	Interventional	2009-02-28	Completed
Double-Blind Switch Study of Vilazodone in the Treatment of Major Depressive Disorder Following Partial Response to or Inability to Tolerate a Generic SSRI [NCT01742832]	Phase 2	79 participants (Actual)	Interventional	2013-05-31	Completed
Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders [NCT00609531]	Phase 1	12 participants (Actual)	Interventional	2007-01-31	Completed
Brain Mechanisms and Targeting Insomnia in Major Depression [NCT00628914]	Phase 4	60 participants (Anticipated)	Interventional	2008-05-31	Active, not recruiting
Determination of the Circadian Resetting Effects of Escitalopram and Testing for Correlations Between Circadian Resetting and Antidepressant Effects [NCT01214044]		19 participants (Actual)	Interventional	2008-05-31	Completed
A Single-dose, Open-label, Randomised, Crossover Bioequivalence Study in Healthy Young Men Comparing Two Formulations of Escitalopram [NCT01395433]	Phase 1	32 participants (Actual)	Interventional	2010-01-31	Completed
Single Dose Crossover Comparative Bioavailability Study of Citalopram 40 mg Tablets in Healthy Male Volunteers/Fed State [NCT00864890]	Phase 1	32 participants (Actual)	Interventional	2003-06-30	Completed
A Pilot Study -- An Open-Label, Rater-blinded, Flexible-dose, 8-week Trial of Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features. [NCT00610506]	Phase 3	15 participants (Actual)	Interventional	2005-10-31	Completed
A Study to Investigate the Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder (MDD) Patients [NCT00926835]	Phase 4	692 participants (Actual)	Interventional	2009-05-31	Terminated(stopped due to due to patient recruitment difficulties)
Can Brain Activation and Connectivity Predict Treatment Response to Two Serotonergic Medications (Citalopram and Tianeptine) in Subjects With Autism Spectrum Disorders (ASD)? [NCT04145076]		100 participants (Anticipated)	Interventional	2014-12-15	Recruiting
Sinusitis and Facial Pain Disorders Anti-Depression Trial [NCT00754793]	Phase 4	3 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to poor recruitment)
Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain [NCT05735756]	Phase 4	1 participants (Actual)	Interventional	2022-01-17	Terminated(stopped due to The clinical trial has ended prematurely due to low patient recruitment)
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms [NCT01919216]	Phase 4	65 participants (Actual)	Interventional	2010-01-31	Completed
Bariatric Surgery and Pharmacokinetics Escitalopram: BAR-MEDS Escitalopram [NCT03460379]		12 participants (Anticipated)	Observational	2016-11-02	Recruiting
Specific Effects of Escitalopram on Neuroendocrine Response [NCT00150527]		8 participants (Actual)	Observational	2005-09-30	Completed
[NCT00532519]		0 participants	Interventional		Not yet recruiting
Prospective Double-Blind Randomized Comparison Study of Improvement in Negative Symptoms With Risperidone vs Risperidone +Citalopram Combination Therapy in Schizophrenia--a Clinical Study [NCT00893256]	Phase 4	48 participants (Actual)	Interventional	2004-12-31	Completed
The Use of Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Major Depressive Disorder [NCT00157547]	Phase 4	95 participants (Actual)	Interventional	2003-04-30	Completed
Symptom Management Trial in Cancer Survivors [NCT00387348]	Phase 3	24 participants (Actual)	Interventional	2006-03-31	Terminated(stopped due to DSMB stopped study because placebo arm had more adverse events)
Serum Brain-Derived Neurotrophic Factor (BDNF) and QEEG as Biological Markers of Response to (Es)Citalopram Treatment in Major Depressive Disorder [NCT00361218]	Phase 3	72 participants (Actual)	Interventional	2005-10-31	Completed
The Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response: A Comparison of Premenopausal, Perimenopausal and Postmenopausal Women [NCT00188396]		44 participants (Actual)	Interventional	2004-04-30	Completed
Escitalopram and Transcranial Direct Current Stimulation in Major Depressive Disorder: a Double-blind, Placebo-controlled, Randomized, Non-inferiority Trial [NCT01894815]	Phase 3	245 participants (Actual)	Interventional	2013-10-31	Completed
The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression [NCT00254020]	Phase 4	138 participants (Actual)	Interventional	2005-06-30	Completed
The Efficacy of Citalopram Treatment in Acute Stroke [NCT01937182]	Phase 2	642 participants (Actual)	Interventional	2013-09-30	Completed
Antidepressants, Emotions and Personality: Comparing the Neuropsychological Effects of the Antidepressant Citalopram in Healthy Volunteers With High and Low Neuroticism [NCT01946607]		42 participants (Actual)	Interventional	2009-07-31	Completed
A Blinded, Placebo- and Comparator-Controlled Three-way Crossover Study to Investigate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of JNJ-40411813 in Healthy Male Subjects [NCT01951053]	Phase 1	18 participants (Actual)	Interventional	2010-01-31	Completed
VISN 20 Prophylactic Treatment of IFN-Induced Depression in Hepatitis C [NCT00108563]	Phase 4	0 participants	Interventional	2003-10-31	Completed
Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL). [NCT01978782]	Phase 1	24 participants (Actual)	Interventional	2014-01-31	Completed
An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Escitalopram Oxalate Tablet Containing Escitalopram (20mg) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Lexapro® Tablet (20mg) [Reference Fo [NCT01996462]	Phase 1	0 participants	Interventional		Completed
An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Escitalopram Oxalate Tablet 20mg [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Lexapro® (Escitalopram Oxalate Tablet 20mg) [Reference Formula [NCT01996475]	Phase 1	0 participants	Interventional		Completed
[NCT02000726]	Phase 2	0 participants (Actual)	Interventional	2013-07-31	Withdrawn(stopped due to Lack of funding to complete the trial phase of the study.)
The Serotonin Transporter Gene Polymorphism and Major Depression Following Traumatic Brain Injury [NCT00254007]	Phase 4	200 participants (Anticipated)	Interventional	2003-07-31	Completed
Randomized Controlled Trial of Treating Rectal Hypersensitivity - Comparing Escitalopram With Sensory Adaptation Training [NCT00584571]	Phase 2	55 participants (Actual)	Interventional	2007-12-31	Completed
Effect of Citalopram on Clinical Symptoms and Visceral Sensitivity in Patients With Irritable Bowel Syndrome [NCT00477165]	Phase 2	54 participants (Actual)	Interventional	2001-04-30	Completed
Combination Therapy With Modafinil and Escitalopram for the Treatment of Cocaine Dependence [NCT01601730]	Phase 1	68 participants (Actual)	Interventional	2010-08-31	Completed
Genetic-pharmacological Neuroimaging of the Serotonergic System in Violent Video Games [NCT01644071]		47 participants (Actual)	Interventional	2012-02-29	Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]		1,037,352 participants (Actual)	Observational	2016-09-30	Completed
Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders: a Randomized Controlled Clinical Trial for the Treatment of Central Sensitization [NCT01601912]		59 participants (Actual)	Observational	2013-02-28	Completed
The Effect of Acute Citalopram on Response to Acute Stress Induction [NCT04161209]		40 participants (Anticipated)	Interventional	2019-10-11	Recruiting
A Comparison of the CNS Effects of Equivalent Doses of Escitalopram and Racemic Citalopram Using BOLD fMRI [NCT00825825]	Phase 4	27 participants (Actual)	Interventional	2007-05-31	Completed
Relapse Prevention in Patients With a Major Depressive Episode Treated With Electroconvulsive Treatment Using a Fixed Dose Range of Escitalopram Compared to a Fixed Dose of Nortriptyline (DUAG-7) A Randomised Controlled 6 Month Double-blind Study [NCT00660062]	Phase 4	47 participants (Actual)	Interventional	2009-08-31	Terminated(stopped due to Slow inclusion)
A Randomized Placebo-Controlled Trial of Citalopram for Anxiety Disorders Following Traumatic Brain Injury [NCT00208572]		104 participants (Anticipated)	Interventional	2003-11-30	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders [NCT01189812]	Phase 2	80 participants (Actual)	Interventional	2010-03-31	Completed
[NCT02711215]	Phase 4	80 participants (Anticipated)	Interventional	2015-05-31	Active, not recruiting
Comparison of Depression Interventions After Acute Coronary Syndrome (CODIACS) [NCT01032018]	Phase 1/Phase 2	150 participants (Actual)	Interventional	2010-01-31	Completed
The Effect of Acute Citalopram on Self-referential Emotional Processing and Social Cognition in Healthy Volunteers [NCT04169230]		44 participants (Anticipated)	Interventional	2019-10-11	Recruiting
A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease [NCT00898807]	Phase 3	186 participants (Actual)	Interventional	2009-07-31	Completed
Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. [NCT00680602]	Phase 4	158 participants (Actual)	Interventional	2006-01-31	Completed
The Efficacy and Tolerability of Seroquel XR Combined With a Selective Serotonin Re-Uptake Inhibitor Versus Seroquel XR Monotherapy in the Acute Treatment of Major Depressive Disorder With Psychotic Features [NCT00955474]	Phase 4	32 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to AstraZeneca halted funding; patent expired for Seroquel (Quetiapine) in 2012)
Combined Administration of Lecozotan SR and Citalopram: a Double Blind, Multiple Dose Study in Young Healthy Subjects [NCT00538889]	Phase 1	40 participants (Anticipated)	Interventional	2007-08-31	Completed
The Effects of PF-04995274 on Emotional Processing in Un-medicated Depressed Patients [NCT03516604]	Phase 1	90 participants (Actual)	Interventional	2018-05-16	Completed
Emotional Processing in Healthy Male Volunteers Treated With GSK424887. A Single Centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study [NCT01424384]	Phase 1	54 participants (Actual)	Interventional	2008-09-19	Completed
Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs in Healthy Korean Adults After a Single Oral Administration of Escitalopram, Quetiapine, and Moxifloxacin [NCT01871701]	Phase 1	40 participants (Actual)	Interventional	2012-11-30	Completed
Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - an Open Study. [NCT00433121]	Phase 4	24 participants (Actual)	Interventional	2006-09-30	Completed
A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment [NCT05145270]	Phase 4	180 participants (Anticipated)	Interventional	2019-11-30	Recruiting
Comparative Evaluation of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Treatment-resistant Burning Mouth Syndrome: a Prospective Longitudinal Clinical Trial With Treatment Response Prediction [NCT06025474]	Phase 3	203 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors [NCT01778686]		24 participants (Actual)	Interventional	2013-01-31	Completed
A Pilot Study to Evaluate Individualized Choice of Antidepressant in Patients With Cancer [NCT01725048]	Early Phase 1	21 participants (Actual)	Interventional	2011-01-31	Completed
PUFA Augmentation in Treatment of Major Depression [NCT00067301]	Phase 3	60 participants	Interventional	2003-09-30	Completed
[NCT00249886]	Phase 3	60 participants	Interventional	2002-09-30	Withdrawn
Continuation Pharmacotherapy for Agitation of Dementia [NCT00073658]	Phase 2	137 participants	Interventional	2000-01-31	Completed
Depression: The Search for Treatment-Relevant Phenotypes [NCT00073697]	Phase 4	290 participants (Actual)	Interventional	2003-05-31	Completed
Serotonin, Impulsivity, and Cocaine Dependence Treatment [NCT00297505]	Phase 2	120 participants	Interventional	2001-04-30	Completed
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder - Results From a Long-term Nation-wide Population-based Study Emulating a Randomized Trial [NCT05952713]		73,336 participants (Actual)	Observational	2022-10-01	Completed
A Randomized, Placebo Controlled Trial of Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Co-infected Individuals Initiating Pegylated Interferon/Ribavirin Therapy [NCT00317746]	Phase 3	76 participants (Actual)	Interventional	2006-11-30	Completed
Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior [NCT00086645]	Phase 2	149 participants (Actual)	Interventional	2004-04-30	Completed
Add-on to Cognitive, ERP and EEG Asymmetry in Affective Disorders (#6559R) [Formerly #5723] [NCT03278938]	Phase 4	0 participants (Actual)	Interventional	2012-06-29	Withdrawn(stopped due to PI Retired and no data was collected)
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major [NCT00351910]	Phase 3	494 participants (Actual)	Interventional	2006-05-31	Completed
Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations in Tablets Containing Escitalopram 10 mg (Product From GlaxoSmithKline México, S.A. de C.V. vs. Lexapro® 10mg, Lundbeck México, S.A. [NCT01745601]	Phase 1	26 participants (Actual)	Interventional	2010-05-04	Completed
The Effects of Increased Central Serotonergic Activity on Psychophysiological Parameters of Human Information Processing [NCT00206934]		40 participants (Actual)	Interventional	2005-03-31	Completed
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder [NCT01254305]	Phase 2	262 participants (Actual)	Interventional	2011-04-30	Completed
The Role of Childhood Adversity and Genetic Polymorphisms in the Serotonin and Brain-Derived Neurotrophic Factor Systems in the Sensitization to Stress in First-Onset Major Depression (Blue Sky Project) [NCT00517764]		299 participants (Actual)	Interventional	2006-12-31	Completed
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause [NCT05346445]		91 participants (Actual)	Interventional	2021-01-20	Completed
The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study [NCT00667121]		85 participants (Anticipated)	Observational	2011-03-16	Active, not recruiting
Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals [NCT00218036]	Phase 2	54 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to PI left institution, end of funding, clinic relocation, recruitment issues)
Molecular Markers of Neuroplasticity During High-Intensity Exercise in Subjects With Incomplete Spinal Cord Injury [NCT01538693]		30 participants (Anticipated)	Interventional	2011-12-31	Completed
Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder [NCT01541475]	Phase 4	60 participants (Actual)	Interventional	2009-03-31	Completed
Serotonergic Pharmacotherapy for Agitation of Dementia [NCT00009204]	Phase 3	0 participants	Interventional	1995-09-30	Completed
Ethnic Variations in Antidepressant Response [NCT00047671]	Phase 4	400 participants (Anticipated)	Interventional	2002-06-30	Completed
[NCT00080158]	Phase 2/Phase 3	120 participants	Interventional	2004-03-31	Completed
Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial) [NCT00015548]		450 participants	Interventional	2001-03-31	Completed
Sequenced Treatment Alternatives to Relieve Depression [NCT00021528]	Phase 4	4,000 participants	Interventional	2001-07-31	Completed
Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) [NCT00018902]	Phase 2/Phase 3	334 participants (Actual)	Interventional	2001-01-31	Completed
Vascular Depression and Magnetic Stimulation Therapy [NCT00044798]	Phase 3	132 participants (Anticipated)	Interventional	2001-09-30	Completed
Citalopram Augmentation in Older Patients With Schizophrenia [NCT00047450]		212 participants (Actual)	Interventional	2001-09-30	Completed
A Double-Blind, Placebo-Controlled Investigation Into the Safety and Efficacy of Escitalopram for Depression in Multiple Sclerosis [NCT00151294]	Phase 4	20 participants	Interventional	2004-11-30	Terminated
A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury [NCT00162916]	Phase 4	21 participants (Actual)	Interventional	2005-05-31	Active, not recruiting
Can Additional Drug Therapy Accelerate Response Time to Antidepressants: A Double-blind, Placebo-controlled Randomization Research Study for Major Depression [NCT00221494]	Phase 4	0 participants (Actual)	Interventional	2004-01-31	Withdrawn(stopped due to PI move)
Assessing Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly Patients With Depression: a Pragmatic, Multicenter, Open-label, Parallel-group, Superiority, Randomized Trial [NCT03779789]	Phase 4	362 participants (Actual)	Interventional	2019-02-01	Completed
A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence [NCT00452543]	Phase 4	23 participants (Actual)	Interventional	2007-03-31	Completed
Combining Medications to Enhance Depression Outcomes [NCT00590863]	Phase 4	665 participants (Actual)	Interventional	2008-03-31	Completed
A Double-blind, Fixed-dose Study of Escitalopram in Adult Patients With Major Depressive Disorder [NCT00668525]	Phase 3	877 participants (Actual)	Interventional	2008-04-30	Completed
Predictors of Antidepressant Response [NCT02178696]	Phase 4	44 participants (Actual)	Interventional	2011-01-31	Completed
[NCT02655354]		635 participants (Actual)	Interventional	2015-10-31	Completed
Randomized, Controlled, Open and Unicentric Phase II Clinical Trial, With Two Parallel Groups, to Evaluate the Antidepressant Efficacy of Psychotherapy and Citalopram in Women Diagnosed With Breast Cancer and Major Depression [NCT05063604]	Phase 2	40 participants (Actual)	Interventional	2022-05-10	Terminated(stopped due to The CAMAD clinical trial has been terminated due to difficulties in recruiting patients.)
Alcohol and Gender Effects on Stress Circuit Function [NCT00226694]		96 participants (Actual)	Interventional	2003-09-30	Completed
Phase 4 Study of Clinical Pharmacogenomics of Antidepressant Response [NCT00269334]	Phase 4	400 participants	Interventional	2005-12-31	Not yet recruiting
Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication. [NCT00296712]	Phase 4	55 participants (Actual)	Interventional	2005-02-28	Completed
Algorithm Guided Treatment Strategies for Major Depressive Disorder [NCT01764867]	Phase 4	1,080 participants (Anticipated)	Interventional	2012-06-30	Recruiting
Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child [NCT01796132]	Phase 4	500 participants (Anticipated)	Interventional	2012-08-31	Recruiting
Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging [NCT02473250]	Phase 4	40 participants (Actual)	Interventional	2015-01-31	Completed
Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture [NCT02579343]		13 participants (Actual)	Interventional	2015-08-31	Completed
Phase III Randomized, Double-Blind, Placebo-Controlled Evaluation of Citalopram for the Treatment of Hot Flashes [NCT00363909]	Phase 3	254 participants (Actual)	Interventional	2006-11-30	Completed
An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia [NCT01716221]	Phase 4	1 participants (Actual)	Interventional	2012-10-31	Completed
Antidepressant Treatment at an Inner City Asthma Clinic [NCT01324700]	Phase 4	139 participants (Actual)	Interventional	2010-07-31	Completed
Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression [NCT01658228]	Phase 4	86 participants (Actual)	Interventional	2011-09-30	Completed
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks [NCT01312922]	Phase 3	555 participants (Actual)	Interventional	2011-09-30	Completed
Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder [NCT01460212]	Phase 4	80 participants (Anticipated)	Interventional	2011-12-31	Recruiting
Personalizing Treatment of Depression Complicated by Panic Features-Pilot Study [NCT00930293]		50 participants (Actual)	Interventional	2009-07-31	Completed
Anxiety and Recurrent Abdominal Pain in Children [NCT00962039]	Phase 2/Phase 3	81 participants (Actual)	Interventional	2004-07-31	Completed
A Placebo-controlled Trial With Citalopram for the Treatment of Typical Reflux Symptoms in Patients With Reflux Hypersensitivity or Functional Heartburn With Incomplete Proton Pump Inhibitor Response [NCT03499171]	Phase 4	100 participants (Anticipated)	Interventional	2019-05-27	Recruiting
A Pilot Study Examining the Gut Microbiota in Patients With Obsessive-Compulsive Disorder vs. Healthy Controls and Following 12-weeks of Open-label Selective Serotonin Reuptake Inhibitors Treatment [NCT02285699]		43 participants (Anticipated)	Interventional	2014-11-01	Completed
Study to Determine Steady-state Level of Citalopram Pharmacokinetic Parameters in Patients With Short Bowel Syndrome [NCT00876226]		0 participants (Actual)	Interventional	2010-05-01	Withdrawn
Effectiveness of the Use of Antidepressants in the Treatment of Muscle Type Temporomandibular Disorders [NCT04777838]	Phase 2/Phase 3	80 participants (Anticipated)	Interventional	2021-03-31	Not yet recruiting
REward Processing And Citalopram Study [NCT06017037]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2023-05-19	Recruiting
Efficacy of Exposure and Response Prevention（ERP） and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder [NCT02022709]	Phase 4	78 participants (Actual)	Interventional	2014-01-31	Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]		74 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Treatment of Pediatric OCD for SRI Partial Responders [NCT00074815]	Phase 3	124 participants (Actual)	Interventional	2003-09-30	Completed
Pharmacotherapy for Minor Depression [NCT00048815]		73 participants (Actual)	Interventional	2003-02-28	Completed
[NCT02423694]		252 participants (Anticipated)	Interventional	2013-09-30	Recruiting
Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder: A Double-blind, Parallel, Randomized Controlled Trial [NCT05950061]	Phase 3	744 participants (Actual)	Interventional	2022-06-01	Completed
Functional MRI Before and After Treatment for Depression [NCT00896441]		31 participants (Actual)	Interventional	2009-02-28	Terminated(stopped due to Funding ended)
Effects of Serotonin Agonist Citalopram on Multimodal Esophageal Stimulation in Healthy Volunteers [NCT04355455]		14 participants (Actual)	Interventional	2011-07-31	Completed
A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease [NCT03652870]	Phase 3	52 participants (Actual)	Interventional	2021-03-05	Completed
Pharmacogenetics and Neuroimaging in Major Depressive Disorder (PAN-D) [NCT01568684]	Phase 1	0 participants (Actual)	Interventional	2012-03-12	Withdrawn
[NCT01575158]		59 participants (Actual)	Interventional	1997-10-31	Completed
Optimizing Treatment for Complicated Grief (Healing Emotions After Loss:HEAL) [NCT01179568]	Phase 2	395 participants (Actual)	Interventional	2010-03-31	Completed
A Double-blinded 6-week Prospective Study to Evaluate the Remission Rate According to Dose of Escitalopram (Lexapro®) in Patients With Major Depressive Disorder: a Preliminary Study [NCT01594866]	Phase 4	60 participants (Anticipated)	Interventional	2012-05-31	Completed
Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia [NCT00376051]	Phase 4	22 participants (Anticipated)	Interventional	2006-09-30	Completed
Ramelteon for Sleep Initiation Insomnia in Panic Disorder Who Are Also on Escitalopram for Anxiety: A Double Blind, Randomized Clinical Trial [NCT00746239]		11 participants (Actual)	Interventional	2008-08-31	Terminated(stopped due to Funding for continuation was not received.)
SPECT Brain Imaging as a Bio-Marker of Major Depression [NCT00655057]	Phase 2/Phase 3	66 participants (Actual)	Interventional	2005-10-31	Completed
Research on Standardized Electronic Cognitive Training Technique in Early Stage of Senile Depression With Cognitive Impairment [NCT05588102]		128 participants (Anticipated)	Interventional	2021-05-18	Recruiting
Escitalopram Effects on CSF Amyloid Beta Total Concentrations [NCT02161458]	Phase 4	98 participants (Actual)	Interventional	2014-06-30	Completed
Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction [NCT02386475]	Phase 4	39 participants (Actual)	Interventional	2015-01-31	Completed
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]	Phase 4	80 participants (Anticipated)	Interventional	2023-12-30	Not yet recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]	Phase 3	407 participants (Actual)	Interventional	2015-01-31	Terminated
Treatment of Depression Concurrent With Alcohol Abuse, an Extension of Alcohol Use Disorder in Patients Treated for Depression [NCT00369746]		674 participants (Actual)	Observational	2006-09-30	Completed
Clinical Trial of Serotonin Medication Combination in Cocaine Dependence [NCT01535573]	Phase 2	108 participants (Actual)	Interventional	2010-12-31	Completed
Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics [NCT01657760]	Phase 1	31 participants (Actual)	Interventional	2014-05-01	Completed
Impact of Pots-stroke Depression Treatment on Stroke Recurrence [NCT04776226]		1,230 participants (Actual)	Interventional	2017-02-11	Completed
A Double-blind, Placebo- and Active-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder [NCT01473381]	Phase 4	1,162 participants (Actual)	Interventional	2011-12-31	Completed
A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression [NCT01436643]	Phase 4	54 participants (Actual)	Interventional	2011-11-30	Terminated(stopped due to Due to slow enrollment the study was terminated early)
Escitalopram in the Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial [NCT00621946]	Phase 4	26 participants (Actual)	Interventional	2008-03-31	Completed
The Use of Methylphenidate to Improve Clinical Outcomes in Geriatric Depression: A Double-blind Placebo-Controlled Trial of Methylphenidate (Ritalin) Augmentation of Citalopram (Celexa) in Depressed Elderly Patients [NCT00602290]	Phase 4	181 participants (Actual)	Interventional	2008-02-29	Completed
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon [NCT00642694]	Phase 3	29 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor)
The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment of Patients With Major Depressive Disorder. [NCT02480400]		52 participants (Actual)	Interventional	2010-06-30	Completed
Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment [NCT01876823]	Phase 2/Phase 3	60 participants (Actual)	Interventional	2006-04-30	Completed
Citalopram in First Episode Schizophrenia [NCT01041274]	Phase 4	95 participants (Actual)	Interventional	2010-01-31	Completed
Effects of Treatment on Decision-making in Major Depression [NCT01916824]	Phase 4	53 participants (Actual)	Interventional	2013-08-31	Completed
Effectiveness and Safety of Transcutaneous Electrical Cranial-auricular Acupoint Stimulation (TECAS) for Patients With Mild-to-moderate Depression. [NCT03909217]	Phase 2/Phase 3	470 participants (Anticipated)	Interventional	2019-07-29	Recruiting
Acupuncture and Escitalopram for Treating Major Depression Clinical Study (AE-TMDCS): Study Design of a Randomized Controlled Trial [NCT05901571]		216 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial [NCT05271084]	Phase 1/Phase 2	100 participants (Actual)	Interventional	2021-11-10	Completed
Brain Imaging and Treatment Studies of the Night Eating Syndrome [NCT01401595]	Phase 3	87 participants (Actual)	Interventional	2009-12-31	Completed
Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia [NCT05389046]		252 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease [NCT04497168]	Phase 2	58 participants (Anticipated)	Interventional	2021-04-01	Recruiting
Depression Treatment and Aβ Dynamics: A Study of Alzheimer's Disease Risk (ABD Study) [NCT05004987]	Phase 4	90 participants (Anticipated)	Interventional	2022-02-04	Recruiting
A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (Bupropion XL 300mg Once Daily), Escitalopram Oxalate (Escitalopram, 10mg-20mg Once Dai [NCT02191397]	Phase 3	534 participants (Actual)	Interventional	2015-02-10	Completed
Brain Function and Structure in Cocaine Dependence [NCT02080832]	Phase 2	54 participants (Actual)	Interventional	2010-02-28	Completed
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression [NCT01557946]	Phase 4	32 participants (Actual)	Interventional	2012-03-31	Completed
Testing an Imaging Biomarker for Treatment Stratification in Major Depression [NCT02137369]	Phase 4	77 participants (Actual)	Interventional	2014-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00048815 (2) [back to overview]	Number of Adverse Events (Physical Symptoms) Emerging or Worsening During 12 Weeks of Treatment
NCT00048815 (2) [back to overview]	Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C)
NCT00074815 (1) [back to overview]	Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT00149825 (2) [back to overview]	Remission of Depression (%)
NCT00149825 (2) [back to overview]	Remission of Insomnia
NCT00220701 (6) [back to overview]	Beck Depression Inventory (BDI)
NCT00220701 (6) [back to overview]	Clinical Global Impressions - Severity (CGI-S)
NCT00220701 (6) [back to overview]	Beck Depression Inventory (BDI)
NCT00220701 (6) [back to overview]	Clinical Global Impressions - Severity (CGI-S)
NCT00220701 (6) [back to overview]	Hamilton-Depression Rating Scale (HDRS-24 Items)
NCT00220701 (6) [back to overview]	Hamilton-Depression Rating Scale (HDRS-24 Items)
NCT00271596 (10) [back to overview]	Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort.
NCT00271596 (10) [back to overview]	Hamilton Rating Scale for Depression Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort
NCT00271596 (10) [back to overview]	Letter Number Sequencing Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort
NCT00271596 (10) [back to overview]	Semantic Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort
NCT00271596 (10) [back to overview]	Stroop Interference Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort
NCT00271596 (10) [back to overview]	Subgroup Analysis of the Hamilton Depression Rating Scale Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort
NCT00271596 (10) [back to overview]	Symbol-Digit Modalities Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort
NCT00271596 (10) [back to overview]	Total Functional Capacity Score Comparing Baseline (Week -4) to Visits 4 (Week 6) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort
NCT00271596 (10) [back to overview]	Trails B Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort
NCT00271596 (10) [back to overview]	Verbal Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort
NCT00361218 (1) [back to overview]	Serum Brain-derived Neurotrophic Factor (BDNF) Levels
NCT00369746 (5) [back to overview]	Quick Inventory of Depression- Self Report 16
NCT00369746 (5) [back to overview]	Quantitative Substance Use Inventory ((SUI)
NCT00369746 (5) [back to overview]	Timeline Follow Back (TLFB) Maximum Drinks Per Drinking Day
NCT00369746 (5) [back to overview]	Timeline Follow Back (TLFB) Average Drinks Per Drinking Day
NCT00369746 (5) [back to overview]	Timeline Follow Back (TLFB) Drinking Days Per 30 Days
NCT00387348 (3) [back to overview]	Side Effect Burden
NCT00387348 (3) [back to overview]	Depression Response Rate of Escitalopram Oxalate 10 mg Once Daily Compared to Placebo Once Daily for Major Depressive Disorder
NCT00387348 (3) [back to overview]	Change in Hamilton Depression Rating Scale (HAM-D) Scores
NCT00452543 (4) [back to overview]	Total Drinks Consumed Per Week on the TLFB
NCT00452543 (4) [back to overview]	Total Drinking Days on the Alcohol Timeline Followback (TLFB)
NCT00452543 (4) [back to overview]	Total Drinks Consumed Per Drinking Day on the TLFB
NCT00452543 (4) [back to overview]	Change in Mean Score on the Hamilton Rating Scale for Depression -- 17 Items (HAM-D-17)
NCT00477165 (4) [back to overview]	"Count of Participants Who Self-reported Adequate Relief"
NCT00477165 (4) [back to overview]	Change From Baseline in IBS-QOL Score at Week 8
NCT00477165 (4) [back to overview]	Mean Sensation Score as a Function of Distending Pressure at the End of the Study
NCT00477165 (4) [back to overview]	Urgency Score as a Function of Distending Pressure at the End of the Study
NCT00519428 (5) [back to overview]	Functioning, as Measured by the Social Adjustment Scale (SAS) Summary Score
NCT00519428 (5) [back to overview]	Quality of Life, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form (SF)
NCT00519428 (5) [back to overview]	Remission: Persistent Hamilton Rating Scale for Depression, 17 Items (HAM-D 17) <= 7, With no HAM-D 17 >7 Through Week 12
NCT00519428 (5) [back to overview]	Severity of Depressive Symptoms as Measured by Hamilton Rating Scale for Depression (HAM-D 17)
NCT00519428 (5) [back to overview]	Time to Remission, Defined by the Week of Onset of Persistent Hamilton Rating Scale for Depression (HAM-D 17) <= 7, With no Subsequent HAM-D 17 > 7
NCT00562861 (1) [back to overview]	MADRS Rating Scale Change
NCT00590863 (2) [back to overview]	Quick Inventory of Depressive Symptoms
NCT00590863 (2) [back to overview]	Quality of Life Inventory
NCT00602290 (2) [back to overview]	Quality of Life Assessment
NCT00602290 (2) [back to overview]	Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16
NCT00621946 (6) [back to overview]	ACQ (Asthma Control Questionnaire)
NCT00621946 (6) [back to overview]	ACQ (Asthma Control Questionnaire)
NCT00621946 (6) [back to overview]	HAM-D (Hamilton Rating Scale for Depression)
NCT00621946 (6) [back to overview]	IDS-SR (Inventory of Depressive Symptomatology - Self-Report)
NCT00621946 (6) [back to overview]	IDS-SR (Inventory of Depressive Symptomatology - Self-Report)
NCT00621946 (6) [back to overview]	HAM-D (Hamilton Rating Scale for Depression)
NCT00642694 (9) [back to overview]	Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
NCT00642694 (9) [back to overview]	Social Adjustment Scale - Self-Report (SAS-SR)
NCT00642694 (9) [back to overview]	Percentage of Remitters on IDS-C30 at Week 12
NCT00642694 (9) [back to overview]	Hamilton Rating Scale for Depression 17-item
NCT00642694 (9) [back to overview]	Work Productivity and Activity Impairment Questionnaire (WPAI)
NCT00642694 (9) [back to overview]	Work and Social Adjustment Scale (WSAS)
NCT00642694 (9) [back to overview]	Sleep Latency
NCT00642694 (9) [back to overview]	Patient Perception of Benefits of Care (PPBC)
NCT00642694 (9) [back to overview]	Short-Form Health Survey - Version 2 (SF-36)
NCT00666757 (25) [back to overview]	Change From Baseline in Systolic Blood Pressure at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in Weight at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Absenteeism at 12-Week Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Absenteeism Score at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Presenteeism (WP)Score, at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Presenteeism Score, at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint]
NCT00666757 (25) [back to overview]	Probability of Remission [17-item Hamilton Depression Rating Scale (HAMD-17) (Mood Measure) Less Than or Equal to 7 at 12-Week Endpoint]
NCT00666757 (25) [back to overview]	Probability of Response [HAMD-17 Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]
NCT00666757 (25) [back to overview]	Probability of Response [QIDS-SR Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]
NCT00666757 (25) [back to overview]	Change From Baseline in Pulse Rate at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in BPI Average 24 Hour Pain Score at 12-Week Endpoint (Pain Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Brief Pain Inventory (BPI) Average 24-hour Pain Score, in Particpants With a Baseline BPI Average 24-hour Pain Score of 3 or Greater, at 12-Week Endpoint (Pain Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Diastolic Blood Pressure at Week-12 Endpoint
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Bech Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Maier Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Retardation Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Sleep Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in HAMD-17 Total Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in QIDS-SR Total Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in SDS Social Item Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in SDS Work/School Item Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Family/Home Item Score at Week-12 Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00668525 (2) [back to overview]	Change From Baseline in Total Montgomery Asberg Depression Rating Scale (MADRS) at 8 Weeks.
NCT00668525 (2) [back to overview]	Change From Baseline in Hamiltion Rating Scale for Depression (HAM-D) at Week 8
NCT00794040 (5) [back to overview]	"Percentage of Participants That Much Improved (Score of 2) in, or Completely Recovered (Score of 1) From Their Irritability Severity, as Measured With the Clinical Global Impression-Improvement (CGI-I)."
NCT00794040 (5) [back to overview]	Irritability Severity at 8th Week of Trial.
NCT00794040 (5) [back to overview]	Functional Impairment at 8th Week of Trial
NCT00794040 (5) [back to overview]	Depressive Symptoms at 8th Week of Trial
NCT00794040 (5) [back to overview]	Anxiety Symptoms at 8th Week of Trial
NCT00807248 (9) [back to overview]	Clinical Global Impression - Global Improvement (CGI-I)
NCT00807248 (9) [back to overview]	Clinical Global Impression - Severity of Illness (CGI-S)
NCT00807248 (9) [back to overview]	Hospital Anxiety and Depression Scale (HADS)
NCT00807248 (9) [back to overview]	Insomnia Severity Index (ISI)
NCT00807248 (9) [back to overview]	MADRS
NCT00807248 (9) [back to overview]	Montgomery and Åsberg Depression Rating Scale (MADRS)
NCT00807248 (9) [back to overview]	SDS: Social Subscale
NCT00807248 (9) [back to overview]	SDS: Work Subscale
NCT00807248 (9) [back to overview]	Sheehan Disability Scale (SDS): Family Subscale
NCT00825825 (7) [back to overview]	Number of Voxels Showing Greater Activation Following Citalopram Compared With Placebo When Affective Faces Are Presented in a Covert Stimulus Presentation and Contrasted With a Fixation Stimulus.
NCT00825825 (7) [back to overview]	Number of Voxels Showing Greater Activation Following Citalopram Compared With Placebo When Affective Faces Are Presented in a Covert Stimulus Presentation and Contrasted With a Fixation Stimulus.
NCT00825825 (7) [back to overview]	Number of Voxels Showing Greater Activation Following Escitalopram Compared With Citalopram When Affective Words Are Contrasted With a Fixation Stimulus.
NCT00825825 (7) [back to overview]	Number of Voxels Showing Greater Activation Following Escitalopram Compared With Citalopram When Faces and a Fixation Stimulus Are Presented in an Overt Presentation.
NCT00825825 (7) [back to overview]	Number of Voxels Showing Greater Activation Following Escitalopram Compared With Placebo When Affective Faces Are Presented in a Covert Stimulus Presentation and Contrasted With a Fixation Stimulus.
NCT00825825 (7) [back to overview]	Number of Voxels Showing Greater Activation Following Placebo Compared With Citalopram When Affective Words Are Contrasted With a Fixation Stimulus.
NCT00825825 (7) [back to overview]	Number of Voxels Showing Greater Activation Following Escitalopram Compared With Citalopram When Happy and Fearful Faces Are Presented in a Rapid Covert Stimulus Presentation.
NCT00834834 (2) [back to overview]	Number of Participants With Suicide Events
NCT00834834 (2) [back to overview]	Suicide Events
NCT00896441 (3) [back to overview]	Hamilton Anxiety Scale
NCT00896441 (3) [back to overview]	Voxel-wise Changes in Resting State Functional Connectivity to the Posterior Cingulate Cortex
NCT00896441 (3) [back to overview]	Hamilton Depression Rating Scale Percent Change From Day 0 to D56
NCT00898807 (4) [back to overview]	Cohen-Mansfield Agitation Inventory (CMAI)
NCT00898807 (4) [back to overview]	Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in Agitation(CGIC)
NCT00898807 (4) [back to overview]	NeuroBehavior Rating Scale-- Agitation
NCT00898807 (4) [back to overview]	Neuropsychiatric Inventory (NPI)-- Agitation Subscore
NCT00930293 (2) [back to overview]	Weeks to Depression Remission
NCT00930293 (2) [back to overview]	Number of Participants Meeting Depression Remission Criteria
NCT00955474 (15) [back to overview]	CPFQ (Cognitive and Psychological Functioning Questionnaire)
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Visuospatial/Constructional Sub-scale.
NCT00955474 (15) [back to overview]	Blood Level of Triglycerides at Baseline and Week 8.
NCT00955474 (15) [back to overview]	Blood Level of Total Cholesterol Levels Were Collected at Baseline and Week 8.
NCT00955474 (15) [back to overview]	Blood Hemoglobin A1C at Baseline and Week 8.
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Attention Sub-scale Scores at Baseline and Week 8.
NCT00955474 (15) [back to overview]	Psychosis
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Delayed Memory Subscale Scores at Baseline and Week 8.
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Immediate Memory Sub-scale Score
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Language Sub-scale Score.
NCT00955474 (15) [back to overview]	RBANS (Repeatable Battery for Assessment of Neuropsychological Status) Total Score
NCT00955474 (15) [back to overview]	LDL Blood Levels at Baseline and Week 8.
NCT00955474 (15) [back to overview]	HDL Blood Levels at Baseline and Week 8.
NCT00955474 (15) [back to overview]	Fasting Blood Glucose
NCT00955474 (15) [back to overview]	Depression
NCT00962039 (6) [back to overview]	Pediatric Anxiety Rating Scale (PARS)
NCT00962039 (6) [back to overview]	Clinical Global Impression Scale - Severity (CGI-S)
NCT00962039 (6) [back to overview]	Clinical Global Impression Scale - Improvement (CGI-I) Will be Used to Assess Overall Global Illness Improvement. CGI-I Scores of 1 (Very Much Improved) or 2 (Much Improved) Indicate an Acceptable Treatment Response.
NCT00962039 (6) [back to overview]	Children's Global Assessment Scale (C-GAS)
NCT00962039 (6) [back to overview]	Children's Depression Rating Scale - Revised (CDRS-R)
NCT00962039 (6) [back to overview]	Abdominal Pain Index (API)
NCT01032018 (2) [back to overview]	Depressive Symptom Reduction
NCT01032018 (2) [back to overview]	Cost for Healthcare Utilization (Psychiatric Medications, Hospitalizations, Cardiac Procedures, Outpatient Services)
NCT01041274 (5) [back to overview]	Calgary Depression Scale for Schizophrenia (CDSS)
NCT01041274 (5) [back to overview]	Brief Psychiatric Rating Scale (BPRS)
NCT01041274 (5) [back to overview]	Heinrich Quality of Life Scale (QOL)
NCT01041274 (5) [back to overview]	InterSePT Scale for Suicidal Thinking (ISST)
NCT01041274 (5) [back to overview]	Scale for the Assessment of Negative Symptoms (SANS)
NCT01179568 (5) [back to overview]	Responder Status Based on Complicated Grief Clinical Global Impression-Improvement (CGI-I) Scale
NCT01179568 (5) [back to overview]	Change From Baseline in Inventory of Complicated Grief (ICG)
NCT01179568 (5) [back to overview]	Change From Baseline in Inventory of Complicated Grief (ICG)
NCT01179568 (5) [back to overview]	Change From Baseline in Work and Social Adjustment Scale (WSAS)
NCT01179568 (5) [back to overview]	Change From Baseline in Work and Social Adjustment Scale (WSAS)
NCT01189812 (1) [back to overview]	Sheehan-Suicidality Tracking Scale (S-STS)
NCT01214044 (4) [back to overview]	Change in Dim Light Melatonin Onset
NCT01214044 (4) [back to overview]	Change in Phase Angle Difference (PAD)
NCT01214044 (4) [back to overview]	Change in Hamilton Depression Rating Scale (HAM-D) Scores
NCT01214044 (4) [back to overview]	Change in Beck Depression Inventory II (BDI-II) Scores
NCT01254305 (3) [back to overview]	Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
NCT01254305 (3) [back to overview]	Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
NCT01254305 (3) [back to overview]	Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward
NCT01312922 (1) [back to overview]	Early and Sustained (Antidepressant) Response (ESR) Rate
NCT01324700 (2) [back to overview]	Asthma Control Questionnaire (ACQ)
NCT01324700 (2) [back to overview]	Hamilton Rating Scale for Depression (HRSD)
NCT01401595 (3) [back to overview]	Nocturnal Ingestions
NCT01401595 (3) [back to overview]	Night Eating Symptoms
NCT01401595 (3) [back to overview]	Change in Symptoms of NES
NCT01436643 (1) [back to overview]	Number of Participants Who Experienced Adverse Events, Serious Adverse Events and Death
NCT01473381 (3) [back to overview]	Change From Baseline to Week 10 in the Clinical Global Impressions-Severity (CGI-S) Scale Score
NCT01473381 (3) [back to overview]	Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 10
NCT01473381 (3) [back to overview]	Percentage of Participants With a Montgomery-Åsberg Depression Rating Scale (MADRS) Sustained Response
NCT01535573 (4) [back to overview]	Proportion of Cocaine-positive Urines Per Week
NCT01535573 (4) [back to overview]	Number of Participants With Cocaine-negative Urines Collected During Treatment Period
NCT01535573 (4) [back to overview]	Retention as Assessed by Number of Participants Remaining in Treatment
NCT01535573 (4) [back to overview]	Number of Participants Who Are Cocaine Abstinent During the Last 2 Weeks of Treatment (Weeks 8-9), as Assessed by Urine Test
NCT01557946 (2) [back to overview]	Mean Difference From Baseline to Day 3 in Glutamine/Glutamate (Gln/Glu) Ratio Within Depressed Group
NCT01557946 (2) [back to overview]	Mean Difference From Baseline to Day 7 in Glutamine/Glutamate (Gln/Glu) Ratio Within Depressed Group
NCT01657760 (2) [back to overview]	Craving for Alcohol in Alcohol Dependence With Citalopram Compared to Placebo
NCT01657760 (2) [back to overview]	Striatal Dopamine Receptor Availability in Alcohol Dependence With Citalopram, Compared to Placebo
NCT01658228 (3) [back to overview]	Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)
NCT01658228 (3) [back to overview]	Selective Reminding Test (SRT) Delayed Recall
NCT01658228 (3) [back to overview]	Selective Reminding Test (SRT) Total Recall
NCT01716221 (4) [back to overview]	Comparison of FARS and ICARS
NCT01716221 (4) [back to overview]	Friedreich Ataxia Rating Scale (FARS)
NCT01716221 (4) [back to overview]	Hamilton Depression Rating Scale
NCT01716221 (4) [back to overview]	International Cooperative Ataxia Rating Scale (ICARS)
NCT01742832 (1) [back to overview]	Montgomery-Åsberg Depression Rating Scale (MADRS)
NCT01876823 (10) [back to overview]	Change in Selective Reminding Test - Total Immediate Recall (SRT-IR)
NCT01876823 (10) [back to overview]	Change in Trails A
NCT01876823 (10) [back to overview]	Change in Trails B
NCT01876823 (10) [back to overview]	Change in Wechsler Memory Scale-III (WMS-III)
NCT01876823 (10) [back to overview]	Conversion to Dementia Using Clinical Dementia Rating (CDR)
NCT01876823 (10) [back to overview]	Change in Clinical Global Impression - Cognitive Change
NCT01876823 (10) [back to overview]	Change in Clinical Global Impression - Depression Change
NCT01876823 (10) [back to overview]	Change in Treatment Emergent Side Effects (TESS)
NCT01876823 (10) [back to overview]	Change in 24-item HAMD
NCT01876823 (10) [back to overview]	Change in Selective Reminding Test - Delayed Recall (SRT-DR)
NCT01916824 (1) [back to overview]	Money Earned
NCT01919216 (1) [back to overview]	Hamilton Rating Scale for Depression
NCT02080832 (4) [back to overview]	Cocaine Use/Treatment Effectiveness Score (TES)
NCT02080832 (4) [back to overview]	fMRI Brain Activation in Right Inferior Frontal Gyrus
NCT02080832 (4) [back to overview]	fMRI Brain Activation in Right Orlandic Operculum
NCT02080832 (4) [back to overview]	fMRI Brain Activation in Right Precentral Gyrus
NCT02137369 (2) [back to overview]	Number of Response to Treatment Events
NCT02137369 (2) [back to overview]	Number of Remission From Major Depressive Episode Events
NCT02161458 (1) [back to overview]	Amyloid Beta Levels in CSF
NCT02178696 (7) [back to overview]	Montgomery-Asberg Depression Rating Scale
NCT02178696 (7) [back to overview]	Hamilton Depression Rating Scale Scores
NCT02178696 (7) [back to overview]	Changes From Baseline in Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16) Score
NCT02178696 (7) [back to overview]	Changes From Baseline in PHQ-9 Depression Scores.
NCT02178696 (7) [back to overview]	Changes in BOLD Response During Reward fMRI Task (Monetary Incentive Delay, MID)
NCT02178696 (7) [back to overview]	Changes in Mu-opioid Binding Potential During PET
NCT02178696 (7) [back to overview]	Changes in Dopamine (D 2/3) Binding Potential During PET.
NCT02191397 (27) [back to overview]	"Percentage of Participants With a Clinical Global Impression Global Improvement (CGI-I) Score of 1 (Very Much Improved) or 2 (Much Improved) at Weeks 1, 2, 4, 6 and 8"
NCT02191397 (27) [back to overview]	Number of Participants With Vital Sign Parameters Outside the Clinical Concern Range
NCT02191397 (27) [back to overview]	Change From Baseline in HAMD-17 Retardation Subscale Score (Sum of Scores of Items 1, 7, 8 and 14) at Weeks 1, 2, 4, 6 and 8
NCT02191397 (27) [back to overview]	Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points
NCT02191397 (27) [back to overview]	Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Weeks 1, 2, 4, 6 and 8
NCT02191397 (27) [back to overview]	Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea at the Indicated Time Points
NCT02191397 (27) [back to overview]	Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transpeptidase (GGT) and Lactose Dehydrogenase (LD) at the Indicated Time Points
NCT02191397 (27) [back to overview]	Number of Participants With Urinalysis Data Outside the Normal Range
NCT02191397 (27) [back to overview]	Sustained Response Rate Based on HAMD-17 Total Score
NCT02191397 (27) [back to overview]	Sustained Remission Rate Based on HAMD-17 Total Score
NCT02191397 (27) [back to overview]	Response Rate Based on HAMD-17 Total Score
NCT02191397 (27) [back to overview]	Remission Rate Based on HAMD-17 Total Score
NCT02191397 (27) [back to overview]	Mean Change in Hamilton Depression Rating Scale - 17 (HAMD-17) Total Score From Baseline to End of Acute Treatment Phase (Week 8)
NCT02191397 (27) [back to overview]	Change From Baseline in Changes in Sexual Function Questionnaire (CSFQ)
NCT02191397 (27) [back to overview]	Change From Baseline in Hematocrit at the Indicated Time Points
NCT02191397 (27) [back to overview]	Change From Baseline in HAMD-17 Depressed Mood Subscale Score (Score of Item 1) at Weeks 1, 2, 4, 6 and 8
NCT02191397 (27) [back to overview]	Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score (Sum of Scores of Items 10, 11, 12, 13, 15 and 17) at Weeks 1, 2, 4, 6 and 8
NCT02191397 (27) [back to overview]	Change From Baseline in HAMD-17 Sleep Disorder Subscale Score (Sum of Scores of Items 4, 5 and 6) at Weeks 1, 2, 4, 6 and 8
NCT02191397 (27) [back to overview]	Change From Baseline in Hemoglobin, Total Protein, Albumin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points
NCT02191397 (27) [back to overview]	Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points
NCT02191397 (27) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Weeks 1, 2, 4, 6 and 8
NCT02191397 (27) [back to overview]	Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points
NCT02191397 (27) [back to overview]	Change From Baseline in Total Bilirubin, Direct Bilirubin and Creatinine at the Indicated Time Points
NCT02191397 (27) [back to overview]	Change From Baseline in White Blood Cell (WBC) Count, Total Neutrophil, Lymphocyte, Basophil, Eosinophil, Monocyte and Platelet Count at the Indicated Time Points
NCT02191397 (27) [back to overview]	Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious AE (SAE)
NCT02191397 (27) [back to overview]	Number of Participants With Electrocardiogram (ECG) Data Outside the Clinical Concern Range
NCT02191397 (27) [back to overview]	Number of Participants With Suicidal Ideation or Behavior During Treatment Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)
NCT02389465 (3) [back to overview]	IL10 Levels
NCT02389465 (3) [back to overview]	IL-6 Levels
NCT02389465 (3) [back to overview]	Montgomery Asberg Depression Rating Scale (MADRS)
NCT02473250 (4) [back to overview]	Clinical Global Impression-1
NCT02473250 (4) [back to overview]	Hamilton Anxiety Rating Scale
NCT02473250 (4) [back to overview]	Young Mania Rating Scale
NCT02473250 (4) [back to overview]	Montgomery-Asberg Depression Rating Scale
NCT02579343 (2) [back to overview]	Change of Mean Score of the Behavioral Health Measure-20 Between Baseline and End of Study
NCT02579343 (2) [back to overview]	Change From Baseline Score of the Sheehan Disability Scale Through 6 Weeks
NCT02655354 (13) [back to overview]	Cognitive Impairment Scale
NCT02655354 (13) [back to overview]	Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]	Brief Pain Inventory
NCT02655354 (13) [back to overview]	Number of Participants With Suicidal Ideation
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Overall Health Care
NCT02655354 (13) [back to overview]	TSOS Patient Satisfaction: Mental Health Care
NCT02655354 (13) [back to overview]	SF-36 Quality of Life
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Stimulant Use
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Opioid Use
NCT02655354 (13) [back to overview]	Number of Participants Endorsing a Single Item That Assesses Marijuana Use
NCT03388164 (2) [back to overview]	Rate of Adherence
NCT03388164 (2) [back to overview]	Adherence Consistency
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score Around End of Blinded Treatment
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score at Day 3
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score Over the Double-Blind Treatment Period
NCT04476030 (16) [back to overview]	Percentage of Participants With MADRS Remission at Day 15
NCT04476030 (16) [back to overview]	Percentage of Participants With MADRS Response at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in CGI-S Score at Day 15
NCT04476030 (16) [back to overview]	Time to First HAMD-17 Response
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score at Days 15 and 42
NCT04476030 (16) [back to overview]	Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT04476030 (16) [back to overview]	Percentage of Participants With CGI-I Response, at Day 3 and Day 15
NCT04476030 (16) [back to overview]	Percentage of Participants With HAMD-17 Remission at Day 15 and Day 42
NCT04476030 (16) [back to overview]	Percentage of Participants With HAMD-17 Response at Day 15 and Day 42
NCT04476030 (16) [back to overview]	Percentage of Participants With TEAEs, Graded by Severity
NCT04476030 (16) [back to overview]	Change From Baseline in Depressive Symptoms at Day 15, as Assessed by PHQ-9
NCT04476030 (16) [back to overview]	Change From Baseline in HAM-A Total Score at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in MADRS Total Score at Day 15

Number of Adverse Events (Physical Symptoms) Emerging or Worsening During 12 Weeks of Treatment

We expect that subjects treated for Minor Depression for 12 weeks with either St. John's Wort or citalopram will have similar safety profiles to subjects treated with placebo, and will not differ by more than 20% in rates of adverse side effects (e.g., nausea, headache, insomnia, hypersomnia, diarrhea) from subjects treated with placebo. This was measured by the number of adverse events (physical symptoms) emerging or worsening during 12 weeks of treatment. (NCT00048815)
Timeframe: Change from Baseline to Week 12

Intervention	Number of events (Mean)
Citalopram	4.7
St. John's Wort	5.0
Placebo	3.4

Intervention	pg/mL (Mean)
	Pre-SSRI BDNF Level	Post-SSRI BDNF Level
Open-label Selective Serotonin Reuptake Inhibitor (SSRI)	6077.270	4393.24

Intervention	units on a scale (Mean)
Placebo-Placebo	3.00
Placebo-Escitalopram	2.50
Escitalopram-Placebo	3.44

Intervention	Change in HAM-D scores (Mean)
Placebo-Placebo	6.23
Placebo-Escitalopram	10.60
Escitalopram-Placebo	6.45

Intervention	Scores on a scale (Mean)
Escitalopram Plus Acamprosate	-5.6
Escitalopram Plus Placebo	-7.8

Intervention	units on a scale (Mean)
	Distending pressure 12mmHg	Distending pressure 24mmHg	Distending pressure 36mmHg	Distending pressure 48mmHg
Citalopram	1	4	5	7
Placebo	2	6	7	6

Intervention	percentage of participants (Number)
Escitalopram + Bupropion SR	46.6
Venlafaxine XR + Mirtazapine	41.8
Escitalopram + Placebo	46.0

Intervention	units on a scale (Mean)
	Baseline	Week 16
1 - Citalopram + Placebo	45.50	54.45
2 - Methylphenidate + Placebo	47.06	53.54
3 - Methylphenidate + Citalopram	47.52	57.79

Intervention	units on a scale (Mean)
1 - Citalopram + Placebo	18.3
2 - Methylphenidate + Placebo	18.7
3 - Methylphenidate + Citalopram	19.8

Intervention	score on a scale (Mean)
	Physical Functioning	Social Functioning	Physical Role Functioning	Emotional Role Functioning	Mental Health	Vitality	Bodily Pain	General Health
Escitalopram + Placebo	88.33	68.75	86.11	75.00	70.42	54.69	87.96	79.25
Escitalopram + Ramelteon	80.50	69.44	75.00	67.59	68.00	49.38	75.31	74.90

Intervention	millimeters of mmercury (mmHg) (Least Squares Mean)
Duloxetine	0.58
Selective Serotonin Reuptake Inhibitor (SSRI)	0.55

Intervention	percent of participants (Number)
MED+CBTI	61.5
MED+CTRL	33.3

Intervention	percent (Number)
MED+CBTI	50.0
MED+CTRL	7.7

Intervention	kilograms (kg) (Least Squares Mean)
Duloxetine	-0.32
Selective Serotonin Reuptake Inhibitor (SSRI)	-0.17

Intervention	hours lost per week (Least Squares Mean)
Duloxetine	-9.56
Selective Serotonin Reuptake Inhibitor (SSRI)	0.41

Intervention	dollars (Least Squares Mean)
Duloxetine	-3978.98
Selective Serotonin Reuptake Inhibitor (SSRI)	-1932.46

Intervention	dollars (Least Squares Mean)
Duloxetine	7250.93
Selective Serotonin Reuptake Inhibitor (SSRI)	5074.09

Intervention	units on a scale (Least Squares Mean)
Duloxetine	24.56
Selective Serotonin Reuptake Inhibitor (SSRI)	20.73

Intervention	beats per minute (bpm) (Least Squares Mean)
Duloxetine	2.74
Selective Serotonin Reuptake Inhibitor (SSRI)	0.47

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-1.83
Selective Serotonin Reuptake Inhibitor (SSRI)	-1.43

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-2.95
Selective Serotonin Reuptake Inhibitor (SSRI)	-2.39

Intervention	mmHg (Least Squares Mean)
Duloxetine	-0.14
Selective Serotonin Reuptake Inhibitor (SSRI)	0.45

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-4.89
Selective Serotonin Reuptake Inhibitor (SSRI)	-4.24

citalopram

Description

Cross-References

Synonyms (120)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (5)

Pathways (3)

Protein Targets (42)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (215)

Molecular Functions (96)

Ceullar Components (64)

Bioassays (289)

Research

Studies (5,018)

Market Indicators

Research Demand Index: 140.85

Study Types

Clinical Trials (247)

Trial Overview

Trial Outcomes

Number of Adverse Events (Physical Symptoms) Emerging or Worsening During 12 Weeks of Treatment

Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C)

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

Remission of Depression (%)

Remission of Insomnia

Beck Depression Inventory (BDI)

Clinical Global Impressions - Severity (CGI-S)

Beck Depression Inventory (BDI)

Clinical Global Impressions - Severity (CGI-S)

Hamilton-Depression Rating Scale (HDRS-24 Items)

Hamilton-Depression Rating Scale (HDRS-24 Items)

Executive Function Composite Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort.

Hamilton Rating Scale for Depression Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Letter Number Sequencing Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Semantic Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Stroop Interference Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Subgroup Analysis of the Hamilton Depression Rating Scale Comparing Screening (Intake Visit) to Visit 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Symbol-Digit Modalities Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Total Functional Capacity Score Comparing Baseline (Week -4) to Visits 4 (Week 6) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Trails B Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Verbal Fluency Score Comparing Visit 2 (Week 0) to Visits 5 (Week 12) & 6 (Week 15) for the Citalopram Cohort Versus Placebo Cohort

Serum Brain-derived Neurotrophic Factor (BDNF) Levels

Quick Inventory of Depression- Self Report 16

Quantitative Substance Use Inventory ((SUI)

Timeline Follow Back (TLFB) Maximum Drinks Per Drinking Day

Timeline Follow Back (TLFB) Average Drinks Per Drinking Day

Timeline Follow Back (TLFB) Drinking Days Per 30 Days

Side Effect Burden

Depression Response Rate of Escitalopram Oxalate 10 mg Once Daily Compared to Placebo Once Daily for Major Depressive Disorder

Change in Hamilton Depression Rating Scale (HAM-D) Scores

Total Drinks Consumed Per Week on the TLFB

Total Drinking Days on the Alcohol Timeline Followback (TLFB)

Total Drinks Consumed Per Drinking Day on the TLFB

Change in Mean Score on the Hamilton Rating Scale for Depression -- 17 Items (HAM-D-17)

"Count of Participants Who Self-reported Adequate Relief"

Change From Baseline in IBS-QOL Score at Week 8

Mean Sensation Score as a Function of Distending Pressure at the End of the Study

Urgency Score as a Function of Distending Pressure at the End of the Study

Functioning, as Measured by the Social Adjustment Scale (SAS) Summary Score

Quality of Life, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Short Form (SF)

Remission: Persistent Hamilton Rating Scale for Depression, 17 Items (HAM-D 17) <= 7, With no HAM-D 17 >7 Through Week 12

Severity of Depressive Symptoms as Measured by Hamilton Rating Scale for Depression (HAM-D 17)

Time to Remission, Defined by the Week of Onset of Persistent Hamilton Rating Scale for Depression (HAM-D 17) <= 7, With no Subsequent HAM-D 17 > 7

MADRS Rating Scale Change

Quick Inventory of Depressive Symptoms

Quality of Life Inventory

Quality of Life Assessment

Hamilton Depression Rating Scale (HDRS) Maintained Scores at Week 16

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-9.21
Selective Serotonin Reuptake Inhibitor (SSRI)	-8.40

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-9.01
Selective Serotonin Reuptake Inhibitor (SSRI)	-8.16

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-5.99
Selective Serotonin Reuptake Inhibitor (SSRI)	-5.49

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-2.77
Selective Serotonin Reuptake Inhibitor (SSRI)	-2.58

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-17.03
Selective Serotonin Reuptake Inhibitor (SSRI)	-15.3

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-13.4
Selective Serotonin Reuptake Inhibitor (SSRI)	-12.6

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-4.69
Selective Serotonin Reuptake Inhibitor (SSRI)	-4.04

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-4.52
Selective Serotonin Reuptake Inhibitor (SSRI)	-3.85

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-4.51
Selective Serotonin Reuptake Inhibitor (SSRI)	-3.94

Intervention	units on a scale (Least Squares Mean)
Duloxetine	-13.56
Selective Serotonin Reuptake Inhibitor (SSRI)	-11.53